1
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.20549
--------------
FORM 8-K/A
CURRENT REPORT
--------------
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
--------------------------------------
Date of Report (Date of earliest event reported): September 6, 2000
IMMUNOGEN, INC.
(Exact name of registrant as specified in its Charter)
Massachusetts 0-17999 04-2726691
------------- ------------ ----------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation File Number) Identification No.)
128 Sidney Street, Cambridge, MA 02139
----------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 995-2500
================================================================================
2
ITEM 5. OTHER EVENTS.
On September 6, 2000, ImmunoGen, Inc. (the "Company") and Abgenix, Inc. of
Fremont, California ("Abgenix") announced a collaboration agreement between the
two companies. The agreement provides Abgenix with broad access to ImmunoGen's
maytansinoid Tumor-Activated Prodrug (TAP) technology for use with Abgenix's
fully human antibodies generated with XenoMouse technology. The multi-year
agreement provides Abgenix with a license to utilize ImmunoGen's maytansinoid
TAP platform in its antibody product research efforts and an option to obtain
product licenses for a large number of antigen targets over the agreement's
ten-year term.
Immunogen will receive $5 million in technology access fee payments, as
well as potential milestone payments, and royalties on net sales of any
resulting products. In addition, Abgenix will purchase $15 million of ImmunoGen
Common Stock at $19.00 per share.
The Agreement and the press release are filed as Exhibits to this Form
8-K/A. The summary of the Agreement set forth above is qualified in its entirety
by the more detailed information contained in the Exhibits, and the information
contained in the Agreement is incorporated herein by reference.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(C) Exhibits.
**10.1 Option and License Agreement dated September 5, 2000 by and
between Abgenix, Inc. and the Company.
**10.2 Letter Agreement for Stock Purchase dated September 6, 2000 by and
between Abgenix, Inc. and the Company
*99.1 The Registrant's Press Release dated September 6, 2000.
- ------------
* Previously filed.
** Portions of this Exhibit were omitted and have been filed separately with
the Secretary of the Commission pursuant to the Company's application
requesting confidential treatment under Rule 24b-2 of the Securities Exchange
Act of 1934.
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereto duly authorized.
ImmunoGen, Inc.
(Registrant)
Date: October 10, 2000 /s/ Mitchel Sayare
--------------------------------------
Mitchel Sayare, Chairman of the Board,
Chief Executive Officer and President
(principal executive officer)
4
EXHIBIT INDEX
EXHIBIT SEQUENTIAL
NUMBER DESCRIPTION PAGE NUMBER(S)
- ------- ----------- --------------
**10.1 Option and License Agreement dated September 5, 2000 by and
between Abgenix, Inc. and the Company.
**10.2 Letter Agreement for Stock Purchase dated September 6, 2000
by and between Abgenix, Inc. and the Company
*99.1 The Registrant's Press Release dated September 6, 2000
- ------------
* Previously filed.
** Portions of this Exhibit were omitted and have been filed separately with
the Secretary of the Commission pursuant to the Company's application
requesting confidential treatment under Rule 24b-2 of the Securities Exchange
Act of 1934.
1
OPTION AND LICENSE AGREEMENT
This Option and License Agreement ("Agreement") is made effective as of
September 5, 2000 (the "Effective Date") by and between IMMUNOGEN, INC., a
Massachusetts corporation with a principal place of business at 128 Sidney
Street, Cambridge, Massachusetts 02139 ("IMMUNOGEN"), and ABGENIX, INC., a
Delaware corporation with a place of business at 7601 Dumbarton Circle, Fremont,
California 94555 ("ABX"). IMMUNOGEN and ABX are each hereafter referred to
individually as a "Party" and together as the "Parties".
WHEREAS, ABX is the owner of or otherwise controls certain patents and
technology relating to antibodies; and
WHEREAS, IMMUNOGEN is the owner of or otherwise controls certain
proprietary patents and technology relating to or otherwise useful in the
conjugation of certain cytotoxic compounds such as DM1 (as hereinafter defined)
to antibodies; and
WHEREAS, ABX desires to have access to certain IMMUNOGEN Background
Technology (as hereinafter defined) in order to use such IMMUNOGEN Background
Technology to research, discover and develop one or more conjugates of certain
cytotoxic compounds and antibodies owned or controlled by ABX; and
WHEREAS, in connection therewith, ABX desires to receive, and IMMUNOGEN
desires to grant, Options to obtain one or more licenses having the terms set
forth herein and in one or more License Agreements to be executed by the
Parties.
NOW, THEREFORE, in consideration of the mutual covenants contained herein,
and for other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the Parties hereby agree as follows:
1. DEFINITIONS
Whenever used in the Agreement with an initial capital letter, the terms
defined in this Section 1 shall have the meanings specified below.
1.1 "ABX ANTIBODY" shall mean any antibody or fragment thereof directed to
a Proposed Licensed Target or a Licensed Target.
1.2 "AFFILIATE" shall mean any corporation, firm, limited liability
company, partnership or other entity which directly or indirectly controls or is
controlled by or is under common control with a Party to this Agreement.
"Control" means, for purposes of this Section 1.2, ownership, directly or
through one or more Affiliates, of more than fifty percent (50%) of the shares
of stock entitled to vote for the election of directors, in the case of a
corporation, or more than fifty percent (50%) of the equity interests in the
case of any other type of
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
1
2
legal entity, status as a general partner in any partnership, or any other
arrangement whereby a Party controls or has the right to control the Board of
Directors or equivalent governing body of a corporation or other entity.
1.3 "BLA" shall mean a biologics license application (as defined in Title
21 of the United States Code of Federal Regulations, as amended from time to
time) filed with the FDA seeking Regulatory Approval to market and sell any
Licensed Product in the United States for a particular indication within the
Field.
1.4 "CLINICAL MATERIALS" shall mean (a) supplies of ansamitocin P-3, DM1,
and/or any other May Compound as manufactured in accordance with all applicable
GMPs and other legal requirements and all applicable Specifications for such May
Compound for use in human clinical testing, and (b) supplies of any Licensed
Product as manufactured in accordance with all applicable GMPs and other legal
requirements and all applicable Specifications for such Licensed Product for use
in human clinical testing of any Licensed Product.
1.5 "COMBINATION PRODUCT" shall mean any Licensed Product that contains, in
addition to any conjugate of any ABX Antibody with any May Compound, one or more
other ingredients that has biologic activity.
1.6 "CONTROL" OR "CONTROLLED" shall mean (a) with respect to patents,
know-how or other intangible rights, the possession by Party of the ability to
grant a license or sublicense of such patent rights, know-how or other
intangible rights as provided for herein without violating the terms of any
arrangement or agreements between such Party and any Third Party and (b) with
respect to any material, the possession by a Party of the ability to use such
material as provided herein without violating the terms of any agreement between
such Party and any Third Party.
1.7 [________________] shall mean any and all [________________], whether
[________________________________________________________], and shall include,
without limitation, [____________________________________________], in each case
[___________ ________________________________]. [_______________] shall include,
without limitation, [_____________].
1.8 "DM1" shall mean that certain maytansine derivative having the specific
chemical name N2'deacetyl - N2'- (3-mercapto-1-oxopropyl) - maytansine.
1.9 "EXCLUSIVE OPTION" shall have the meaning set forth in Section 2.1.1.
1.10 "EXCLUSIVE OPTION PERIOD" shall have the meaning set forth in Section
2.1.3.
1.11 "EXCLUSIVE OPTION REQUEST" shall have the meaning set forth in
Sections 2.1.2.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
2
3
1.12 "EXCLUSIVE OPTION RESPONSE" shall have the meaning set forth in
Sections 2.1.2.
1.13 "FDA" shall mean the United States Food and Drug Administration and
any successor agency or authority thereto.
1.14 "FIELD" shall mean any human medical use.
1.15 "FOREIGN REGULATORY AUTHORITIES" shall mean any applicable
supranational, national, federal, state or local regulatory agency, department,
bureau or other governmental entity of any country or jurisdiction in the
Territory (other than the FDA in the United States), having responsibility in
such country or jurisdiction for any Regulatory Approvals of any kind in such
country or jurisdiction, and any successor agency or authority thereto.
1.16 "FULLY BURDENED MANUFACTURING COST" shall mean, with respect to any
Preclinical Materials or Clinical Materials produced by IMMUNOGEN for ABX under
this Agreement, the sum of the following components, as determined by IMMUNOGEN
in accordance with generally accepted accounting principles in the United
States, consistently applied, and consistent with the application given to other
goods produced by IMMUNOGEN: (a) the costs of goods produced, including, without
limitation, direct labor, material and product testing costs of such Preclinical
Materials or Clinical Materials; (b) any Third Party royalty costs that are
actually paid by IMMUNOGEN and are based solely and directly on the manufacture
and sale to ABX of such Preclinical Materials or Clinical Materials; (c) all
overhead costs incurred by IMMUNOGEN directly and solely attributable to the
cost of goods under clause (a) above, including, without limitation, supervisory
services, occupancy costs, payroll, information systems, human relations,
purchasing, accounts receivable or accounts payable functions, and other general
and administrative functions; and (d) any other costs borne by IMMUNOGEN
directly and solely for the transport, customs clearance, duty and/or insurance
for such Preclinical Materials or Clinical Materials to ABX hereunder.
1.17 "GMPS" shall mean all good manufacturing practices under Title 21 of
the United States Code of Federal Regulations, as amended from time to time.
1.18 "IMMUNOGEN BACKGROUND TECHNOLOGY" shall mean all inventions,
discoveries, patent rights, trade secrets and know-how, including without
limitation, laboratory scientific information and procedural techniques,
Controlled by IMMUNOGEN during the Term of this Agreement or any License
Agreement that are necessary or useful for ABX to research, develop, make, have
made, use, have used, sell, offer for sale, have sold, import or have imported
Licensed Products (or any component thereof, including any linker) for use in
the Field, together with all patent rights covering the foregoing; provided,
however, that IMMUNOGEN Background Technology shall expressly exclude any Target
Specific Rights. IMMUNOGEN Background Technology covered by issued patents
and/or filed patent applications as of the Effective Date is listed on Schedule
I attached hereto.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
3
4
1.19 "JOINT INVENTION" shall have the meaning set forth in Article 6.
1.20 "LICENSE AGREEMENT" shall mean a license agreement executed by the
Parties upon exercise of any Option pursuant to Section 2.1 or 2.2 in
substantially the form set forth in Appendix A or B attached hereto.
1.21 "LICENSED PRODUCT" shall mean any product containing any conjugate of
any ABX Antibody with any May Compound, and shall include, without limitation,
any formulation thereof (including, without limitation, any lyophilized, liquid,
sustained release or aerosolized formulation). "Licensed Product" shall also
include any and all Combination Products (if any).
1.22 "LICENSED TARGET" shall mean a Proposed Licensed Target selected by
ABX and approved by IMMUNOGEN as set forth in Section 2.1.2 or 2.2.2, which is
the subject of a License Agreement between the Parties.
1.23 "MAY COMPOUND" shall mean any and all maytansinoid compounds
(including, without limitation, maytansine, ansamitocin P-3 and DM1), whether
produced by a botanical source, natural fermentation or chemical synthesis, and
shall include, without limitation, all variants, fragments or derivatives of any
of the foregoing, in each case owned or otherwise Controlled by IMMUNOGEN. May
Compounds shall include, without limitation, DM1.
1.24 "NDA" shall mean a new drug application (as defined in Title 21 of the
United States Code of Federal Regulations, as amended from time to time) filed
with the FDA seeking Regulatory Approval to market and sell any Licensed Product
in the United States for a particular indication within the Field.
1.25 "NONEXCLUSIVE OPTION" shall have the meaning set forth in Section
2.2.1.
1.26 "NONEXCLUSIVE OPTION PERIOD" shall have the meaning set forth in
Section 2.2.3.
1.27 "NONEXCLUSIVE OPTION REQUEST" shall have the meaning set forth in
Sections 2.2.2.
1.28 "NONEXCLUSIVE OPTION RESPONSE" shall have the meaning set forth in
Sections 2.2.2.
1.29 "OPTION" shall mean, an Exclusive Option or a Nonexclusive Option.
1.30 "OPTION GRANT FEE" shall have the meaning set forth in Section 4.1
hereof.
1.31 "OPTION PERIOD" shall have the meaning set forth in Sections 2.1.3 and
2.2.3.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
4
5
1.32 "PHASE II CLINICAL STUDY" shall mean, as to a particular Licensed
Product for a particular indication, a controlled and lawful study in humans of
the safety, dose ranging and efficacy of such Licensed Product for such
indication, which is prospectively designed to generate sufficient data (if
successful) to commence a Phase III Clinical Trial of such Licensed Product for
such indication.
1.33 "PHASE III CLINICAL TRIAL" shall mean, as to a particular Licensed
Product for a particular indication, a controlled and lawful study in humans of
the safety and efficacy of such Licensed Product for such indication, which is
prospectively designed to demonstrate statistically whether such Licensed
Product is safe and effective for use in such indication in a manner sufficient
to file a BLA or NDA to obtain Regulatory Approval to market and sell that
Licensed Product in the United States for the indication under investigation in
such study.
1.34 "PRECLINICAL MATERIALS" shall mean (a) supplies of ansamitocin P-3,
DM1 and/or any other May Compound as manufactured in accordance with all
applicable legal requirements and all applicable Specifications for such May
Compound for use in preclinical testing, and (b) supplies of any Licensed
Product as manufactured in accordance with all applicable legal requirements and
all applicable Specifications for such Licensed Product for use in preclinical
testing of any Licensed Product.
1.35 "REGULATORY APPROVAL" shall mean any and all approvals (including
pricing and reimbursement approvals), product and establishment licenses,
registrations or authorizations of any kind of the FDA or its foreign equivalent
necessary for the development, pre-clinical and/or human clinical testing,
manufacture, quality testing, supply, use, storage, importation, export,
transport, marketing and sale of a Licensed Product (or any component thereof)
for use in the Field in any country or other jurisdiction in the Territory.
1.36 "RESEARCH ACTIVITIES" shall mean research conducted by, on behalf of
or with ABX using the IMMUNOGEN Background Technology for the purpose of
developing information necessary or useful to determine whether to exercise an
Option with respect to a Proposed Licensed Target.
1.37 "RESEARCH DATA" shall mean any data generated by or on behalf of ABX
(including by IMMUNOGEN at the request and on behalf of ABX) resulting from its
direct and material use of the IMMUNOGEN Background Technology during the
Research Term. ABX shall solely own all Research Data and all patent rights and
other intellectual property rights therein.
1.38 "RESEARCH INVENTION" shall mean any discovery, invention, know-how or
trade secret (other than Research Data and Research Materials) conceived or made
by or on behalf of ABX (including by IMMUNOGEN at the request and on behalf of
ABX) through the direct and material use of IMMUNOGEN Background Technology,
Research Data or Research Materials during the Research Term. ABX shall solely
own all Research Inventions and all patent rights and other intellectual
property rights therein.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
5
6
1.39 "RESEARCH MATERIALS" shall mean any materials, including but not
limited to, antibodies or drug candidates, identified or developed by or on
behalf of ABX (including by IMMUNOGEN at the request and on behalf of ABX)
through the direct and material use of IMMUNOGEN Background Technology during
the Research Term. ABX shall solely own all Research Materials and all patent
rights and other intellectual property rights therein.
1.40 "RESEARCH PATENT RIGHTS" shall mean the rights and interests in and to
issued patents and pending patent applications in any country, including, but
not limited to, all provisional applications, substitutions, continuations,
continuations-in-part, divisions, and renewals, all letters patent granted
thereon, and all reissues, reexaminations and extensions thereof, wherein at
least one claim of such Research Patent Right is directed to any Research Data,
Research Inventions or Research Materials. ABX shall solely own all Research
Patent Rights.
1.41 "RESEARCH TERM" shall have the meaning set forth in Section 2.4.4.
1.42 "SPECIFICATIONS" shall mean any specifications specified by ABX and
reasonably acceptable to IMMUNOGEN relating to the manufacturing and supply of
any May Compound and/or Licensed Product hereunder.
1.43 "TARGET" shall mean (a) any particular antigen, and (b) any and all
epitopes of that antigen.
1.44 "TARGET SPECIFIC RIGHTS" shall mean all inventions, discoveries,
patent rights, trade secrets and know-how, including without limitation,
laboratory scientific information and procedural techniques Controlled by
IMMUNOGEN during the Term of this Agreement or the term of any License Agreement
constituting (a) the composition of matter or use of a Target, (b) the
composition of matter or use of an antibody binding to a Target, or (c) the
composition of matter or use of a conjugate of an antibody binding to a Target
with a May Compound.
1.45 "TECHNOLOGY" shall mean and include any and all unpatented proprietary
ideas, inventions, discoveries, Confidential Information, materials, data,
results, formulae, designs, specifications, methods, processes, formulations,
techniques, ideas, know-how, technical information (including, without
limitation, structural and functional information), process information,
pre-clinical information, clinical information, and any and all proprietary
biological, chemical, pharmacological, toxicological, pre-clinical, clinical,
assay, control and manufacturing data and materials.
1.46 "TERM" shall have the meaning set forth in Section 8.1.
1.47 "TERRITORY" shall mean the world.
1.48 "THIRD PARTY" shall mean any person or entity other than IMMUNOGEN,
ABX and their respective Affiliates.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
6
7
1.49 "THIRD PARTY LICENSEE" shall mean a Third Party to which IMMUNOGEN has
granted rights to use IMMUNOGEN Background Technology or rights with respect to
any Target.
1.50 "UNEXERCISED EXCLUSIVE OPTION" shall have the meaning set forth in
Section 2.1.3.
1.51 "UNEXERCISED NONEXCLUSIVE OPTION" shall have the meaning set forth in
Sections 2.2.3.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
7
8
2. GRANT OF RIGHTS
2.1 OPTIONS FOR EXCLUSIVE LICENSES.
2.1.1 EXCLUSIVE OPTION RIGHTS. Subject to the limitations set forth in
Sections 2.1.2, 2.1.3 and 2.1.4 of this Agreement, IMMUNOGEN hereby grants to
ABX the right, prior to the [________] anniversary of the Effective Date, to
obtain an exclusive option (the "Exclusive Option") to obtain an exclusive
license in the Territory under the IMMUNOGEN Background Technology, under Target
Specific Rights with respect to any Target specified in ABX's notice of election
of Option (the "Proposed Licensed Target"), for the sole purpose of researching,
developing, making, having made, using, having used, selling, offering for sale,
having sold, importing and having imported Licensed Products directed to such
Proposed Licensed Target, for any and all uses within the Field, under the
relevant terms and subject to the conditions set forth in the applicable License
Agreement.
2.1.2 EXCLUSIVE OPTION GRANT. ABX may from time to time during the
term of this Agreement request any Exclusive Option pursuant to Section 2.1.1
[_____________ _______________________________________], which [______] shall
specify in detail the [_________________] to be
[_____________________________________________________ __________]. IMMUNOGEN
shall [____________________________________] of any [___
_____________________________________________________________________________];
provided, however, that [__________________________________
________________________________________] if: (a)
[_______________________________ ______________] with
[_________________________________________________________ _____]; or (b)
[_______________________________] with [____________________________
____________________________________________________________] and has [_________
________________________________________________________________________] for a,
[_________________] whose [_____________________________________] to
[___________ _____________________], or (c)
[_________________________________________________ ___] to [__________] for a
[______________________________________________________ ________]; or (d)
[____________________________________] with [__________] that is [___ _____] as
of [__________________________] that [___________________________________
______] a [______] for such [_________________] on the terms and conditions of
this Agreement. Upon the grant of an Exclusive Option to ABX as provided in this
Section 2.1.2, [___________________________________________________________]
concerning the [________] regarding, or otherwise [_______________], or
otherwise [_______________] any [______ ] concerning, any [______] regarding a
[__________________________] to the [__________________________________]. If in
an [_______________________, ________________] that the [______________________]
is [_______________] for a [______ __________], IMMUNOGEN shall [_____________]
in such [__________________________ _______________________________] is [_____]
for [______________________]. If, within [________] of
[_______________________________] that [_________________] is [______] for
[__________________________________________________________________________
________________________] for [_______________________], then [_____________]
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
8
9
_____________________________] for [_______________________] without the
[______] for any [_________________________].
2.1.3 OPTION PERIOD; UNEXERCISED OPTIONS. The rights set forth in this
Section 2.1 shall be exercisable with respect to any Proposed Licensed Target at
any time during the period commencing on the date of the Exclusive Option
Response granting an Exclusive Option to such Proposed Licensed Target and
continuing until the earlier of (a) [____________ ______] following the date of
such Exclusive Option Response (subject to extension as provided below), and (b)
[________________________________________________________________ ____________]
(such period being referred to herein as the "Exclusive Option Period"). ABX
shall have the right to extend the Exclusive Option Period for any Exclusive
Option regarding a Proposed Licensed Target [___________________________] by
giving to IMMUNOGEN written notice thereof prior to the expiration of
[_____________] following the date of the applicable Exclusive Option Response,
and paying the applicable extension fee as set forth in Section 4.3. In the
event that ABX fails to exercise or otherwise abandons any Exclusive Option
during the applicable Exclusive Option Period (such Exclusive Option in either
case being referred to herein as an "Unexercised Exclusive Option"), (a) all
rights under the IMMUNOGEN Background Technology regarding Licensed Products
directed to the Proposed Licensed Target, and under Target Specific Rights with
respect to the Proposed Licensed Target, that is the subject of the Unexercised
Exclusive Option [_____________________________], and (b)
[_______________________________________________________________] with [_____
_______] concerning [_________], or otherwise [_______________________], or
otherwise [__________] any [_______] concerning,
[___________________________________________ _______] to the
[__________________] by [__________________].
2.1.4 LIMITATIONS ON EXCLUSIVE OPTION EXERCISE. Notwithstanding anything to
the contrary set forth in this Agreement, the Parties hereby agree that ABX
shall have the right to select and maintain no more than [_____] active
Exclusive Options at any one time during the Term of this Agreement; provided,
that, Unexercised Exclusive Options shall not count as Exclusive Options for
purposes of this limitation.
2.1.5 EXERCISE OF EXCLUSIVE OPTIONS. Upon exercise of an Exclusive Option
by ABX in accordance with Section 2.1.3, (a) the Parties shall execute a License
Agreement in the form of Appendix A attached hereto and, upon payment of the
license fee specified in the License Agreement, such Proposed Licensed Target
shall become a Licensed Target and shall be licensed to ABX as specified in the
relevant License Agreement and (b) IMMUNOGEN shall thereafter not grant any
license or other rights to any Third Party or pursue any internal development
program regarding a May Compound conjugate product to the Licensed Target.
2.1.6 OPTION TO OBTAIN NONEXCLUSIVE LICENSES. Upon the written request of
ABX given at the time of ABX's exercise of an Exclusive Option, ABX shall have
the right to obtain a nonexclusive license under the IMMUNOGEN Background
Technology and Target Specific Rights pursuant to Section 2.2.5 as if such
Exclusive Option were a Nonexclusive Option.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
9
10
2.2 OPTIONS FOR NONEXCLUSIVE LICENSES.
2.2.1 NONEXCLUSIVE OPTION RIGHTS. Subject to the limitations set forth
in Sections 2.2.2, 2.2.3 and 2.2.4 of this Agreement, IMMUNOGEN hereby grants to
ABX the right, prior to the [________] anniversary of the Effective Date, to
obtain a nonexclusive option (the "Nonexclusive Option") to obtain a
nonexclusive license in the Territory under the IMMUNOGEN Background Technology,
under Target Specific Rights with respect to any Proposed Licensed Target, for
the sole purpose of researching, developing, making, having made, using, having
used, selling, offering for sale, having sold, importing and having imported
Licensed Products directed to such Proposed Licensed Target, for any and all
uses within the Field, under the relevant terms and subject to the conditions
set forth in the applicable License Agreement.
2.2.2 NONEXCLUSIVE OPTION GRANT. ABX may from time to time during the
term of this Agreement request any Nonexclusive Option pursuant to Section 2.2.1
[_______ _____________________________________________], which [_______] shall
specify in detail the [___________________] to be
[________________________________________________ _____________]. IMMUNOGEN
shall [_______________________________________] of any
[_____________________________________________] the [______________________
_________________________________________]; provided, however, that the
[______________________________________________________________________] if: (a)
[______________] is [________________________] with a [________________________
_____] to [________________________]; or (b) [____________] is
[____________________ _________] for a [______] for a
[_________________________________________________ ______] and has
[________________________________________], or [_________________ __________]
for a [_______] with [_________], whose [_______________________________ ___] to
[_______________________], or (c) [_______________________________________
______________] to a [__________] for a [___________________________] to
[___________ ____________]; or (d) [_________________________________________]
with a [________] that is [______] as of [________________________________]that
[______________________ _________________________] for
[________________________] on the terms and conditions of this Agreement. Upon
the grant of a Nonexclusive Option to ABX as provided in this Section 2.2.2,
[_________________________________________________________________] concerning
the [______________] regarding, or otherwise [______________], or otherwise
[__________] any [______] concerning, [_________] regarding
[_________________________ __________] to the
[________________________________________________].
2.2.3 OPTION PERIOD; UNEXERCISED OPTIONS. The rights set forth in this
Section 2.2 shall be exercisable with respect to any Proposed Licensed Target at
any time during the period commencing on the date of the Nonexclusive Option
Response granting a Nonexclusive Option to such Proposed Licensed Target and
continuing until the earlier of (a) [_____ _______] following the date of such
Nonexclusive Option Response (subject to extension as provided below), and (b)
[_____________________________________________ ________________________________]
(such period being referred to herein as the "Nonexclusive Option Period"). ABX
shall have the right to extend the Nonexclusive Option
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
10
11
Period for any Nonexclusive Option for any Proposed Licensed Target
[____________________ ____________] by giving to IMMUNOGEN written notice
thereof prior to the expiration of [_____________] following the date of the
applicable Nonexclusive Option Response, and paying the applicable extension fee
as set forth in Section 4.3. In the event that ABX fails to exercise or
otherwise abandons any Nonexclusive Option during the applicable Nonexclusive
Option Period (such Nonexclusive Option in either case being referred to herein
as an "Unexercised Nonexclusive Option"), (a) [_____________] under the
[_______________ _____________] regarding [__________________] to the
[____________________], and under [_______________] with respect to the
[__________________], that is the [____________ ___________________________]
shall [____________________________], and (b) IMMUNOGEN shall
[______________________________________] with [___________] concerning the
[__________] regarding, or otherwise [__________________] any [__________
____________] regarding [__________________________] to the
[______________________ ______________________________].
2.2.4 LIMITATIONS ON NONEXCLUSIVE OPTION EXERCISE. Notwithstanding anything
to the contrary set forth in this Agreement, the Parties hereby agree that ABX
shall have the right to select and maintain no more than [_______] active
Nonexclusive Options at any one time during the Term of this Agreement;
provided, that, Unexercised Nonexclusive Options shall not count as Nonexclusive
Options for purposes of this limitation.
2.2.5 EXERCISE OF NONEXCLUSIVE OPTIONS. Upon exercise of a Nonexclusive
Option by ABX in accordance with Section 2.2.3(a), the Parties shall execute a
License Agreement in the form of Appendix B attached hereto and, upon payment of
the license fee specified in the License Agreement, such Proposed Licensed
Target shall become a Licensed Target and shall be licensed to ABX as specified
in the relevant License Agreement and (b) IMMUNOGEN shall not grant any
exclusive license or other rights to any Third Party regarding a May Compound
conjugate antibody product to the Licensed Target.
2.2.6 OPTION TO CONVERT TO EXCLUSIVE OPTIONS. Upon the written request of
ABX given at any time during the Nonexclusive Option Period applicable to a
Nonexclusive Option for a Proposed Licensed Target, ABX shall have the right to
convert such Nonexclusive Option into an Exclusive Option, provided that
[________] of [_________], an [____________] for [_____________________] is
[__________] in accordance with Section 2.1.2. [__________ _________________] of
any [________________________________] shall give [___________
___________________] an [___________] for the [________________________] is
[________ _______] in accordance with Section 2.1.2. If [_____________________],
then such Nonexclusive Option shall be converted to an Exclusive Option
effective as of the date of such request, and ABX shall pay to IMMUNOGEN a
conversion fee as set forth in clause (c) of Section 4.2.
2.2.7 OPTION TO OBTAIN EXCLUSIVE LICENSES. Upon the written request of ABX
given at the time of ABX's exercise of a Nonexclusive Option, ABX shall have the
right to obtain an exclusive license under the IMMUNOGEN Background Technology
and Target Specific Rights pursuant to Section 2.1.5 as if such Nonexclusive
Option were an Exclusive
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
11
12
Option, provided that [_______] of [___________], an [___________] for the
[_____________ ____________________] is [__________] in accordance with Section
2.1.2. [______________ _____________] of any [______________________] shall give
[_______________________ ______ ]an [________________________________________]
is [___________] in accordance with Section 2.1.2.
2.3 NON-EXCLUSIVE LICENSE. On and after the expiration of a Nonexclusive
Option Period or Exclusive Option Period, as the case may be, with respect to a
Proposed Licensed Target, ABX shall thereafter be granted a non-exclusive
license in the Territory under the IMMUNOGEN Background Technology, but not
under any Target Specific Rights with respect to such Proposed Licensed Target,
solely during the Research Term for the sole purpose of conducting preclinical
research with respect to Licensed Products directed to such Proposed Licensed
Target, for any and all uses in the Field. Such License shall continue during
the Research Term until such time as IMMUNOGEN gives express written notice to
ABX of IMMUNOGEN's grant to a Third Party of a bona fide exclusive license
regarding a May Compound conjugate product to such Proposed Licensed Target, in
which case such license shall immediately terminate.
2.4 NON-EXCLUSIVE RESEARCH LICENSES TO ABX.
2.4.1 RESEARCH LICENSE. IMMUNOGEN hereby grants to ABX a non-exclusive,
royalty-free license under IMMUNOGEN Background Technology, solely during the
Research Term and as further described below (i) to conjugate a May Compound to
one (1) or more additional ABX Antibodies that are not part of a Licensed
Product for use as a control for any Licensed Product licensed to it under a
License Agreement, (ii) to conduct toxicity studies (i.e., in vivo animal
studies designed to identify and measure the toxicity of a Licensed Product) on
any Licensed Product licensed to it hereunder and (iii) to conduct Research
Activities. The foregoing licenses may be sublicensed only in connection with a
sublicense of the IMMUNOGEN Background Technology hereunder or under a License
Agreement.
2.4.2 RESEARCH RECORDS. ABX shall maintain records of access to and
use of the IMMUNOGEN Background Technology.
2.4.3 EXPIRATION OF RESEARCH TERM. Unless otherwise provided in a
License Agreement or otherwise set forth in this Agreement, upon termination or
expiration of the Research Term, ABX shall discontinue use of the IMMUNOGEN
Background Technology and destroy all portions and copies of the IMMUNOGEN
Background Technology; provided, however, that ABX shall have the right to
retain one (1) copy for its legal files.
2.4.4 RESEARCH TERM. The term of the Research shall expire upon the
last to expire of the Option Periods, unless this Agreement is earlier
terminated by either Party pursuant to the provisions of Section 8 (the
"Research Term").
2.5 [_____________________] hereby [__________________] a
[__________________________________________________] of [_____________] under
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
12
13
[____________], if any, in [____________] within the
[_____________________________ ________] to the extent [__________________] or
[_________] of the [_________] that are [____________________________________]
to the [___________] to [_______________] and [___________________] and
[__________] to [_________________________________ __________] to
[_______________________________________] (other than [____________] to a
[____________________] or a [____________]). [_______________________________
_____________] of the [________] of [_____________] of which it [____________].
[_______ ______] to [__________] includes [___________________________] to
[_________] from whom [________________________________________] to the
[________] they [___________ __________] or
[_____________________________________] to [____________] with the [______] to
[______________] hereunder, and [_________________________ ]to
[________________________________], but [__________________] with respect to
[_______________]. Notwithstanding the foregoing, the [________________________]
pursuant to this Section 2.5 [________________________________] of [______] to
any [_______________].
2.6 TECHNOLOGY TRANSFER. As soon as practicable after, and in any event on
or before [_____________] from, the Effective Date, (a) ABX and IMMUNOGEN will
agree upon a schedule to permit two (2) representatives designated by ABX to
visit IMMUNOGEN's facilities for a period of no more than
[______________________________________________ ________________] to
[_______________________________________________] to an [__________] and to
[______] the [______________] and [____________] used [____________
____________], and (b) [______] shall [_______________] with [______________] of
such [__ ____________] to
[_____________________________________________________________ ___________].
During such visit, IMMUNOGEN shall deliver to ABX all IMMUNOGEN Background
Technology existing as of the Effective Date. [______________________], the
[________________] shall [______] to [__________] and
[______________________________
____________________________________________________________________]. As soon
as practicable thereafter, but in any event on or before [______________] from
[_____________ ________] of [_________________________________], the Parties
shall, in order to [________
___________________________________________________________________] attached
hereto and [____________________________________], and the
[______________________ _________________] between the [________], if any. The
initial technology transfer under this Section 2.6 shall be complete for
purposes of Section 4.1 at such time as [__________________
_______________________________________________________]. Promptly, but not less
than quarterly thereafter, IMMUNOGEN shall deliver to ABX all IMMUNOGEN
Background Technology not previously delivered to ABX. From time to time during
the Research Term, IMMUNOGEN shall provide ABX with such technical assistance as
reasonably requested by ABX regarding the use of the IMMUNOGEN Background
Technology. Such technical assistance and expertise shall include, but not be
limited to, visits by IMMUNOGEN personnel to ABX and visits by ABX personnel to
IMMUNOGEN, at ABX's expense, at such times and for such periods of time as may
be reasonably acceptable to the Parties. Additionally, at the reasonable request
of ABX, IMMUNOGEN shall transfer all applicable IMMUNOGEN Background Technology,
and provide such technical assistance, to such Third Party collaborator,
sublicensee or contract manufacturer as ABX designates.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
13
14
2.7 NO OTHER RIGHTS. ABX shall receive no rights to utilize IMMUNOGEN
Background Technology, or rights with respect to use of IMMUNOGEN Background
Technology, except as expressly set forth herein or in a License Agreement.
IMMUNOGEN shall receive no rights to Research Data, Research Materials, Research
Technology or Research Patent Rights thereon except as expressly set forth
herein. ABX's rights in Research Patent Rights are subject to
[___________________________________].
2.8 IN LICENSES. IMMUNOGEN represents and warrants to ABX that it has
provided ABX true and correct copies of all agreements pursuant to which
IMMUNOGEN Background Technology existing as of the Effective Date, is licensed
to or otherwise acquired by IMMUNOGEN from a third party. IMMUNOGEN promptly
shall provide ABX with true and correct copies of all agreements pursuant to
which IMMUNOGEN Background Technology licensed or acquired after the Effective
Date, is licensed to or otherwise acquired by IMMUNOGEN from a Third Party;
provided, however, that IMMUNOGEN shall have the right to redact confidential
financial information and any provisions that shall not bind ABX. To the extent
the IMMUNOGEN Background Technology is licensed to or acquired by IMMUNOGEN from
a Third Party and is reasonably necessary to permit ABX to exercise its rights
granted hereunder, IMMUNOGEN shall use reasonable commercial efforts to maintain
in full force and effect such license. In the event of the termination of any
such license with a Third Party, IMMUNOGEN shall cause such Third Party to grant
a direct license to ABX to the extent necessary to permit ABX to exercise its
rights granted hereunder, and all sums owing by ABX to such Third Party shall be
fully deducted from any amounts owing to IMMUNOGEN under the License Agreements.
3. JOINT PROCESS DEVELOPMENT COMMITTEE
3.1 ESTABLISHMENT OF COMMITTEE. Promptly after the Effective Date, the
Parties shall form a Joint Process Development Committee ("JPDC") whose mandate
shall be to serve as a forum for coordination and communication between the
Parties with respect to development (to the extent ABX requests the assistance
or services of IMMUNOGEN) of manufacturing processes applicable to any May
Compound or Licensed Product covered by this Agreement (including, without
limitation, all process science and process development work, formulation work,
and quality control/assurance work hereunder) to assist ABX in its exercise of
its rights to make or have made Licensed Products under this Agreement. Within
thirty (30) days following the Effective Date, the Parties shall each nominate
an equal number of representatives (which shall be no less than two (2)) for
membership on the JPDC. Each Party may change its representatives as it may deem
necessary by notice to the other Party. The input of the IMMUNOGEN
representatives on the JPDC shall be reasonably considered by the JPDC;
provided, however, that, all decisions of the JPDC shall be subject to the final
approval of ABX.
3.2 CHAIR OF COMMITTEE; MEETINGS. The chair of the JPDC shall be one of the
ABX representatives on the JPDC, as designated by ABX. All decisions of the JPDC
shall be subject to the approval of the ABX chair. The JPDC shall meet on a
semi-annual basis or other schedule agreed upon by the Parties, unless at least
thirty (30) days in advance of any meeting there is a determination by the Chair
of the JPDC that no new business or other activity
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
14
15
has transpired since the previous meeting, and that there is no need for a
meeting. In such instance, the next JPDC meeting shall also be scheduled as
agreed upon by the Parties. The location of such meetings shall alternate
between IMMUNOGEN's offices in the Cambridge, Massachusetts metropolitan area
and ABX's offices in the Fremont, California metropolitan area unless otherwise
agreed upon between the Parties. As agreed upon by the Parties, JPDC meetings
may be face-to-face meetings or may be conducted through teleconferences and/or
videoconferences. In addition to its JPDC representatives, each Party shall be
entitled to have such additional number (as the Parties mutually agree) of other
employees attend such meetings to present and participate, though not in a
decision-making capacity. Each Party shall bear all costs and expenses,
including travel and lodging expense, that may be incurred by its JPDC
representatives or other of its attendees at JPDC meetings. Minutes of each JPDC
meeting will be transcribed and issued to the members of the JPDC by the Chair
within thirty (30) days after each meeting and shall be reviewed and modified as
mutually required to obtain approval promptly thereafter.
3.3 SUPPLY OF PRECLINICAL MATERIALS. In the event that, during the Term of
this Agreement, ABX desires IMMUNOGEN to supply ABX with sufficient quantities
of Preclinical Materials to enable it to conduct pre-clinical development
activities relating to Licensed Products, ABX shall provide IMMUNOGEN with
written notice of same and the Parties shall negotiate in good faith and execute
a supply agreement providing for such supply. IMMUNOGEN shall deliver all
ordered amounts of Preclinical Materials in accordance with advance ordering
timeframes and delivery timeframes to be agreed upon by the Parties through such
mutually acceptable written supply agreement for such purpose. In connection
with any ordering of Preclinical Materials by ABX, IMMUNOGEN shall provide ABX
promptly with IMMUNOGEN's good faith estimate of the Fully Burdened
Manufacturing Cost for manufacture and supply of such Preclinical Materials.
IMMUNOGEN's price to supply Preclinical Materials to ABX shall equal [______] of
IMMUNOGEN's Fully Burdened Manufacturing Cost for such Preclinical Materials as
approved by ABX. Nothing herein shall preclude ABX from making its own
arrangements for manufacture and supply of Preclinical Materials on its own or
with Third Parties. ABX hereby agrees that (a) it shall not use the Preclinical
Materials in any human subject, and (b) it shall use the Preclinical Materials
in compliance with all applicable federal, state and local laws and regulations.
3.4 SUPPLY OF CLINICAL MATERIALS. In the event that, during the Term of
this Agreement, ABX desires IMMUNOGEN to supply to ABX with sufficient
quantities of Clinical Materials to enable it to conduct human clinical trials
of Licensed Products through the conclusion of Phase II Clinical Studies, ABX
shall provide IMMUNOGEN with written notice of same and the Parties shall
negotiate in good faith and execute a supply agreement providing for such
supply. IMMUNOGEN shall deliver all ordered amounts of Clinical Materials in
accordance with forecasting parameters, advance ordering timeframes and delivery
timeframes to be agreed upon by the Parties through such mutually acceptable
written supply agreement for such purpose. In connection with any ordering of
Clinical Materials by ABX, IMMUNOGEN shall provide ABX promptly with IMMUNOGEN's
good faith estimate of the Fully Burdened Manufacturing Cost for manufacture and
supply of such Clinical Materials. IMMUNOGEN's price to supply Clinical
Materials to ABX shall equal [___] of IMMUNOGEN's Fully Burdened
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
15
16
Manufacturing Cost for such Clinical Materials as approved by ABX. Nothing
herein shall preclude ABX from making its own arrangements for manufacture and
supply of Clinical Materials on its own or with Third Parties. ABX hereby agrees
that it shall use the Clinical Materials in compliance with all applicable
federal, state and local laws. IMMUNOGEN shall provide ABX with all information,
filings and assistance regarding manufacturing as reasonably requested by ABX in
connection with applications for Regulatory Approvals.
4. FINANCIAL TERMS
4.1 INITIAL FEES. ABX shall to pay to IMMUNOGEN a non-refundable fee in the
amount of [________] within [__________] after the Effective Date. Additionally,
ABX shall to pay to IMMUNOGEN a non-refundable fee in the amount of [________]
within [_____ _______]after [________________________________________________].
4.2 OPTION FEES. ABX agrees to pay to IMMUNOGEN an option fee (a) in the
amount of [______] for each Exclusive Option granted hereunder, (b) in the
amount of [_______] for each Nonexclusive Option granted hereunder and (c) in
the amount of [_____] for each conversion of a Nonexclusive Option into an
Exclusive Option in accordance with Section 2.2.6 hereof. Such fees shall be
paid on or before [_______] from the date of grant of such Exclusive Option or
Nonexclusive Option, or conversion of such Nonexclusive Option, as the case may
be.
4.3 OPTION EXTENSION FEES. ABX agrees to pay to IMMUNOGEN option extension
fees (a) in the amount of [______] for the extension of each option under
Section 2.1.3 hereof and (b) in the amount of [______] for the extension of each
option extension under Section 2.2.3 hereof. Such fees shall be paid on or
before [__________] after the date of each such extension.
5. TREATMENT OF CONFIDENTIAL INFORMATION
5.1 CONFIDENTIAL INFORMATION. During the Term of this Agreement, each Party
may disclose to the other Party confidential information, including but not
limited to IMMUNOGEN Background Technology, Research Inventions, Research Data
and Research Materials. Such information of the disclosing Party hereunder, if
so identified in writing by the disclosing Party to the receiving Party either
pursuant to this Section 5.1 or otherwise upon disclosure to the receiving
Party, shall be "Confidential Information" of the disclosing Party. During the
Term of this Agreement and during the term of any License Agreement, and for a
period of five (5) years thereafter, except as expressly permitted hereunder,
the receiving Party shall keep confidential all such Confidential Information of
the other Party and will not disclose such Confidential Information of the other
Party to Third Parties by publication or otherwise. Each Party further agrees
not to use Confidential Information of the other Party for any purpose other
than conducting research hereunder or exercising any rights granted to it or
reserved by it hereunder. Upon any termination or expiration of this Agreement,
upon request, a Party shall return to a requesting Party all copies of any of
such requesting Party's Confidential Information which is not the subject of a
License Agreement or the grant of a license hereunder, provided that
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
16
17
it may retain one copy for its legal files. Notwithstanding the foregoing, it is
understood and agreed that the receiving Party's obligations of confidentiality
and nonuse herein shall not apply to any information which:
(a) is, at the time of disclosure by the disclosing Party
hereunder, or thereafter becomes, a part of the public domain or publicly known
or available through no fault or negligence of the receiving Party or any of its
Affiliates; or
(b) was otherwise in the receiving Party's lawful possession
prior to disclosure by the disclosing Party, other than under an obligation of
confidentiality; or
(c) was independently discovered or developed by the receiving
Party or any of its Affiliates, without use of the other Party's Confidential
Information, as can be demonstrated by competent proof; or
(d) is lawfully disclosed to the receiving Party or any of its
Affiliates on a non-confidential basis by a third party who is not in violation
of an obligation of confidentiality to the disclosing Party relative to such
information.
Each Party may disclose information to the extent such disclosure is
reasonably necessary in (i) filing and prosecuting patent applications and
maintaining patents, or (ii) filing, prosecuting or defending litigation or
(iii) complying with applicable laws, regulations or court orders; provided,
however, that if a Party is required to make any such disclosure of the other
Party's Confidential Information or the terms of this Agreement, it will give
reasonable advance notice to the other Party of such disclosure requirement and
will use reasonable efforts to assist such other Party in efforts to secure
confidential treatment of such information required to be disclosed.
5.2 PUBLICITY. A Party may not use the name of the other Party in any
publicity or advertising and, except as provided in Section 5.1, may not issue a
press release or otherwise publicize or disclose any information related to this
Agreement or the terms or conditions hereof, without the prior written consent
of the other Party. The Parties shall mutually agree on a press release
announcing the execution of this Agreement. The Parties shall also be permitted
hereunder to disclose the general nature of this Agreement to the extent
reasonably necessary to obtain financing from Third Parties or potential
collaborators, and to make such other disclosures as mutually agreed by the
Parties. Once any written statement is approved for disclosure by both Parties,
either Party may make subsequent public disclosures of the contents of such
statement without the further approval of the other Party. Nothing in the
foregoing, however, shall prohibit a Party from making such disclosures to the
extent deemed necessary under applicable federal or state securities laws or any
rule or regulation of any nationally recognized securities exchange; provided,
that, in such event, the disclosing Party shall use good faith efforts to
consult with the other Party prior to such disclosure and, where applicable,
shall request confidential treatment to the extent available.
6. INTELLECTUAL PROPERTY RIGHTS
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
17
18
Except as otherwise expressly provided herein, all inventions and
discoveries governed by this Agreement shall be owned based on inventorship, as
inventorship is determined in accordance with United States patent law.
Notwithstanding anything to the contrary in this Agreement, Research Inventions,
Research Data, Research Materials and Research Patent Rights shall be solely
owned by ABX. Any inventions jointly invented by the Parties ("Joint
Inventions") shall be jointly owned, and any patent rights obtained thereon
shall be jointly owned by the Parties. The rights and interests of IMMUNOGEN and
ABX in Joint Inventions, and any patent rights obtained thereon, shall be
subject to the provisions of this Section 6. Each Party shall have the right,
subject to the terms of this Agreement and any License Agreement, to freely
exploit, transfer, license or encumber its rights and interests in Joint
Inventions, and any patent rights obtained thereon.
7. PROVISIONS CONCERNING THE FILING, PROSECUTION
AND MAINTENANCE OF PATENT RIGHTS
7.1 APPLICABILITY. The provisions of this Section 7 shall be applicable to
all patents covering IMMUNOGEN Background Technology and all Research Patent
Rights thereon unless and until they become subject to a License Agreement,
whereupon the License Agreement will govern the rights of the Parties with
respect to the subject matter thereof.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
18
19
7.2 PATENT FILING.
7.2.1 Subject to the License Agreements, IMMUNOGEN shall have the
obligation to prepare, file, prosecute, obtain and maintain patent applications
and patents covering IMMUNOGEN Background Technology, with the expenses for any
such preparation, filing, prosecution and maintenance to be borne by IMMUNOGEN.
7.2.2 ABX shall have the right (but not the obligation) to prepare,
file, prosecute, obtain and maintain patent applications and patents
constituting Research Patent Rights, with the expenses for any such preparation,
filing, prosecution and maintenance to be borne by ABX.
7.2.3 Subject to the License Agreements, as regards any joint
invention hereunder (other than Research Inventions, Research Data and Research
Materials), the Party from whom the majority of the data underlying any such
joint invention arose (the "controlling Party") will have the first right, but
not the obligation, to undertake filing(s), prosecution and maintenance of
inventorship certificate(s) and patent(s) thereon. In connection with any such
filing(s), the controlling Party will use patent counsel mutually acceptable to
each Party (in its reasonable determination) and the Parties will, prior to
filing of the patent application, agree on mutually acceptable sharing of the
costs and expenses of such filing(s), prosecution and maintenance. In any case
the controlling Party (i) will provide the non-controlling Party with a copy of
any such proposed patent application for review and comment reasonably in
advance of filing, and (ii) will keep the non-controlling Party reasonably
informed of the status of such filing, prosecution and maintenance, including,
without limitation, (A) by providing the non-controlling Party with copies of
all communications received from or filed in patent office(s) with respect to
such filing, and (B) by providing the non-controlling Party, a reasonable time
prior to taking or failing to take any action that would affect the scope or
validity of any such filing (including the substantially narrowing, cancellation
or abandonment of any claim(s) without retaining the right to pursue such
subject matter in a separate application, or the failure to file or perfect the
filing of any claim(s) in any country), with prior written notice of such
proposed action or inaction so that the non-controlling Party has a reasonable
opportunity to review and comment. If the controlling Party fails to undertake
the filing(s) of any such patent application with respect to any such invention
within ninety (90) days after receipt of written notice from the other Party
that the other Party believes filing(s) of such an application by such Party is
appropriate, the other Party may undertake such filing(s) at its own expense, in
which case the controlling Party will assign all of its rights to such joint
invention to the other Party and any subsequently issued patent thereon will be
owned solely by the other Party. Either Party, in its discretion, may assign its
rights hereunder to any jointly owned invention, inventorship certificate,
patent application or patent to the other Party, who will then have the right,
in its discretion, to assume the filing, prosecution and/or maintenance thereof
as the sole owner thereof and at its sole cost and expense.
7.2.4 Each Party agrees to cooperate reasonably with the other party
in the preparation, filing, and prosecution of any patent applications pursuant
to this Section 7.2. Such cooperation includes, but is not limited to, executing
all papers and instruments, or
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
19
20
requiring its employees or agents to execute such papers and instruments, so as
to effectuate the ownership of such patent applications and any patents thereon
and to enable the filing and prosecution of applications in any country.
7.3 INFRINGEMENT.
7.3.1 ABX shall have all rights, at its own expense, to bring suit (or
other appropriate legal action) against any actual or suspected infringement of
Research Patent Rights.
7.3.2 Subject to the License Agreements, IMMUNOGEN shall have all
rights, at its own expense, to bring suit (or other appropriate legal action)
against any actual or suspected infringement of patents covering IMMUNOGEN
Background Technology.
7.3.3 Subject to the License Agreements, in the event of the
infringement of any patent claiming any Joint Invention hereunder (other than
Research Inventions, Research Data and Research Materials), the parties shall
meet and in good faith discuss the appropriate course of action to enforce such
patent(s) and which Party shall control such action.
7.4 COOPERATION. Each Party shall give notice to the other party of any
potential infringement or actual infringement by a third party of any Research
Patent Right or patents covering IMMUNOGEN Background Technology and shall
execute all papers and perform such other acts (other than monetary) as may be
reasonably required to maintain any infringement suit brought in accordance with
Section 7.3 above (including giving legal consent for bringing such suit, and
agreeing to be named as a plaintiff or otherwise joined in such suit), and at
its option and expense, may be represented in such suit by counsel of its
choice. In addition, the Parties shall reasonably cooperate with each other in
obtaining patent term restoration or supplemental protection certificates or
their equivalents in any country in the Territory where applicable to Research
Patent Rights and IMMUNOGEN Background Technology.
7.5 NO OBLIGATION. No Party shall have any obligation to the other Party
under this Agreement to pay any fees or costs: (i) for that Party's bringing a
lawsuit or other action to enforce any of the Research Patent Rights, any
patents covering IMMUNOGEN Background Technology, or any other patent owned by a
Party against an actual or suspected infringement or (ii) for any other Party to
obtain for its own benefit independent business or legal advice concerning any
of the patent rights set forth in clause (i) hereof.
8. TERM AND TERMINATION
8.1 TERM. Unless earlier terminated as provided in this Section 8, the term
of this Agreement shall expire upon the expiration of the last to expire Option
(the "Term").
8.2 TERMINATION. This Agreement and the rights and options granted
herein may be terminated by either Party upon any material breach by the other
Party of any material
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
20
21
obligation or condition, effective [____________] after giving written notice to
the breaching Party of such termination in the case of a payment breach and
[____________] after giving written notice to the breaching Party of such
termination in the case of any other breach, which notice shall describe such
breach in reasonable detail. The foregoing notwithstanding, if such default or
breach is cured or shown to be non-existent within the aforesaid [______] or
[______ ____] period, the notice shall be automatically withdrawn and of no
effect. However, prior to giving any notice for breach, the Parties shall first
attempt to resolve any disputes as to the existence of any breach as set forth
in Section 9.14.
8.3 REMEDIES. If either Party shall fail to perform or observe or otherwise
breaches any of its material obligations under this Agreement, in addition to
any right to terminate this Agreement, the non-defaulting Party may elect to
obtain other relief and remedies available under law.
8.4 SURVIVING PROVISIONS. Notwithstanding any provision herein to the
contrary, the rights and obligations set forth in Sections 5, 6, 7, 8.3, 9.3,
9.4, 9.7, 9.14, 9.16, 9.17, 9.18 and 9.19 hereof shall survive the expiration or
termination of the Term of this Agreement.
9. MISCELLANEOUS
9.1 IMMUNOGEN REPRESENTATIONS. IMMUNOGEN represents and warrants to ABX
that: (a) the execution and delivery of this Agreement and the performance of
the transactions contemplated hereby have been duly authorized by all
appropriate IMMUNOGEN corporate action; (b) this Agreement is a legal and valid
obligation binding upon IMMUNOGEN and enforceable in accordance with its terms,
and the execution, delivery and performance of this Agreement by the Parties
does not conflict with any agreement, instrument or understanding to which
IMMUNOGEN is a party or by which it is bound; (c) IMMUNOGEN has the full right
and legal capacity to grant the rights to ABX pursuant to Section 2 above
without violating the rights of any third party; (d) IMMUNOGEN is the sole owner
or exclusive licensee of the IMMUNOGEN Background Technology; (e) IMMUNOGEN is
not aware of any Third Party patent, patent application or other intellectual
property rights that would be infringed (i) by practicing any process or method
or by making, using or selling any composition which is claimed or disclosed in,
or which constitutes, IMMUNOGEN Background Technology, or (ii) by making, using,
offering for sale, selling or importing Licensed Products; and (f) IMMUNOGEN is
not aware of any infringement or misappropriation by a Third Party of the
IMMUNOGEN Background Technology.
9.2 ABX REPRESENTATIONS. ABX represents and warrants to IMMUNOGEN that: (a)
the execution and delivery of this Agreement and the performance of the
transactions contemplated hereby have been duly authorized by all appropriate
ABX corporate action; (b) this Agreement is a legal and valid obligation binding
upon ABX and enforceable in accordance with its terms, and the execution,
delivery and performance of this Agreement by the Parties does not conflict with
any agreement, instrument or understanding to which ABX is a party of or by
which it is bound; and (c) ABX has the full right and legal capacity to grant
the rights to IMMUNOGEN pursuant to Section 2 above without violating the rights
of any Third Party.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
21
22
9.3 NO WARRANTIES.
9.3.1 Nothing in this Agreement is or shall be construed as:
(a) a warranty or representation by either Party as to the
validity or scope of any patent application or patent licensed hereunder;
(b) a warranty or representation that anything made, used, sold
or otherwise disposed of under any license granted pursuant to this Agreement is
or will be free from infringement of patents, copyrights, and other rights of
third parties.
9.3.2 Except as expressly set forth in this Agreement, NEITHER PARTY
MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS
OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE, OR OF NON-INFRINGEMENT OF ANY PATENT,
COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF THIRD PARTIES, OR ANY OTHER EXPRESS OR
IMPLIED WARRANTIES.
9.4 [________]. NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR
OTHERWISE, [_______________] WILL BE [___________________] TO [________________]
OF THIS AGREEMENT [_________________________________
_______________________________] OR [____________] OR [__________________] FOR
(I) [____________________________________________________________________] OR
[_____________] OR (II) [___________________________________________________
_____________________________].
9.5 NOTICES. Any notices, requests, deliveries, approvals or consents
required or permitted to be given under this Agreement to ABX or IMMUNOGEN shall
be in writing and shall be effective on receipt when delivered to the applicable
address specified below (or to such other address as may be specified in writing
to the other Party hereto):
If to IMMUNOGEN: IMMUNOGEN, Inc.
128 Sidney Street
Cambridge, MA 02139
Attn: Chief Executive Officer
With a copy to: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, MA 02111
Attn: Jeffrey M. Wiesen, Esq
Telecopy: 617-542-2241
If to ABX: Abgenix, Inc.
7601 Dumbarton Circle
Fremont, California 94555
Attn: President
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
22
23
With a copy to: Gray Cary Ware & Freidenrich LLP
4365 Executive Drive, Suite 1600
San Diego, California 92121-2189
Attn: Mark R. Wicker
9.6 GOVERNING LAW. This Agreement will be construed, interpreted and
applied in accordance with the laws of the Commonwealth of Massachusetts
(excluding its body of law controlling conflicts of law).
9.7 LIMITATIONS. Except as set forth elsewhere in this Agreement, neither
Party grants to the other Party any right or license to any of its intellectual
property.
9.8 ENTIRE AGREEMENT. This is the entire Agreement between the Parties with
respect to the subject matter hereof and supersedes all prior representations,
understandings and agreements between the Parties with respect to the subject
matter hereof. No modification shall be effective unless in writing with
specific reference to this Agreement and signed by the Parties.
9.9 WAIVER. The terms or conditions of this Agreement may be waived only by
a written instrument executed by the Party waiving compliance. The failure of
either Party at any time or times to require performance of any provision hereof
shall in no manner affect its rights at a later time to enforce the same. No
waiver by either Party of any condition or term shall be deemed as a continuing
waiver of such condition or term or of another condition or term.
9.10 HEADINGS. Section and subsection headings are inserted for convenience
of reference only and do not form part of this Agreement.
9.11 ASSIGNMENT. Neither this Agreement nor any right or obligation
hereunder may be assigned, delegated or otherwise transferred , in whole or
part, by either party without the prior express written consent of the other;
provided, however, that either party may, without the written consent of the
other, assign this Agreement and its rights and delegate its obligations
hereunder to its Affiliates, or in connection with the transfer or sale of all
or substantially all of such party's assets or business related to this
Agreement, or in the event of its merger, consolidation, change in control or
similar transaction. Any permitted assignee shall assume all obligations of its
assignor under this Agreement. Any purported assignment in violation of this
Section 9.11 shall be void. The terms and conditions of this Agreement shall be
binding upon and inure to the benefit of the permitted successors and assigns of
the parties.
9.12 FORCE MAJEURE. Neither Party shall be liable for failure of or delay
in performing obligations set forth in this Agreement, and neither shall be
deemed in breach of its obligations, if such failure or delay is due to natural
disasters or any causes beyond the reasonable control of such Party. In event of
such force majeure, the Party affected thereby shall use reasonable efforts to
cure or overcome the same and resume performance of its obligations hereunder.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
23
24
9.13 CONSTRUCTION. The Parties hereto acknowledge and agree that: (i) each
Party and its counsel reviewed and negotiated the terms and provisions of this
Agreement and have contributed to its revision; (ii) the rule of construction to
the effect that any ambiguities are resolved against the drafting Party shall
not be employed in the interpretation of this Agreement; and (iii) the terms and
provisions of this Agreement shall be construed fairly as to all Parties hereto
and not in favor of or against any Party, regardless of which Party was
generally responsible for the preparation of this Agreement.
9.14 DISPUTES.
9.14.1 The Parties recognize that a bona fide dispute as to certain
matters may from time to time arise during the term of this Agreement which
relates to either Party's rights and/or obligations hereunder. In the event of
the occurrence of such a dispute, either Party may, by written notice to the
other Party, have such dispute referred to their respective senior officials
designated below or their successors, for attempted resolution by good faith
negotiations within thirty (30) days after such notice is received. Said
designated senior officials are as follows:
For ABX: Chief Executive Officer
For IMMUNOGEN: Chief Executive Officer
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
24
25
In the event the designated senior officials are not able to resolve such
dispute within the thirty (30) day period, either Party may invoke the
provisions of Section 9.14.2.
9.14.2 Any dispute, controversy or claim initiated by either Party
arising out of, resulting from or relating to this Agreement, or the performance
by either Party of its obligations under this Agreement (other than bona fide
third party actions or proceedings filed or instituted in an action or
proceeding by a Third Party against a Party), whether before or after
termination of this Agreement, shall be finally resolved by binding arbitration.
Whenever a Party shall decide to institute arbitration proceedings, it shall
give written notice to that effect to the other Party. Any such arbitration
shall be conducted under the Commercial Arbitration Rules of the American
Arbitration Association by a panel of three arbitrators appointed in accordance
with such rules. Any such arbitration shall be held in Boston, Massachusetts if
initiated by ABX, and in San Francisco, California if initiated by IMMUNOGEN.
The method and manner of discovery in any such arbitration proceeding shall be
governed by California Code of Civil Procedure ss.1282 ET SEQ. (including
without limitation California Code of Civil Procedure ss.1283.05). The
arbitrators shall have the authority to grant specific performance and to
allocate between the parties the costs of arbitration in such equitable manner
as they determine. Judgment upon the award so rendered may be entered in any
court having jurisdiction or application may be made to such court for judicial
acceptance of any award and an order of enforcement, as the case may be. In no
event shall a demand for arbitration be made after the date when institution of
a legal or equitable proceeding based upon such claim, dispute or other matter
in question would be barred by the applicable statute of limitations.
Notwithstanding the foregoing, either Party shall have the right, without
waiving any right or remedy available to such Party under this Agreement or
otherwise, to seek and obtain from any court of competent jurisdiction any
interim or provisional relief that is necessary or desirable to protect the
rights or property of such Party, pending the selection of the arbitrators
hereunder or pending the arbitrators' determination of any dispute, controversy
or claim hereunder.
9.15 SEVERABILITY. If any provision(s) of this Agreement are or become
invalid, are ruled illegal by any court of competent jurisdiction or are deemed
unenforceable under then current applicable law from time to time in effect
during the Term hereof, it is the intention of
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
25
26
the Parties that the remainder of this Agreement shall not be affected thereby
provided that a Party's rights under this Agreement are not materially affected.
The Parties hereto covenant and agree to renegotiate any such term, covenant or
application thereof in good faith in order to provide a reasonably acceptable
alternative to the term, covenant or condition of this Agreement or the
application thereof that is invalid, illegal or unenforceable, it being the
intent of the Parties that the basic purposes of this Agreement are to be
effectuated.
9.16 STATUS. Nothing in this Agreement is intended or shall be deemed to
constitute a partner, agency, employer-employee, or joint venture relationship
between the Parties.
9.17 INDEMNIFICATION.
9.17.1 ABX INDEMNITY. ABX shall [________] and [_____________
_____________________] and [__________________________________], and [______]
and [______________________________](the "Indemnitees")
[____________________________ ____________________] (including
[______________________] and [_______________]) [_________] or
[_______________________], or [________], in connection with [_________
______________________________________], including, without limitation,
[____________ ________________] matters (but
[_________________________________________________ ______], which are
[______________________]), to the extent arising out of (i) [_________
______________] in the [______________________________________________________
__________________________________] of any [_________________________________
______________________________________] under this Agreement, (ii)
[_______________] of this Agreement [_____], or (iii)
[_____________________________] of the [__________], in any [_______] under this
Section 9.17.1 except to [_______________________________] therefor under
Section 9.17.2 below.
9.17.2 IMMUNOGEN INDEMNITY. Subject to Section 9.17.1 above,
IMMUNOGEN shall indemnify, defend and hold harmless ABX, its Affiliates and
their respective directors, officers, employees, and agents, and their
respective successors, heirs and assigns (also the "Indemnitees"), from and
against any liability, damage, loss or expense (including reasonable attorneys'
fees and expenses of litigation) incurred by or imposed upon such Indemnitees,
or any of them, in connection with any Third Party claims, suits, actions,
demands or judgments, including, without limitation, personal injury and product
liability matters (but excluding any patent, trademark or tradename infringement
matters, which are governed by Section 7 above), to the extent arising out of
(i) any actions or omissions of IMMUNOGEN or subcontractor of IMMUNOGEN in the
development, testing, production, manufacture or supply of any Licensed Product
(or any component thereof) manufactured and supplied by IMMUNOGEN or any
subcontractor of IMMUNOGEN under this Agreement, (ii) any material breach of
this Agreement by IMMUNOGEN, or (iii) gross negligence or willful misconduct on
the part of IMMUNOGEN.
9.18 INDEMNIFICATION PROCEDURES. In the event that any Indemnitee is
seeking indemnification under Section 9.17 above from a Party (the "Indemnifying
Party"), the other
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
26
27
Party shall notify the Indemnifying Party of such claim with respect to such
Indemnitee as soon as reasonably practicable after the Indemnitee receives
notice of the claim, and the Party (on behalf of itself and such Indemnitee)
shall permit the Indemnifying Party to assume direction and control of the
defense of the claim (including the right to settle the claim solely for
monetary consideration) and shall cooperate as requested (at the expense of the
Indemnifying Party) in the defense of the claim. The indemnification obligations
under Section 9.17 shall not apply to amounts paid in settlement of any claim,
demand, action or other proceeding if such settlement is effected without the
consent of the Indemnifying Party, which consent shall not be withheld or
delayed unreasonably. The Indemnitee, its employees and agents, shall reasonably
cooperate with the Indemnifying Party and its legal representatives in the
investigation of any claim, demand, action or other proceeding covered by
Section 9.17.
9.19 SECTION 365(n). All licenses granted under this Agreement are deemed
to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of
right to "intellectual property" as defined in Section 101 of such Code. The
Parties agree that the licensee may fully exercise all of its rights and
elections under the U.S. Bankruptcy Code, regardless of whether either Party
files for bankruptcy in the United States or other jurisdiction. The Parties
further agree that, in the event a licensee elects to retain its rights as a
licensee under such Code, the licensee shall be entitled to complete access to
any technology licensed to it hereunder and all embodiments of such technology.
Such embodiments of the technology shall be delivered to the licensee not later
than:
9.19.1 the commencement of bankruptcy proceedings against the
licensor, upon written request, unless the licensor elects to perform its
obligations under the Agreement, or
9.19.2 if not delivered under Section 9.19.1 above, upon the
rejection of this Agreement by or on behalf of the licensor, upon written
request.
9.20 FURTHER ASSURANCES. Each Party agrees to execute, acknowledge and
deliver such further instructions, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.
9.21 COUNTERPARTS. This Agreement may be executed simultaneously in one or
more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
27
28
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed
by their duly authorized representative in two (2) originals.
ABGENIX, INC. IMMUNOGEN, INC.
By: By:
---------------------------- -----------------------------
Title: Title:
-------------------------- --------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
28
29
SCHEDULE I
IMMUNOGEN BACKGROUND TECHNOLOGY
[____________________________]
_________________________________________________________________________________________________________________________________
Attorney Country Appl. No. Filing Date Priority Date Patent No. Issue Date Exp. Date
Reference No.
_________________________________________________________________________________________________________________________________
[________] [________] [________] [________] [________]
_________________________________________________________________________________________________________________________________
[________] [________]
[________] [________] [________] [________] [_______] [______]
_________________________________________________________________________________________________________________________________
[________] [________] [________] [________] [________] [______]
[________] [_______]
_________________________________________________________________________________________________________________________________
[________] [________] [________] [________] [________] [________] [______] [______]
_________________________________________________________________________________________________________________________________
[________]
_________________________________________________________________________________________________________________________________
[________] [________] [________] [________] [________] [________]
_________________________________________________________________________________________________________________________________
[________] [________] [________] [________] [________] [________]
_________________________________________________________________________________________________________________________________
[___________________________________________________________]
_________________________________________________________________________________________________________________________________
Attorney Country Appl. No. Filing Date Priority Date Patent No. Issue Date Exp. Date
Reference No.
_________________________________________________________________________________________________________________________________
[________] [________] [________] [________] [________]
_________________________________________________________________________________________________________________________________
[_____________________________]
_________________________________________________________________________________________________________________________________
Attorney Country Appl. No. Filing Date Priority Date Patent No. Issue Date Exp. Date
Reference No.
_________________________________________________________________________________________________________________________________
[________] [________] [________] [________] [________]
_________________________________________________________________________________________________________________________________
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
29
30
SCHEDULE II
[___________________________]
[____________________________________________________________________________
________________________________________________________].
[___________________________________________________].
___________________________________________________________________________________________________________________
[________] [________] [________]
___________________________________________________________________________________________________________________
___________________________________________________________________________________________________________________
[________________] [________] [________]
(a)________________________________________________________________________________________________________________
[________] [________] [________]
___________________________________________________________________________________________________________________
[________]
___________________________________________________________________________________________________________________
[________]
___________________________________________________________________________________________________________________
[________] [________] [________] (b)
___________________________________________________________________________________________________________________
[________] [________] [________](b)
___________________________________________________________________________________________________________________
[________] [________] [________](b)
___________________________________________________________________________________________________________________
[________] [________] [________]
___________________________________________________________________________________________________________________
[________] [________] [________]
___________________________________________________________________________________________________________________
[________] [________] [________]
___________________________________________________________________________________________________________________
[________]:
[________] (c) [________] [________]
and/or
___________________________________________________________________________________
___________________________________________________________________________________
[________] (c) [________]
[________] (d)
___________________________________________________________________________________________________________________
(a) [________]
(b) [________].
(c) [________].
(d) [________].
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
30
31
FORM OF EXCLUSIVE LICENSE AGREEMENT
This Exclusive License Agreement ("Agreement") is made effective as of as
of _________, 20__ (the "Effective Date") by and between IMMUNOGEN, INC., a
Massachusetts corporation with a principal place of business at 128 Sidney
Street, Cambridge, Massachusetts 02139 ("IMMUNOGEN"), and ABGENIX, INC., a
Delaware corporation with a place of business at 7601 Dumbarton Circle, Fremont,
California 94555 ("ABX"). IMMUNOGEN and ABX are each hereafter referred to
individually as a "Party" and together as the "Parties".
WHEREAS, ABX is the owner of or otherwise controls certain patents and
technology relating to antibodies; and
WHEREAS, IMMUNOGEN is the owner of or otherwise controls certain
proprietary patents and technology relating to or otherwise useful in the
conjugation of certain cytotoxic compounds such as DM1 (as hereinafter defined)
to antibodies; and
WHEREAS, ABX desires to obtain certain rights from IMMUNOGEN to develop and
commercialize one or more conjugates of certain cytotoxic compounds and
antibodies and IMMUNOGEN is willing to grant to ABX such rights on the terms
provided herein; and
WHEREAS, the Parties have heretofore executed an Option and License
Agreement (as hereinafter defined) pursuant to which IMMUNOGEN has granted ABX
certain options related to IMMUNOGEN's proprietary technology and know-how; and
WHEREAS, ABX has exercised an Option (as hereinafter defined) to obtain
such rights and, in connection therewith, desires to enter into this Agreement
in accordance with the terms of the Option and License Agreement.
NOW, THEREFORE, in consideration of the mutual covenants contained herein,
and for other good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the Parties hereby agree as follows:
1. DEFINITIONS
Whenever used in the Agreement with an initial capital letter, the terms
defined in this Section 1 shall have the meanings specified.
1.1 "ABX ANTIBODY" shall mean any antibody or fragment thereof directed to
the Target.
1.2 "ADVERSE EVENT" shall mean any serious adverse event or medical
occurrence in a patient or subject who is administered a Licensed Product,
whether or not
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
1
32
considered related to the Licensed Product, including, without limitation, any
undesirable sign (including abnormal laboratory findings of clinical concern),
symptom or disease temporally associated with the use of such Licensed Product.
1.3 "AFFILIATE" shall mean any corporation, firm, limited liability
company, partnership or other entity which directly controls or is controlled by
or is under common control with a Party to this Agreement. "Control" for
purposes of this Section 1.3 means ownership, directly or indirectly through one
or more Affiliates, of fifty percent (50%) or more of the shares of stock
entitled to vote for the election of directors, in the case of a corporation, or
fifty percent (50%) or more of the equity interests in the case of any other
type of legal entity, status as a general partner in any partnership, or any
other arrangement whereby a Party controls or has the right to control the Board
of Directors or equivalent governing body of a corporation or other entity.
1.4 "BLA" shall mean a biologics license application (as defined in Title
21 of the United States Code of Federal Regulations, as amended from time to
time) filed with the FDA seeking Regulatory Approval to market and sell any
Licensed Product in the United States for a particular indication within the
Field.
1.5 "CLINICAL MATERIALS" shall mean (a) supplies of ansamitocin P-3, DM1,
and/or any other May Compound as manufactured in accordance with all applicable
GMPs and other legal requirements and all applicable Specifications for such May
Compound for use in human clinical testing, and (b) supplies of any Licensed
Product as manufactured in accordance with all applicable GMPs and other legal
requirements and all applicable Specifications for such Licensed Product for use
in human clinical testing of any Licensed Product.
1.6 "COMBINATION PRODUCT" shall mean any Licensed Product that contains, in
addition to any conjugate of any ABX Antibody with any May Compound, one or more
other ingredients that has biologic activity.
1.7 "CONTROL" OR "CONTROLLED" shall mean (a) with respect to patents,
know-how or other intangible rights, the possession by Party of the ability to
grant a license or sublicense of such patent rights, know-how or other
intangible rights as provided for herein without violating the terms of any
arrangement or agreements between such Party and any Third Party and (b) with
respect to any material, the possession by a Party of the ability to use such
material as provided herein without violating the terms of any agreement between
such Party and any Third Party.
1.8 [________________] shall mean [_________________________], whether
[________________________________________________________], and shall include,
without limitation, [_____________________________________________], in each
case [_____________________________________]. [___________________] shall
include, without limitation, [________________].
1.9 "DEVELOPMENT" AND "DEVELOP" shall mean, with respect to any Licensed
Product, all activities with respect to such Licensed Product relating to
research, development
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
2
33
and seeking, obtaining and/or maintaining any Regulatory Approval for such
Licensed Product in the Field in the Territory, including without limitation,
all pre-clinical research and development activities, all human clinical
studies, all activities relating to developing the ability to manufacture any
Licensed Product or any component thereof (including, without limitation,
process development work), and all other activities relating to seeking,
obtaining and/or maintaining any Regulatory Approvals from the FDA and/or any
Foreign Regulatory Authority.
1.10 "DM1" shall mean that certain maytansine derivative having the
specific chemical name N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine.
1.11 "DRUG APPROVAL APPLICATION" shall mean any application for Regulatory
Approval (including pricing and reimbursement approvals) required prior to any
commercial sale or use of a Licensed Product in any country or jurisdiction in
the Territory, including, without limitation, (a) any BLA, NDA or other
regulatory application filed with the FDA required prior to any commercial sale
or use of a Licensed Product in the United States, and (b) any equivalent
application (including an MAA) filed with any Foreign Regulatory Authority for
Regulatory Approval (including pricing and reimbursement approvals) required
prior to any commercial sale or use of a Licensed Product in any country or
jurisdiction in the Territory.
1.12 "FDA" shall mean the United States Food and Drug Administration and
any successor agency or authority thereto.
1.13 "FIELD" shall mean any human medical use.
1.14 "FIRST COMMERCIAL SALE" shall mean the date of the first commercial
sale (other than for purposes of obtaining Regulatory Approval) of a Licensed
Product by or on behalf of ABX or an Affiliate or Sublicensee of ABX.
1.15 "FOREIGN REGULATORY AUTHORITIES" shall mean any applicable
supranational, national, federal, state or local regulatory agency, department,
bureau or other governmental entity of any country or jurisdiction in the
Territory (other than the FDA in the United States), having responsibility in
such country or jurisdiction for any Regulatory Approvals of any kind in such
country or jurisdiction, and any successor agency or authority thereto.
1.16 "FULLY BURDENED MANUFACTURING COST" shall mean, with respect to any
Preclinical Materials or Clinical Materials produced by IMMUNOGEN for ABX under
this Agreement, the sum of the following components as determined by IMMUNOGEN
in accordance with generally accepted accounting principles in the United
States, consistently applied, and consistent with the application given to other
goods produced by IMMUNOGEN: (a) the costs of goods produced, including, without
limitation, direct labor, material and product testing costs of such Preclinical
Materials or Clinical Materials; (b) any Third Party royalty costs that are
actually paid by IMMUNOGEN and are based solely and directly on the manufacture
and sale to ABX of such Preclinical Materials or Clinical Materials; (c) all
overhead costs incurred by IMMUNOGEN directly and solely attributable to the
cost of goods under clause (a) above, including, without limitation, supervisory
services, occupancy costs, payroll, information
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
3
34
systems, human relations, purchasing, accounts receivable or accounts payable
functions, and other general and administrative functions; and (d) any other
costs borne by IMMUNOGEN directly and solely for the transport, customs
clearance, duty and/or insurance for such Preclinical Materials or Clinical
Materials to ABX hereunder.
1.17 "GMPS" shall mean all good manufacturing practices under Title 21 of
the United States Code of Federal Regulations, as amended from time to time.
1.18 "IMMUNOGEN BACKGROUND TECHNOLOGY" shall mean all inventions,
discoveries, patent rights, trade secrets and know-how, including without
limitation, laboratory scientific information and procedural techniques,
Controlled by IMMUNOGEN during the term of the Option and License Agreement or
the Term of this Agreement that are necessary or useful for ABX to research,
develop, make, have made, use, have used, sell, offer for sale, have sold,
import or have imported Licensed Products (or any component thereof, including
any linker) for use in the Field; provided, however, that IMMUNOGEN Background
Technology shall expressly exclude any Target Specific Rights.
1.19 "IND" shall mean an investigational new drug application (as defined
in Title 21 of the United States Code of Federal Regulation, as amended from
time to time) filed or to be filed with the FDA with regard to any Licensed
Product.
1.20 "IND ACCEPTANCE" shall mean the expiration of thirty (30) days
following receipt by ABX of a notice from the FDA to ABX that the FDA has
received an IND for a Licensed Product filed by ABX for the purpose of obtaining
approval or authority to commence human clinical trials in the United States
with such Licensed Product; provided, however, that if the FDA puts a clinical
hold on the IND during such thirty (30) day period, the term "IND Acceptance"
shall mean that date during the term of this Agreement when ABX receives written
confirmation from the FDA that the clinical hold has been removed and that ABX
has the approval or authority to commence human clinical trials of such Licensed
Product under such IND in the United States. Notwithstanding anything set forth
herein, "IND Acceptance" shall not have occurred in any circumstances where ABX
withdraws any IND filed with the FDA for a Licensed Product at any time prior to
the commencement of human clinical trials with such Licensed Product in the
United States.
1.21 "INDEMNITEES" AND "INDEMNIFYING PARTY" shall have the meanings set
forth in Section 9.
1.22 "JPDC" shall have the meaning set forth in Section 3.4.1.
1.23 "LICENSED PATENT RIGHTS" shall mean all Patent Rights covering
IMMUNOGEN Background Technology. All Licensed Patent Rights as of the Effective
Date are listed on Schedule I attached hereto.
1.24 "LICENSED PRODUCT" shall mean any product containing any conjugate of
any ABX Antibody with any May Compound, and shall include, without limitation,
any formulation thereof (including, without limitation, any lyophilized, liquid,
sustained release or
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
4
35
aerosolized formulation). "Licensed Product" shall also include any and all
Combination Products (if any).
1.25 "MAA" shall mean an application filed with the relevant Foreign
Regulatory Authorities in Europe seeking Regulatory Approval to market and sell
any Licensed Product in Europe or any country or territory therein for a
particular indication within the Field.
1.26 "MAY COMPOUND" shall mean any and all maytansinoid compounds
(including, without limitation, maytansine, ansamitocin P-3 and DM1), whether
produced by a botanical source, natural fermentation or chemical synthesis, and
shall include, without limitation, all variants, fragments or derivatives of any
of the foregoing, in each case owned or otherwise Controlled by IMMUNOGEN. May
Compounds shall include, without limitation, DM1.
1.27 "NDA" shall mean a new drug application (as defined in Title 21 of the
United States Code of Federal Regulations, as amended from time to time) filed
with the FDA seeking Regulatory Approval to market and sell any Licensed Product
in the United States for a particular indication within the Field.
1.28 "NET SALES" shall mean, as to each calendar quarter during the Term,
the gross invoiced sales prices charged for all Licensed Products sold by ABX,
its Affiliates or its Sublicensees to Third Parties throughout the Territory
during such calendar quarter, less the following amounts incurred or paid by ABX
or its Affiliates or Sublicensees during such calendar quarter with respect to
sales of Licensed Products regardless of the calendar quarter in which such
sales were made:
1.28.1 trade, cash and quantity discounts or rebates actually allowed
or taken, including discounts or rebates to governmental or managed care
organizations;
1.28.2 credits or allowances actually given or made for rejection of
or return of, and for uncollectible amounts on, previously sold Licensed
Products or for retroactive price reductions (including Medicare and similar
types of rebates);
1.28.3 any charges for insurance, freight, and other transportation
costs directly related to the delivery of Licensed Product to the extent
included in the gross invoiced sales price;
1.28.4 any tax, tariff, duty or governmental charge levied on the
sales, transfer, transportation or delivery of a Licensed Product (including any
tax such as a value added or similar tax or government charge) borne by the
seller thereof, other than franchise or income tax of any kind whatsoever; and
1.28.5 any import or export duties or their equivalent borne by the
seller. "Net Sales" shall not include sales or transfers between ABX and its
Affiliates or Sublicensees, unless the Licensed Product is consumed by the
Affiliate or Sublicensee.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
5
36
1.29 "OPTION" shall have the meaning set forth in the Option and License
Agreement.
1.30 "OPTION AND LICENSE AGREEMENT" shall mean that certain Option and
License Agreement dated as of September 5, 2000, by and between IMMUNOGEN and
ABX.
1.31 "PATENT RIGHTS" shall mean the rights and interests in and to any and
all issued patents and pending patent applications (including inventor's
certificates and utility models) in any country or jurisdiction in the
Territory, including any and all provisionals, non-provisionals, substitutions,
continuations, continuations-in-part, divisionals and other continuing
applications, supplementary protection certificates, renewals, all letters
patent on any of the foregoing, and any and all reissues, reexaminations,
extensions, confirmations, registrations and patents of addition on any of the
foregoing.
1.32 "PHASE II CLINICAL STUDY" shall mean, as to a particular Licensed
Product for a particular indication, a controlled and lawful study in humans of
the safety, dose ranging and efficacy of such Licensed Product for such
indication, which is prospectively designed to generate sufficient data (if
successful) to commence a Phase III Clinical Trial of such Licensed Product for
such indication.
1.33 "PHASE III CLINICAL TRIAL" shall mean, as to a particular Licensed
Product for a particular indication, a controlled and lawful study in humans of
the safety and efficacy of such Licensed Product for such indication, which is
prospectively designed to demonstrate statistically whether such Licensed
Product is safe and effective for use in such indication in a manner sufficient
to file a BLA or NDA to obtain Regulatory Approval to market and sell that
Licensed Product in the United States for the indication under investigation in
such study.
1.34 "PRECLINICAL MATERIALS" shall mean (a) supplies of ansamitocin P-3,
DM1 and/or any other May Compound as manufactured in accordance with all
applicable legal requirements and all applicable Specifications for such May
Compound for use in preclinical testing, and (b) supplies of any Licensed
Product as manufactured in accordance with all applicable legal requirements and
all applicable Specifications for such Licensed Product for use in preclinical
testing of any Licensed Product.
1.35 "REGULATORY APPROVAL" shall mean any and all approvals (including
pricing and reimbursement approvals), product and establishment licenses,
registrations or authorizations of any kind of the FDA or its foreign equivalent
necessary for the development, pre-clinical and/or human clinical testing,
manufacture, quality testing, supply, use, storage, importation, export,
transport, marketing and sale of a Licensed Product (or any component thereof)
for use in the Field in any country or other jurisdiction in the Territory.
1.36 "SPECIFICATIONS" shall mean any specifications specified by ABX and
reasonably acceptable to IMMUNOGEN relating to the manufacturing and supply of
any May Compound and/or Licensed Product hereunder.
1.37 "SUBLICENSEE" shall have the meaning set forth in Section 2.1.1(b).
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
6
37
1.38 "TARGET" shall mean _________________________.
1.39 "TARGET SPECIFIC RIGHTS" shall mean all inventions, discoveries,
patent rights, trade secrets and know-how, including without limitation,
laboratory scientific information and procedural techniques, Controlled by
IMMUNOGEN during the term of the Option and License Agreement or the Term of
this Agreement constituting (a) the composition of matter or use of the Target,
(b) the composition of matter or use of an antibody binding to the Target, or
(c) the composition of matter or use of a conjugate of an antibody binding to
the Target with a May Compound.
1.40 "TECHNOLOGY" shall mean and include any and all unpatented proprietary
ideas, inventions, discoveries, Confidential Information, materials, data,
results, formulae, designs, specifications, methods, processes, formulations,
techniques, ideas, know-how, technical information (including, without
limitation, structural and functional information), process information,
pre-clinical information, clinical information, and any and all proprietary
biological, chemical, pharmacological, toxicological, pre-clinical, clinical,
assay, control and manufacturing data and materials.
1.41 "TERM" shall mean the period commencing on the Effective Date and
continuing until the expiration or termination of this Agreement in accordance
with the terms hereof (including Section 7).
1.42 "TERRITORY" shall mean all countries and jurisdictions of the world.
1.43 "THIRD PARTY" shall mean any person or entity other than ABX,
IMMUNOGEN and their respective Affiliates.
1.44 "THIRD PARTY PAYMENTS" shall have the meaning set forth in Section
4.3.2.
1.45 "VALID CLAIM" shall mean a claim in an issued, unexpired patent within
the Licensed Patent Rights that (i) has not been finally cancelled, withdrawn,
abandoned or rejected by any administrative agency or other body of competent
jurisdiction, and (ii) has not been revoked, held invalid, or declared
unpatentable or unenforceable in a decision of a court or other body of
competent jurisdiction that is unappealable or unappealed within the time
allowed for appeal, and (iii) has not been rendered unenforceable through
disclaimer or otherwise, and (iv) is not lost through an interference
proceeding.
2. GRANT OF RIGHTS
2.1 LICENSE GRANT.
2.1.1 LICENSE TO ABX.
(a) IMMUNOGEN hereby grants to ABX an exclusive (even
as to IMMUNOGEN) license within the Territory, including the right to grant
sublicenses as described in Section 2.2 below, under the Licensed Patent Rights
and IMMUNOGEN
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
7
38
Background Technology to research, develop, make, have made, use, have used,
sell, offer for sale, have sold, import and have imported Licensed Products, for
any and all uses within the Field, subject to the other terms and conditions of
this Agreement. Promptly, but not less than quarterly, IMMUNOGEN shall deliver
to ABX all IMMUNOGEN Background Technology not previously delivered to ABX.
(b) ABX shall have the right freely to grant
sublicenses to all or any portion of its rights under the license granted
pursuant to Section 2.1.1 hereof to any Affiliate or Third Party (in any case, a
"Sublicensee"); provided, however, that ABX shall remain obligated for payment
of royalty and milestone obligations as set forth in Section 4.
(c) [_____________________________] or [_______] to
[________________], or otherwise [______________________] concerning, a
[_____________ __________] to the [__________].
2.1.2 LICENSE TO IMMUNOGEN.
(a) To the extent legally possible, [______] hereby
[_________ __________] a [____________________________________________________
_______________________], if any, in any [_____________________________________]
to the [_____________________] to or [____________] of the [____________] that
are [______ ________________] of this Agreement, [__________] to the
[__________] to [______________ ______________________] and [____________] to
[__________________________________ __________] to [________] and/or
[_________________] and/or [__________(____________] to a [________________] or
a [____________], each as defined in the Option and License Agreement).
(b) Such [______] to [_________] includes the
[__________ ________] to [___________] from [_____________________________
_____________________________] to the [________] they [_____________] or
[___________] of the [____________ _____] to [______________] with the
[_________] to [_______________] hereunder, and [_____________________________]
to [________________________]. Notwithstanding the foregoing, the
[______________________________] pursuant to this Section 2.1.2 [_________
_________________] of [__________] to [__________________] (as defined in the
Option and License Agreement).
2.2 IMMUNOGEN RETAINED RIGHTS; ABX TECHNOLOGY OR PATENT RIGHTS.
2.2.1 RETAINED RIGHTS. Subject to the other terms of this
Agreement and the Option and License Agreement, IMMUNOGEN retains the right to
use the IMMUNOGEN Background Technology and practice the Licensed Patent Rights
(i) to perform its work under Sections 3.3, 3.4, 3.5 and 3.6 hereof relating to
the JPDC and to manufacture and supply of Preclinical Materials and Clinical
Materials for ABX (and its Sublicensees), and (ii) to research, develop, make,
have made, use, have used, sell, offer for sale, have sold, import and have
imported any product that is not a Licensed Product.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
8
39
2.2.2 NO RIGHTS TO ABX TECHNOLOGY OR PATENT RIGHTS. Except
as otherwise expressly set forth in Section 2.1.2, nothing in this Agreement
shall be construed as a grant to IMMUNOGEN of any license or other rights with
respect to any Technology (including, without limitation, any Confidential
Information) or Patent Rights owned or Controlled (in whole or in part) by ABX.
2.3 IN LICENSES. IMMUNOGEN represents and warrants to ABX that it
has provided ABX true and correct copies of all agreements pursuant to which
Licensed Patent Rights or IMMUNOGEN Background Technology, existing as of the
Effective Date, is licensed to or otherwise acquired by IMMUNOGEN from a Third
Party. IMMUNOGEN promptly shall provide ABX with true and correct copies of all
agreements pursuant to which Licensed Patent Rights or IMMUNOGEN Background
Technology, licensed or acquired after the Effective Date, is licensed to or
otherwise acquired by IMMUNOGEN from a Third Party; provided, however, that
IMMUNOGEN shall have the right to redact confidential financial information and
any provisions that shall not bind ABX. To the extent the Licensed Patent Rights
or IMMUNOGEN Background Technology are licensed to or acquired by IMMUNOGEN from
a Third Party and are reasonably necessary to permit ABX to exercise its rights
granted hereunder, IMMUNOGEN shall use reasonable commercial efforts to maintain
in full force and effect such license. In the event of the termination of any
such license with a Third Party, IMMUNOGEN shall cause such Third Party to grant
a direct license to ABX to the extent necessary to permit ABX to exercise its
rights granted hereunder, and all sums owing by ABX to such Third Party shall be
fully deducted from any amounts owing to IMMUNOGEN hereunder.
3. DEVELOPMENT AND COMMERCIALIZATION OF LICENSED PRODUCTS.
3.1 DEVELOPMENT AND COMMERCIALIZATION.
3.1.1 RESPONSIBILITY. On and after the Effective Date, ABX shall have
full control and authority over all Development and commercialization of
Licensed Products in the Field in the Territory, including, without limitation,
(i) all pre-clinical Development activities (including any pharmaceutical
development work on formulations or process development relating to any Licensed
Product), (ii) all activities related to human clinical trials (including any
phase I studies, any Phase II Clinical Studies or any Phase III Clinical
Trials), (iii) all activities relating to manufacture and supply of all ABX
Antibodies, all May Compounds (including ansamitocin P-3 and DM1) and all
Licensed Products, solely to the extent such activities relate to the
Development and commercialization of Licensed Products (including all required
process development and scale up work with respect thereto), (iv) all marketing,
promotion, sales, distribution, import and export activities relating to any
Licensed Product (including any post-marketing trials or databases and
post-marketing safety surveillance), and (v) all activities relating to any
regulatory filings, registrations, applications and Regulatory Approvals
relating to any of the foregoing (including any INDs or foreign equivalents, any
manufacturing facility validation and/or licensure, any Drug Approval
Applications and any other Regulatory Approvals). Except as described in the
next sentence, ABX shall own all data, results and all other information arising
from any such activities under this Agreement, including, without limitation,
all regulatory filings, registrations, applications and Regulatory Approvals
relating to
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
9
40
Licensed Products (including any INDs or foreign equivalents, any Drug Approval
Applications and any other Regulatory Approvals), and all of the foregoing
information, documentation and materials shall be considered Confidential
Information and Technology solely owned by ABX. IMMUNOGEN shall own all data,
results and all other information arising from IMMUNOGEN's activities directly
regarding the manufacture and supply of May Compounds to ABX (other than
activities undertaken at the request of ABX), and all of the foregoing
information, documentation and materials shall be considered Confidential
Information and Technology solely owned by IMMUNOGEN. All activities relating to
Development and commercialization by or on behalf of ABX under this Agreement
shall be undertaken at ABX's sole cost and expense, except as otherwise
expressly provided in this Agreement.
3.1.2 DILIGENCE. ABX will exercise its commercially reasonable efforts
and diligence in Developing and commercializing Licensed Products in accordance
with its business, legal, medical and scientific judgment, and in undertaking
investigations and actions required to obtain appropriate Regulatory Approvals
necessary to market Licensed Products in the Field in the Territory, such
reasonable efforts and diligence to be in accordance with the efforts and
resources ABX would use for a compound owned by it or to which it has rights,
which is of similar market potential at a similar stage in development as the
applicable Licensed Product, taking into account the competitiveness of the
marketplace, the proprietary position of the Licensed Product, the relative
potential safety and efficacy of the Licensed Product, the regulatory
requirements involved in its Development, commercialization and Regulatory
Approval, the cost of goods and availability of capacity to manufacture and
supply the Licensed Product at commercial scale, the profitability of the
applicable Licensed Product, and other relevant factors including, without
limitation, technical, legal, scientific or medical factors. In the event that
[_______________] its [___________] to [___________________________], then on a
Licensed Product-by-Licensed Product basis as to the Licensed Product [_________
___________________________________________________________________________,
___________________________] shall be, in its [___________], (i) to
[__________________ _________________] of this Agreement [____________________
___________] (including the [________] and [______] therein) or (ii) to
[_______________________________] of this Agreement from [____________________
________], in either case [____] as [__________] apply to [_____________], which
[_________] or [__________], as the case may be, shall [_______________________
___________________________________________] provided that [___ ________]
remains [___________________________].
3.2 UPDATES AND REPORTS; EXCHANGES OF ADVERSE EVENT INFORMATION.
3.2.1 UPDATES AND REPORTS. ABX (or its Sublicensee) shall provide
IMMUNOGEN with brief written reports no less frequently than on [___________] of
the [________________ (______________] with the [____________] of the
[____________]) summarizing ABX's material efforts to Develop and commercialize
all Licensed Products hereunder, identify the Drug Approval Applications with
respect to any Licensed Product that ABX and its Sublicensees have filed, sought
or obtained in the prior [______________] period, and any they reasonably expect
to make, seek or attempt to obtain in the following [__________ ____] period. In
addition, ABX (or its Sublicensee) shall provide IMMUNOGEN with prompt written
notice of the occurrence of any event giving rise to an obligation to make a
milestone
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
10
41
payment to IMMUNOGEN under Section 4.2, and shall provide IMMUNOGEN with prompt
written notice of the occurrence of the First Commercial Sale of any particular
Licensed Product.
3.2.2 ADVERSE EVENTS. In addition to such reports, ABX agrees to
provide IMMUNOGEN with Adverse Event information relating to Licensed Products
(but not relating to any other products of ABX) as compiled by ABX in the normal
course of business in connection with the Development, commercialization or sale
of any Licensed Product, within time frames consistent with IMMUNOGEN's
reporting obligations under applicable laws and regulations. IMMUNOGEN agrees to
provide ABX with Adverse Event information relating to any product containing
any May Compound (but not any other products of IMMUNOGEN or such Third Party)
that is compiled by IMMUNOGEN or any Third Party in the normal course of
business in connection with the development, commercialization or sale of any
such product, within time frames consistent with ABX's reporting obligations
under applicable laws and regulations.
3.2.3 CONFIDENTIAL INFORMATION. All reports, updates, Adverse Event
and other information provided by one Party to the other Party under this
Agreement (including under this Section 3), shall be considered Confidential
Information of the disclosing Party, subject to the terms of Section 5.
3.3 TECHNICAL ASSISTANCE BY IMMUNOGEN. In connection with the exclusive
grant of rights to ABX under Section 2.1 above, and subject to the other terms
of this Agreement, IMMUNOGEN shall provide ABX such information and materials
comprising the IMMUNOGEN Background Technology and/or Licensed Patent Rights as
ABX may reasonably request. Without limiting the generality of the foregoing,
IMMUNOGEN shall provide all of such technical assistance within IMMUNOGEN's area
of expertise concerning the Development and commercialization of Licensed
Products as may be reasonably requested by ABX from time to time during the
Term, provided that such technical assistance and expertise is within the scope
of the IMMUNOGEN Background Technology and/or Licensed Patent Rights covered
under this Agreement. Such technical assistance and expertise shall include, but
not be limited to, visits by IMMUNOGEN personnel to ABX and visits by ABX
personnel to IMMUNOGEN, at ABX's expense, at such times and for such periods of
time as may be reasonably acceptable to the Parties. Additionally, at the
reasonable request of ABX, IMMUNOGEN shall transfer all applicable IMMUNOGEN
Background Technology, and provide such technical assistance, to such Third
Party collaborator, sublicensee or contract manufacturer as ABX designates.
3.4 JOINT PROCESS DEVELOPMENT COMMITTEE.
3.4.1 MANDATE AND ESTABLISHMENT OF COMMITTEE. The Joint Process
Development Committee ("JPDC") formed pursuant to the Option and License
Agreement, shall serve as a forum for coordination and communication between the
Parties with respect to Development (to the extent ABX requests the assistance
or services of IMMUNOGEN) of manufacturing processes applicable to any May
Compound or Licensed Product covered by this Agreement (including, without
limitation, all process science and process development work, formulation work,
and quality control/assurance work hereunder), to assist ABX in its exercise of
its rights to make or have made Licensed Products under this Agreement. The
input of the
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
11
42
IMMUNOGEN representatives on the JPDC shall be reasonably considered by the
JPDC; provided, however, that, all decisions of the JPDC shall be subject to the
final approval of ABX.
3.4.2 CHAIR OF COMMITTEE; MEETINGS. The chair of the JPDC shall be one
of the ABX representatives on the JPDC, as designated by ABX. All decisions of
the JPDC shall be subject to the approval of ABX. The JPDC shall meet on a
semi-annual basis or other schedule agreed upon by the Parties, unless at least
thirty (30) days in advance of any meeting there is a determination by the Chair
of the JPDC that no new business or other activity has transpired since the
previous meeting, and that there is no need for a meeting. In such instance, the
next JPDC meeting shall also be scheduled as agreed upon by the Parties. The
location of such meetings shall alternate between IMMUNOGEN's offices in the
Cambridge, Massachusetts metropolitan area and ABX's offices in the Fremont,
California metropolitan area unless otherwise agreed upon between the Parties.
As agreed upon by the Parties, JPDC meetings may be face-to-face meetings or may
be conducted through teleconferences and/or videoconferences. In addition to its
JPDC representatives, each Party shall be entitled to have such additional
number (as the Parties mutually agree) of other employees attend such meetings
to present and participate, though not in a decision-making capacity. Each Party
shall bear all costs and expenses, including travel and lodging expense, that
may be incurred by its JPDC representatives or other of its attendees at JPDC
meetings. Minutes of each JPDC meeting will be transcribed and issued to the
members of the JPDC by the Chair within thirty (30) days after each meeting and
shall be reviewed and modified as mutually required to obtain approval promptly
thereafter.
3.5 SUPPLY OF PRECLINICAL MATERIALS. In the event that, during the Term of
this Agreement, ABX desires IMMUNOGEN to supply ABX with quantities of
Preclinical Materials in order to conduct all pre-clinical Development
activities relating to Licensed Products, ABX shall provide IMMUNOGEN with
written notice of same and the Parties shall negotiate in good faith and execute
a supply agreement providing for such supply. IMMUNOGEN shall deliver all
ordered amounts in accordance with advance ordering timeframes and delivery
timeframes to be agreed upon by the Parties through such mutually acceptable
written supply agreement for such purpose. In connection with any ordering of
Preclinical Materials by ABX, IMMUNOGEN shall provide ABX promptly with
IMMUNOGEN's good faith estimate of the Fully Burdened Manufacturing Cost for
manufacture and supply of such Preclinical Materials. IMMUNOGEN's price to
supply Preclinical Materials to ABX shall equal [_____] of IMMUNOGEN's Fully
Burdened Manufacturing Cost for such Preclinical Materials as approved by ABX.
Nothing herein shall preclude ABX from making its own arrangements for
manufacture and supply of Preclinical Materials on its own or with Third
Parties. ABX hereby agrees that (a) it shall not use the Preclinical Materials
in any human subject, and (b) it shall use the Preclinical Materials in
compliance with all applicable federal, state and local laws and regulations.
3.6 SUPPLY OF CLINICAL MATERIALS. In the event that, during the Term of
this Agreement, IMMUNOGEN desires to supply ABX with quantities of Clinical
Materials in order to conduct all human clinical trials of Licensed Products
through the conclusion of Phase II Clinical Studies, ABX shall provide IMMUNOGEN
with written notice of same and the Parties shall negotiate in good faith and
execute a supply agreement providing for such supply. IMMUNOGEN shall deliver
all ordered amounts in accordance with forecasting parameters,
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
12
43
advance ordering timeframes and delivery timeframes to be agreed upon by the
Parties such mutually acceptable written supply agreement for such purpose. In
connection with any ordering of Clinical Materials by ABX, IMMUNOGEN shall
provide ABX promptly with IMMUNOGEN's good faith estimate of the Fully Burdened
Manufacturing Cost for manufacture and supply of such Clinical Materials.
IMMUNOGEN's price to supply Clinical Materials to ABX shall equal [_______] of
IMMUNOGEN's Fully Burdened Manufacturing Cost for such Clinical Materials as
approved by ABX. Nothing herein shall preclude ABX from making its own
arrangements for manufacture and supply of Clinical Materials on its own or with
Third Parties. ABX hereby agrees that it shall use the Clinical Materials in
compliance with all applicable federal, state and local laws. IMMUNOGEN shall
provide ABX with all information, filings and assistance regarding manufacturing
as reasonably requested by ABX in connection with applications for Regulatory
Approvals.
4. PAYMENTS AND ROYALTIES
4.1 LICENSE FEE. Within thirty (30) days after the Effective Date, ABX
shall pay to IMMUNOGEN the nonrefundable, noncreditable license fee of [________
___________].
4.2 MILESTONE PAYMENTS FOR LICENSED PRODUCTS.
4.2.1 MILESTONES. ABX will make the following nonrefundable,
noncreditable payments to IMMUNOGEN within thirty (30) days after the first
achievement of each of the milestones set forth below:
MILESTONE MILESTONE PAYMENT
--------- -----------------
(a) [__________________________] [________________]
(b) [__________________________] [________________]
(c) [__________________________] [________________]
(d) [__________________________] [________________]
(e) [__________________________] [________________]
(f) [__________________________] [________________]
(g) [__________________________] [________________]
4.2.2 If the milestone described in [__________], is [___________
__________] of the milestone described in [________________], then [__________
_______] to IMMUNOGEN hereunder of the milestone payment described in
[_______________], [_______ ____________________________________________] of the
milestone payment described in [_________________].
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
13
44
4.2.3 It is hereby acknowledged and agreed that any milestone payment
shall be made only once, with respect to the first achievement of the relevant
milestone for the first Licensed Product, regardless of how many times such
milestones are achieved by Licensed Products and regardless of how many times a
particular Licensed Product achieves such milestones. ABX shall notify IMMUNOGEN
of the achievement of milestones hereunder as provided in Section 3.2.1 above.
4.3 PAYMENT OF ROYALTIES; ROYALTY RATES; ACCOUNTING FOR ROYALTIES AND
RECORDS.
4.3.1 ROYALTY PAYMENTS.
(a) In consideration of the grant of the license by IMMUNOGEN
hereunder, and subject to the other terms of this Agreement (including the
remainder of this Section 4), commencing on the first date of First Commercial
Sale of each Licensed Product in such country or jurisdiction in the Territory,
ABX shall pay to IMMUNOGEN the following royalties based on total Net Sales of
each Licensed Product sold by ABX and/or its Affiliates, on an incremental basis
in each calendar year during the Term, at the following rates:
For Net Sales of Licensed Product Royalty Rate
in any Calendar Year During the Term: (% of Net Sales)
------------------------------------ ----------------
[__________________________________________________________]
[__________________________________________________________]
(b) In consideration of the grant of the license by IMMUNOGEN
hereunder, and subject to the other terms of this Agreement (including the
remainder of this Section 4), commencing on the first date of First Commercial
Sale of each Licensed Product in such country or jurisdiction in the Territory,
ABX shall pay to IMMUNOGEN the following royalties based on total Net Sales of
each Licensed Product sold by each Sublicensee, on an incremental basis in each
calendar year during the Term, at a rate equal to [____________________________
_________________________________________________] in consideration for the
grant of the sublicense under the Licensed Patents and IMMUNOGEN Background
Technology; provided, however, that the royalty rate under this Section 4.3.1(b)
for any royalty period shall not be (i) less than [__________________________
______________________________] or (ii) more than [___________________________]
4.3.2 [______________________]. Notwithstanding anything set forth in
Section 4.3.1 above, [___________] set forth therein shall apply, [___________
__________________________________________], to [__________] of [_____________
_________________________] or [______________________] would, [_______________
___________________ _____________________________________________________]
(excluding any [_________ _________________________________________________]).
Subject to the other terms of this
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
14
45
Agreement, [_______________________________________________________] where and
as of when [______________] under Section 4.3.1 [___________________] this
Section 4.3.2, [_____________________________] a [___________________________
_______] set forth in Section 4.3.1 for [______________] of [_______________].
4.3.3 [____________]. In the event that in any royalty period,
[_____], in order to [_______________________________________] of this
Agreement, [____ _______], is [_____________________________________] to
[____________ ("_________________]") (a) to [____________] to
[__________________] in the [__________] the [_________________] of a
[__________________________________________________________________] and/or (b)
to [_____________] to [_____________________________] to the [__________________
__] to [_____________________] to [________], in the [_______________] the
[_______________] to [____________________] to [______________________] as part
of a [________________________________] (as [_________], to the [______________
_______________], by [___________________ _______]), then [_________] the [____]
to [_______________________________________________________________________] for
[___________________] by [_______________________] of [______________].
Notwithstanding the foregoing, such [____________________________________] for
[_____________] in [__________________] to [________________________] of
[____________________] in [_______________].
4.3.4 [__________________]. In determining [_______] of any
[_________________] under this Agreement, [________] shall first [_______] in
accordance with the definition of "Net Sales" above, then [________] by
[___________] of the [________________________] in the [________________],
[__________________________________________________________________] of the
[______________________________________] of the [______________]. The
[_______________] of the [_________________] shall be for a [_______] to that
[_____________________________________] and [___________________________.] When
[___________________] is [___________] for the [___________________] shall
[___________] a [________________________] for the [______________________] the
[_____________________________________] as are then [___________] to all
[_______________________________________] and having an [__________________];
provided, however, that if [______________________________________________], the
Parties shall [__________ _____________] to [__________________________] and a
[______________________________________________].
4.4 ONE ROYALTY. Only one royalty, calculated at the highest applicable
royalty rate under this Section 4, shall be payable to IMMUNOGEN hereunder for
each sale of a Licensed Product.
4.5 ROYALTY TERM. ABX shall pay royalties with respect to each Licensed
Product on a country-by-country and Licensed Product-by-Licensed Product basis
until [ ______ __] (a) the [_______________________] of [_______________] of
[__________] that [_______
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
15
46
________________] or (b) [________________________] of the [___________________
_____] of [_________________________]. Following such royalty term, ABX shall
have a fully paid-up, irrevocable, freely transferable and sublicensable license
in such country under the relevant Licensed Patent Rights and IMMUNOGEN
Background Technology, to research, develop, make, have made, use, have used,
sell, offer for sale, have sold, import and have imported Licensed Products for
any and all uses within the Field in such country.
4.6 PAYMENT TERMS.
4.6.1 PAYMENT OF MILESTONES; PAYMENT OF ROYALTIES; ROYALTY REPORTS.
ABX shall make any milestone payments owed to IMMUNOGEN hereunder in United
States Dollars, using the wire transfer provisions of this Section 4.6. ABX
shall make any royalty payments owed to IMMUNOGEN in United States Dollars,
[______________________ ______] the [_______________________] for which
[________________] (as provided in the next sentence), using the wire transfer
provisions of this Section 4.6. For purposes of determining when a sale of any
Licensed Product occurs under this Agreement, royalties shall accrue on the date
of the invoice to the purchaser of the Licensed Product. Each royalty payment
[_________________________________________________] in which [_____________
______________] in the [_________________________________], specifying: the
[_______] (if available) and [_____] in [_________________]; the [_____________]
under this Agreement; the[__________________________________], including an
[________________ ______________] in the [__________________]; the [__________
_______] to [_______] from [__________________] to [_______________] under this
Section 4.6; and the [_____________ _________________].
4.6.2 FOREIGN CURRENCY EXCHANGE. All royalties shall be payable in
full in the United States in United States Dollars, regardless of the countries
in which sales are made. For the purpose of computing Net Sales for Licensed
Products sold in any currency other than United States Dollars, the quarterly
royalty payment will be calculated as follows:
(A/B) x C = United States Dollars royalty payment on foreign current
sales, where
A = foreign "Net Sales" (as defined above) per quarter;
B = foreign exchange conversion rate, expressed in local currency per
United States Dollar (using as the applicable foreign exchange rate
the rate published in the western edition of THE WALL STREET JOURNAL,
under the heading "Money Rates," or any other mutually agreed upon
source, for the last business day of the calendar quarter); and
C = the royalty rate applicable to such Net Sales under this
Agreement.
4.6.3 TAX WITHHOLDING; RESTRICTIONS ON PAYMENT. All payments hereunder
shall be made free and clear of any taxes, duties, levies, fees or charges,
except for withholding taxes (to the extent applicable). ABX shall make any
applicable withholding payments due on behalf of IMMUNOGEN and shall promptly
provide IMMUNOGEN with such written documentation of any such payment as
available to ABX relating to an application by IMMUNOGEN for a foreign tax
credit for such payment with the United States Internal Revenue Service. If by
law, regulations or fiscal policy of a particular country in the Territory,
remittance of royalties in United States Dollars is restricted or forbidden,
written notice thereof shall
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
16
47
promptly be given to IMMUNOGEN, and payment of the royalty shall be made by the
deposit thereof in local currency to the credit of IMMUNOGEN in a recognized
banking institution reasonably designated by IMMUNOGEN by written notice to ABX.
When in any country in the Territory the law or regulations prohibit both the
transmittal and the deposit of royalties on sales in such country, royalty
payments shall be suspended for as long as such prohibition is in effect and as
soon as such prohibition ceases to be in effect, all royalties that ABX would
have been under an obligation to transmit or deposit but for the prohibition
shall forthwith be deposited or transmitted, to the extent allowable.
4.6.4 WIRE TRANSFERS. All payments hereunder shall be made to
IMMUNOGEN by bank wire transfer in immediately available funds to the account
designated by IMMUNOGEN by written notice to ABX from time to time.
4.7 RECORDS RETENTION; REVIEW.
4.7.1 ROYALTIES. Commencing as of the date of First Commercial Sale of
the first Licensed Product, ABX and its Sublicensees shall keep for at least
[_________] from the end of the calendar year to which they pertain complete and
accurate records of sales by ABX or its Sublicensees, as the case may be, of
each Licensed Product, in sufficient detail to allow the accuracy of the
royalties to be confirmed.
4.7.2 FULLY BURDENED MANUFACTURING COSTS. Commencing as of the
Effective Date, IMMUNOGEN shall keep for at least [________] following the end
of the calendar year to which they pertain complete and accurate records of all
of IMMUNOGEN's Fully Burdened Manufacturing Costs for Preclinical Materials and
Clinical Materials supplied to ABX (or its Sublicensee) hereunder, in sufficient
detail to allow the accuracy of the Fully Burdened Manufacturing Costs to be
confirmed.
4.7.3 REVIEW. Subject to the other terms of this Section 4.7.3, at the
request of either Party, upon at least thirty (30) days' prior written notice
from the requesting Party, and at the expense of the requesting Party (except as
otherwise provided herein), the other Party shall permit an independent
certified public accountant of nationally recognized standing reasonably
selected by the requesting Party and reasonably acceptable to the other Party to
inspect (during regular business hours) the relevant records required to be
maintained by the other Party under this Section 4.7. At IMMUNOGEN's request
(which shall not be made more frequently than once per year during the Term),
the accountant shall be entitled to review the then-preceding [_______] of ABX's
records under this Section 4.7 for purposes of verifying ABX's royalty
calculations. At ABX's request (which shall not be made more frequently than
once per year during the Term), the accountant shall be entitled to review the
then-preceding [_________] of IMMUNOGEN's records under this Section 4.7 for
purposes of verifying IMMUNOGEN's Fully Burdened Manufacturing Cost
calculations. In every case the accountant must have previously entered into a
confidentiality agreement with both Parties substantially similar to the
provisions of Section 5 and limiting the disclosure and use of such information
by such accountant to authorized representatives of the Parties and the purposes
germane to this Section 4.7. Such accountant shall report to the Parties only
whether or not such calculations are correct and the amount of any discrepancy.
No other information shall be shared. Results of any
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
17
48
such review shall be binding on both Parties absent manifest error. Each Party
agrees to treat the results of any such accountant's review of the other Party's
records under this Section 4.7 as Confidential Information of the other Party
subject to the terms of Section 5. If any review reveals a deficiency in the
calculation of royalties resulting from any underpayment by ABX, ABX shall
promptly pay IMMUNOGEN the amount remaining to be paid, and if such underpayment
is by [______________] or more, ABX shall pay the reasonable out-of-pocket costs
and expenses of the review. If any review reveals a deficiency in the
calculation of Fully Burdened Manufacturing Costs resulting from any overpayment
by ABX, IMMUNOGEN shall promptly refund ABX the amount of any such overpayment,
and if such overpayment is by [___ ___________] or more, IMMUNOGEN shall pay the
reasonable out-of-pocket costs and expenses of the review.
5. TREATMENT OF CONFIDENTIAL INFORMATION
5.1 CONFIDENTIAL INFORMATION. During the Term of this Agreement, each Party
may disclose to the other Party confidential information, including but not
limited to IMMUNOGEN Background Technology, Research Inventions, Research Data
and Research Materials. Such information of the disclosing Party hereunder, if
so identified in writing by the disclosing Party to the receiving Party either
pursuant to this Section 5.1 or otherwise upon disclosure to the receiving
Party, shall be "Confidential Information" of the disclosing Party. During the
Term of this Agreement and during the term of any License Agreement, and for a
period of five (5) years thereafter, except as expressly permitted hereunder,
the receiving Party shall keep confidential all such Confidential Information of
the other Party and will not disclose such Confidential Information of the other
Party to Third Parties by publication or otherwise. Each Party further agrees
not to use Confidential Information of the other Party for any purpose other
than conducting research hereunder or exercising any rights granted to it or
reserved by it hereunder. Upon any termination or expiration of this Agreement,
upon request, a Party shall return to a requesting Party all copies of any of
such requesting Party's Confidential Information which is not the subject of a
License Agreement or the grant of a license hereunder, provided that it may
retain one copy for its legal files. Notwithstanding the foregoing, it is
understood and agreed that the receiving Party's obligations of confidentiality
and nonuse herein shall not apply to any information which:
(a) is, at the time of disclosure by the disclosing Party
hereunder, or thereafter becomes, a part of the public domain or publicly known
or available through no fault or negligence of the receiving Party or any of its
Affiliates; or
(b) was otherwise in the receiving Party's lawful possession
prior to disclosure by the disclosing Party, other than under an obligation of
confidentiality; or
(c) was independently discovered or developed by the
receiving Party or any of its Affiliates, without use of the other Party's
Confidential Information, as can be demonstrated by competent proof; or
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
18
49
(d) is lawfully disclosed to the receiving Party or any of
its Affiliates on a non-confidential basis by a third party who is not in
violation of an obligation of confidentiality to the disclosing Party relative
to such information.
Each Party may disclose information to the extent such disclosure is
reasonably necessary in (i) filing and prosecuting patent applications and
maintaining patents, or (ii) filing, prosecuting or defending litigation or
(iii) complying with applicable laws, regulations or court orders; provided,
however, that if a Party is required to make any such disclosure of the other
Party's Confidential Information or the terms of this Agreement, it will give
reasonable advance notice to the other Party of such disclosure requirement and
will use reasonable efforts to assist such other Party in efforts to secure
confidential treatment of such information required to be disclosed.
5.2 PUBLICITY. A Party may not use the name of the other Party in any
publicity or advertising and, except as provided in Section 5.1, may not issue a
press release or otherwise publicize or disclose any information related to the
other Party's activities under this Agreement or the terms or conditions hereof,
without the prior written consent of the other Party. Prior to execution of this
Agreement, the parties have agreed upon the substance of information that can be
used to describe the terms and conditions of this Agreement, and each party may
disclose such information, as modified by mutual written agreement the parties,
without the consent of the other party. Once any written statement is approved
for disclosure by both Parties, either Party may make subsequent public
disclosures of the contents of such statement without the further approval of
the other Party. Nothing in the foregoing, however, shall prohibit a Party from
making such disclosures to the extent deemed necessary under applicable federal
or state securities laws or any rule or regulation of any nationally recognized
securities exchange; PROVIDED, HOWEVER, that such party shall provide written
notice thereof to the other party, consult with the other party with respect to
such disclosure and provide the other party sufficient opportunity to comment on
or object to any such disclosure or to request confidential treatment thereof.
6. PROVISIONS CONCERNING THE FILING, PROSECUTION AND
MAINTENANCE OF PATENT RIGHTS
6.1 PATENT FILING, PROSECUTION AND MAINTENANCE. Subject to the other terms
of this Section 6.1, IMMUNOGEN shall have the right to prepare, file, prosecute,
obtain and maintain, at its sole cost and expense, all Licensed Patent Rights.
Any such preparation, filing, prosecution and maintenance shall be conducted
with commercially reasonable diligence by IMMUNOGEN, using patent counsel
selected by IMMUNOGEN and reasonably acceptable to ABX. IMMUNOGEN (i) will
provide ABX with a copy of any proposed patent application within Licensed
Patent Rights for review and comment reasonably in advance of filing (which
shall under no circumstances be in excess of thirty (30) days), and (ii) will
keep ABX reasonably informed of the status of such filing, prosecution and
maintenance, including, without limitation, (A) by providing ABX with copies of
all communications received from or filed in patent office(s) with respect to
such filing, and (B) by providing ABX, a reasonable time prior to taking or
failing to take any action that would affect the scope or validity of any such
of any such filing (including the substantially narrowing, cancellation or
abandonment of any claim(s) without
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
19
50
retaining the right to pursue such subject matter in a separate application, or
the failure to file or perfect the filing of any claim(s) in any country), with
prior written notice of such proposed action or inaction so that ABX has a
reasonable opportunity to review and comment. [____ ____________] for
[__________] of [____________________________________________ ______] with
respect to [________________] shall be [_____________________________
_________]. If IMMUNOGEN fails to undertake the filing(s) of any patent
application or submission with respect to any invention under such Licensed
Patent Rights, then not less than ninety (90) days prior to the last date for
making the applicable filing or submission to preserve rights under such patent
application, ABX may undertake such filing(s) at its own expense, in which case
IMMUNOGEN will assign to ABX all of its rights to such patent application and
invention and any subsequently issued patent thereon, each of which thereafter
will be owned solely by ABX.
6.2 NOTICE OF INFRINGEMENT. If, during the Term of this Agreement, either
Party learns of any actual, alleged or threatened infringement by a Third Party
of any Licensed Patent Rights under this Agreement, such Party shall promptly
notify the other Party and shall provide such other Party with available
evidence of such infringement.
6.3 INFRINGEMENT OF PATENT RIGHTS. IMMUNOGEN shall have the first right
(but not the obligation), at its own expense and with legal counsel of its own
choice, to bring suit (or take other appropriate legal action) against any
actual, alleged or threatened infringement of the Licensed Patent Rights caused
by the research, development, manufacture, use, offer for sale, sale or import
of Licensed Products. ABX shall have the right, at its own expense, to be
represented in any such action by IMMUNOGEN by counsel of ABX's own choice;
provided, however, that under no circumstances shall the foregoing affect the
right of IMMUNOGEN to control the suit as described in the first sentence of
this Section 6.3. If IMMUNOGEN does not file any action or proceeding against
such infringement within one hundred twenty (120) days after the later of (i)
IMMUNOGEN's notice to ABX under Section 6.2 above, (ii) ABX's notice to
IMMUNOGEN under Section 6.2 above, or (iii) a written request from ABX to take
action with respect to such infringement, then ABX shall have the right (but not
the obligation), at its own expense, to bring suit (or take other appropriate
legal action) against such actual, alleged or threatened infringement, with
legal counsel of its own choice. Any damages, monetary awards or other amounts
recovered, whether by judgment or settlement, pursuant to any suit, proceeding
or other legal action taken under this Section 6.3, shall applied as follows:
6.3.1 First, to reimburse the Parties for their respective costs and
expenses (including reasonable attorneys' fees and costs) incurred in
prosecuting such enforcement action;
6.3.2 Second, [_________________________________] associated with
[_________________] and to [__________________________________________________]
based on [_______________];
6.3.3 Third, any amounts remaining shall be allocated as follows: (a)
if IMMUNOGEN is the Party bringing such suit or proceeding or taking such other
legal action, [_________________________], (b) if ABX is the Party bringing such
suit or proceeding or
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
20
51
taking such other legal action, [________________________] and (c) if the suit
is brought jointly, [____________________].
If a Party brings any such action or proceeding hereunder, the other Party
agrees to be joined as party plaintiff if necessary to prosecute such action or
proceeding, and to give the Party bringing such action or proceeding reasonable
assistance and authority to file and prosecute the suit; provided, however, that
neither Party shall be required to transfer any right, title or interest in or
to any property to the other Party or any Third Party to confer standing on a
Party hereunder.
6.4 THIRD PARTY PATENTS. If any Third Party claims that a patent it owns or
controls claims any aspect of a Licensed Product or its manufacture, use or
sale, the Party with notice of such claim shall notify the other Party promptly,
and the Parties shall as soon as practicable thereafter discuss in good faith
regarding a response.
6.5 TRADEMARKS. All Licensed Products shall be sold under one (1) or more
trademarks and tradenames selected by ABX (or its Sublicensee) in the Territory.
IMMUNOGEN shall notify ABX promptly upon learning of any actual, alleged or
threatened infringement of a trademark or tradename applicable to a Licensed
Product in the Territory, or of any unfair trade practices, trade dress
imitation, passing off of counterfeit goods, or like offenses in the Territory.
All of the costs, expenses and legal fees in bringing, maintaining and
prosecuting any action to maintain, protect or defend any trademarks or
tradenames owned by ABX (or its Sublicensee) hereunder, and any damages or other
recovery, shall be ABX's (or its Sublicensee's) sole responsibility, and taken
in its sole discretion.
7. TERM AND TERMINATION
7.1 TERM; EXPIRATION. The term of this Agreement shall expire upon the
expiration of the final royalty payment obligation under Section 4.5 above. Upon
such expiration of the Term of this Agreement, ABX shall have a fully paid-up,
irrevocable, freely transferable and sublicensable license in such country under
the relevant Licensed Patent Rights and IMMUNOGEN Background Technology, to
research, develop, make, have made, use, have used, sell, offer for sale, have
sold, import and have imported Licensed Products, for any and all uses within
the Field in the Territory.
7.2 TERMINATION. Subject to the other terms of this Agreement:
7.2.1 BREACH. This Agreement and the rights and options granted herein
may be terminated by either Party upon any material breach by the other Party of
any material obligation or condition, effective [____________] after giving
written notice to the breaching Party of such termination in the case of a
payment breach and [_____________] after giving written notice to the breaching
Party of such termination in the case of any other breach, which notice shall
describe such breach in reasonable detail. The foregoing notwithstanding, if
such default or breach is cured or shown to be non-existent within the aforesaid
[______] or [_____ _______] period, the notice shall be automatically withdrawn
and of no effect. However, prior to giving any notice for breach, the Parties
shall first attempt to resolve any disputes as to the existence of any breach as
set forth in Section 8.14.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
21
52
7.2.2 UNILATERAL TERMINATION BY ABX. ABX, in its sole discretion, at
any time may terminate this Agreement, and the rights and obligations hereunder,
or may remove any Licensed Product and the licenses related thereto from
operation of this Agreement, in any case effective [______________] after
written notice thereof to IMMUNOGEN. In the event of any termination under this
Section 7.2.2 only as to a Licensed Product, the consequences set forth in
Section 7.3 below relating to termination of the Agreement under this Section
7.2.2 shall apply only with respect to such terminated Licensed Product, and
this Agreement and the rights and obligations hereunder shall continue in full
force and effect as to any and all other Licensed Products.
7.3 EFFECTS OF TERMINATION.
7.3.1 Upon any termination of this Agreement by IMMUNOGEN under
Section 7.2.1 or by ABX under Section 7.2.2, as of the effective date of such
termination, all relevant licenses and sublicenses granted by IMMUNOGEN to ABX
hereunder shall terminate automatically. Notwithstanding the foregoing, (a) no
such termination of this Agreement shall be construed as a termination of any
valid sublicense of any Sublicensee hereunder, and thereafter each such
Sublicensee shall be considered a direct licensee of IMMUNOGEN, provided that
(i) such Sublicensee is then in full compliance with all terms and conditions of
its sublicense, (ii) all accrued payments obligations to IMMUNOGEN have been
paid, and (iii) such Sublicensee agrees in writing to assume all applicable
obligations of ABX under this Agreement, and (b) ABX and its Sublicensees shall
have the right, [_________________] or such longer time period (if any) on which
the Parties mutually agree in writing, to sell or otherwise dispose of all
Licensed Products then on hand, with royalties to be paid to IMMUNOGEN on all
Net Sales of such Licensed Products as provided for in this Agreement. Nothing
set forth in this Section 7 or any other provision of this Agreement shall
entitle IMMUNOGEN to any ownership interest in, or to any license under or other
rights with respect to (including any rights to use or request any transfer to
IMMUNOGEN or any Third Party), any Confidential Information of ABX or any
Technology or Patent Rights owned by ABX under this Agreement.
7.3.2 Upon any termination of this Agreement by ABX under Section
7.2.1, as of the effective date of such termination, ABX thereafter
automatically shall have a fully sublicensable, fully paid up (subject to the
remainder of this Section 7.3.2), exclusive license in the Territory under the
Licensed Patent Rights and IMMUNOGEN Background Technology, to research,
develop, make, have made, use, have used, sell, offer for sale, have sold,
import and have imported Licensed Products, for any and all uses within the
Field in the Territory, provided that ABX shall pay, for the remainder of the
royalty term under Section 4.5 above, in lieu of any payments including
milestones or royalties it would otherwise owe to IMMUNOGEN under this
Agreement, a royalty equal to [____________________________________________]
with respect to the Licensed Product under Section 4 of this Agreement.
7.4 REMEDIES. Except as otherwise expressly set forth in this Agreement,
the termination provisions of this Section 7 are in addition to any other relief
and remedies available to either Party at law.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
22
53
7.5 SURVIVING PROVISIONS. Notwithstanding any provision herein to the
contrary, the rights and obligations of the Parties set forth in Sections 4.7,
5, 6, 7.3, 7.4, 8.3, 8.4, 8.7, 8.14, 8.16, 8.17, 8.18 and 8.19 hereof, as well
as any rights or obligations otherwise accrued hereunder (including any accrued
payment obligations), shall survive the expiration or termination of the Term of
this Agreement. Without limiting the generality of the foregoing, ABX shall have
no obligation to make any milestone or royalty payment to IMMUNOGEN that has not
accrued prior to the effective date of any termination of this Agreement, but
shall remain liable for all such payment obligations accruing prior to the
effective date of such termination.
8. MISCELLANEOUS
8.1 IMMUNOGEN REPRESENTATIONS. IMMUNOGEN represents and warrants to ABX
that: (a) the execution and delivery of this Agreement and the performance of
the transactions contemplated hereby have been duly authorized by all
appropriate IMMUNOGEN corporate action; (b) this Agreement is a legal and valid
obligation binding upon IMMUNOGEN and enforceable in accordance with its terms,
and the execution, delivery and performance of this Agreement by the Parties
does not conflict with any agreement, instrument or understanding to which
IMMUNOGEN is a party or by which it is bound; (c) IMMUNOGEN has the full right
and legal capacity to grant the rights to ABX pursuant to Section 2 above
without violating the rights of any Third Party; (d) IMMUNOGEN is the sole owner
or exclusive licensee of the IMMUNOGEN Background Technology; (e) IMMUNOGEN is
not aware of any Third Party patent, patent application or other intellectual
property rights that would be infringed (i) by practicing any process or method
or by making, using or selling any composition which is claimed or disclosed in,
or which constitutes, IMMUNOGEN Background Technology, or (ii) by making, using,
offering for sale, selling or importing Licensed Products; and (f) IMMUNOGEN is
not aware of any infringement or misappropriation by a Third Party of the
IMMUNOGEN Background Technology.
8.2 ABX REPRESENTATIONS. ABX represents and warrants to IMMUNOGEN that: (a)
the execution and delivery of this Agreement and the performance of the
transactions contemplated hereby have been duly authorized by all appropriate
ABX corporate action; (b) this Agreement is a legal and valid obligation binding
upon ABX and enforceable in accordance with its terms, and the execution,
delivery and performance of this Agreement by the Parties does not conflict with
any agreement, instrument or understanding to which ABX is a party of or by
which it is bound; and (c) ABX has the full right and legal capacity to grant
the rights to IMMUNOGEN pursuant to Section 2 above without violating the rights
of any Third Party.
8.3 NO WARRANTIES.
8.3.1 Nothing in this Agreement is or shall be construed as:
(a) a warranty or representation by either Party as to the
validity or scope of any patent application or patent licensed hereunder;
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
23
54
(b) a warranty or representation that anything made, used, sold
or otherwise disposed of under any license granted pursuant to this Agreement is
or will be free from infringement of patents, copyrights, and other rights of
third parties.
8.3.2 Except as expressly set forth in this Agreement, NEITHER PARTY
MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS
OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE, OR OF NON-INFRINGEMENT OF ANY PATENT,
COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF THIRD PARTIES, OR ANY OTHER EXPRESS OR
IMPLIED WARRANTIES.
8.4 [_____________] NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT, OR
OTHERWISE, [_____________________________________________] TO [_______________
__________] OF THIS AGREEMENT [_______________________________________________
_______________________________________________] FOR (I) [____________________
_____________________________________________________ _________] OR (II)
[____________________________________________________________________________].
8.5 NOTICES. Any notices, requests, deliveries, approvals or consents
required or permitted to be given under this Agreement to ABX or IMMUNOGEN shall
be in writing and shall be effective on receipt when delivered to the applicable
address specified below (or to such other address as may be specified in writing
to the other Party hereto):
If to IMMUNOGEN: IMMUNOGEN, Inc.
128 Sidney Street
Cambridge, MA 02139
Attn: Chief Executive Officer
With a copy to: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, MA 02111
Attn: Jeffrey M. Wiesen, Esq
Telecopy: 617-542-2241
If to ABX: Abgenix, Inc.
7601 Dumbarton Circle
Fremont, California 94555
Attn: President
With a copy to: Gray Cary Ware & Freidenrich LLP
4365 Executive Drive, Suite 1600
San Diego, California 92121-2189
Attn: Mark R. Wicker
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
24
55
8.6 GOVERNING LAW. This Agreement will be construed, interpreted and
applied in accordance with the laws of the Commonwealth of Massachusetts
(excluding its body of law controlling conflicts of law).
8.7 LIMITATIONS. Except as set forth elsewhere in this Agreement, neither
Party grants to the other Party any right or license to any of its intellectual
property.
8.8 ENTIRE AGREEMENT. This is the entire Agreement between the Parties with
respect to the subject matter hereof and supersedes all prior representations,
understandings and agreements between the Parties with respect to the subject
matter hereof. No modification shall be effective unless in writing with
specific reference to this Agreement and signed by the Parties.
8.9 WAIVER. The terms or conditions of this Agreement may be waived only by
a written instrument executed by the Party waiving compliance. The failure of
either Party at any time or times to require performance of any provision hereof
shall in no manner affect its rights at a later time to enforce the same. No
waiver by either Party of any condition or term shall be deemed as a continuing
waiver of such condition or term or of another condition or term.
8.10 HEADINGS. Section and subsection headings are inserted for convenience
of reference only and do not form part of this Agreement.
8.11 ASSIGNMENT. Neither this Agreement nor any right or obligation
hereunder may be assigned, delegated or otherwise transferred , in whole or
part, by either party without the prior express written consent of the other;
provided, however, that either party may, without the written consent of the
other, assign this Agreement and its rights and delegate its obligations
hereunder to its Affiliates, or in connection with the transfer or sale of all
or substantially all of such party's assets or business related to this
Agreement, or in the event of its merger, consolidation, change in control or
similar transaction. Any permitted assignee shall assume all obligations of its
assignor under this Agreement. Any purported assignment in violation of this
Section 8.11 shall be void. The terms and conditions of this Agreement shall be
binding upon and inure to the benefit of the permitted successors and assigns of
the parties.
8.12 FORCE MAJEURE. Neither Party shall be liable for failure of or delay
in performing obligations set forth in this Agreement, and neither shall be
deemed in breach of its obligations, if such failure or delay is due to natural
disasters or any causes beyond the reasonable control of such Party. In event of
such force majeure, the Party affected thereby shall use reasonable efforts to
cure or overcome the same and resume performance of its obligations hereunder.
8.13 CONSTRUCTION. The Parties hereto acknowledge and agree that: (i) each
Party and its counsel reviewed and negotiated the terms and provisions of this
Agreement and have contributed to its revision; (ii) the rule of construction to
the effect that any ambiguities are resolved against the drafting Party shall
not be employed in the interpretation of this Agreement; and (iii) the terms and
provisions of this Agreement shall be construed fairly as to all Parties hereto
and not in favor of or against any Party, regardless of which Party was
generally responsible for the preparation of this Agreement.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
25
56
8.14 DISPUTES.
8.14.1 The Parties recognize that a bona fide dispute as to certain
matters may from time to time arise during the term of this Agreement which
relates to either Party's rights and/or obligations hereunder. In the event of
the occurrence of such a dispute, either Party may, by written notice to the
other Party, have such dispute referred to their respective senior officials
designated below or their successors, for attempted resolution by good faith
negotiations within thirty (30) days after such notice is received. Said
designated senior officials are as follows:
For ABX: Chief Executive Officer
For IMMUNOGEN: Chief Executive Officer
In the event the designated senior officials are not able to resolve such
dispute within the thirty (30) day period, either Party may invoke the
provisions of Section 8.14.2.
8.14.2 Any dispute, controversy or claim initiated by either Party
arising out of, resulting from or relating to this Agreement, or the performance
by either Party of its obligations under this Agreement (other than bona fide
third party actions or proceedings filed or instituted in an action or
proceeding by a Third Party against a Party), whether before or after
termination of this Agreement, shall be finally resolved by binding arbitration.
Whenever a Party shall decide to institute arbitration proceedings, it shall
give written notice to that effect to the other Party. Any such arbitration
shall be conducted under the Commercial Arbitration Rules of the American
Arbitration Association by a panel of three arbitrators appointed in accordance
with such rules. Any such arbitration shall be held in Boston, Massachusetts if
initiated by ABX, and in San Francisco, California if initiated by IMMUNOGEN.
The method and manner of discovery in any such arbitration proceeding shall be
governed by California Code of Civil Procedure ss.1282 ET SEQ. (including
without limitation California Code of Civil Procedure ss.1283.05). The
arbitrators shall have the authority to grant specific performance and to
allocate between the parties the costs of arbitration in such equitable manner
as they determine. Judgment upon the award so rendered may be entered in any
court having jurisdiction or application may be made to such court for judicial
acceptance of any award and an order of enforcement, as the case may be. In no
event shall a demand for arbitration be made after the date when institution of
a legal or equitable proceeding based upon such claim, dispute or other matter
in question would be barred by the applicable statute of limitations.
Notwithstanding the foregoing, either Party shall have the right, without
waiving any right or remedy available to such Party under this Agreement or
otherwise, to seek and obtain from any court of competent jurisdiction any
interim or provisional relief that is necessary or desirable to protect the
rights or property of such Party, pending the selection of the arbitrators
hereunder or pending the arbitrators' determination of any dispute, controversy
or claim hereunder.
8.15 SEVERABILITY. If any provision(s) of this Agreement are or become
invalid, are ruled illegal by any court of competent jurisdiction or are deemed
unenforceable under then current applicable law from time to time in effect
during the Term hereof, it is the intention of the Parties that the remainder of
this Agreement shall not be affected thereby provided that a
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
26
57
Party's rights under this Agreement are not materially affected. The Parties
hereto covenant and agree to renegotiate any such term, covenant or application
thereof in good faith in order to provide a reasonably acceptable alternative to
the term, covenant or condition of this Agreement or the application thereof
that is invalid, illegal or unenforceable, it being the intent of the Parties
that the basic purposes of this Agreement are to be effectuated.
8.16 STATUS. Nothing in this Agreement is intended or shall be deemed to
constitute a partner, agency, employer-employee, or joint venture relationship
between the Parties.
8.17 INDEMNIFICATION.
8.17.1 ABX INDEMNITY. ABX shall [______________] and [________
__________________________________________________________] and [_______] and
[___________________________________](the "Indemnitees") [_____________________
_____________________] (including [___________________] and [_______________])
[__________] or [______________________], or [___________], in connection with
[_____ _______________________________________], including, without limitation,
[_________ ______________________] (but [_____________________________________
________], [________________________]), to the extent arising out of (i)
[_______________________] in the [____________________________________________
___________________________] of any [________________(___________________)
_______________________________________] under this Agreement, (ii) [_________]
of this Agreement [_____], or (iii) [____________________________] of the
[________], in any [________] under this Section 8.17.1 except to [___________
___________________] therefor under Section 8.17.2 below.
8.17.2 IMMUNOGEN INDEMNITY. Subject to Section 8.17.1 above, IMMUNOGEN
shall indemnify, defend and hold harmless ABX, its Affiliates and their
respective directors, officers, employees, and agents, and their respective
successors, heirs and assigns (also the "Indemnitees"), from and against any
liability, damage, loss or expense (including reasonable attorneys' fees and
expenses of litigation) incurred by or imposed upon such Indemnitees, or any of
them, in connection with any Third Party claims, suits, actions, demands or
judgments, including, without limitation, personal injury and product liability
matters (but excluding any patent, trademark or tradename infringement matters,
which are governed by Section 6 above), to the extent arising out of (i) any
actions or omissions of IMMUNOGEN or subcontractor of IMMUNOGEN in the
development, testing, production, manufacture or supply of any Licensed Product
(or any component thereof) manufactured and supplied by IMMUNOGEN or any
subcontractor of IMMUNOGEN under this Agreement, (ii) any material breach of
this Agreement by IMMUNOGEN, or (iii) gross negligence or willful misconduct on
the part of IMMUNOGEN.
8.18 INDEMNIFICATION PROCEDURES. In the event that any Indemnitee is
seeking indemnification under Section 8.17 above from a Party (the "Indemnifying
Party"), the other Party shall notify the Indemnifying Party of such claim with
respect to such Indemnitee as soon as reasonably practicable after the
Indemnitee receives notice of the claim, and the Party (on
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
27
58
behalf of itself and such Indemnitee) shall permit the Indemnifying Party to
assume direction and control of the defense of the claim (including the right to
settle the claim solely for monetary consideration) and shall cooperate as
requested (at the expense of the Indemnifying Party) in the defense of the
claim. The indemnification obligations under Section 8.17 shall not apply to
amounts paid in settlement of any claim, demand, action or other proceeding if
such settlement is effected without the consent of the Indemnifying Party, which
consent shall not be withheld or delayed unreasonably. The Indemnitee, its
employees and agents, shall reasonably cooperate with the Indemnifying Party and
its legal representatives in the investigation of any claim, demand, action or
other proceeding covered by Section 8.17.
8.19 SECTION 365(n). All licenses granted under this Agreement are deemed
to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of
right to "intellectual property" as defined in Section 101 of such Code. The
Parties agree that the licensee may fully exercise all of its rights and
elections under the U.S. Bankruptcy Code, regardless of whether either Party
files for bankruptcy in the United States or other jurisdiction. The Parties
further agree that, in the event a licensee elects to retain its rights as a
licensee under such Code, the licensee shall be entitled to complete access to
any technology licensed to it hereunder and all embodiments of such technology.
Such embodiments of the technology shall be delivered to the licensee not later
than:
8.19.1 the commencement of bankruptcy proceedings against the
licensor, upon written request, unless the licensor elects to perform its
obligations under the Agreement, or
8.19.2 if not delivered under Section 8.19.1 above, upon the rejection
of this Agreement by or on behalf of the licensor, upon written request.
8.20 FURTHER ASSURANCES. Each Party agrees to execute, acknowledge and
deliver such further instructions, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.
8.21 COUNTERPARTS. This Agreement may be executed simultaneously in one or
more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed
by their duly authorized representative in two (2) originals.
ABGENIX, INC. IMMUNOGEN, INC.
By: ______________________________ By: ________________________________
Title: ___________________________ Title: _____________________________
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
28
59
SCHEDULE I
LICENSED PATENT RIGHTS
[___________________________________________]
- ---------------------------------------------------------------------------------------------------------------------------------
Attorney Country Appl. No. Filing Date Priority Date Patent No. Issue Date Exp. Date
Reference No.
- ---------------------------------------------------------------------------------------------------------------------------------
- ---------------------------------------------------------------------------------------------------------------------------------
[________] [________] [________] [________] [________]
- ---------------------------------------------------------------------------------------------------------------------------------
[________] [________] [________] [________] [________] [________] [_______] [_______]
--------------------------------------------------------------------------------------------------------------------------------
[________] [________] [________] [________] [________] [________] [_______] [_______]
- ---------------------------------------------------------------------------------------------------------------------------------
[________] [________]* [________] [________] [________] [________] [_______] [_______]
- ---------------------------------------------------------------------------------------------------------------------------------
*[________]
- ---------------------------------------------------------------------------------------------------------------------------------
[________] [________] [________] [________] [________] [________]
- ---------------------------------------------------------------------------------------------------------------------------------
[________] [________] [________] [________] [________] [________]
- ---------------------------------------------------------------------------------------------------------------------------------
[_____________________________________________________________________________]
- ---------------------------------------------------------------------------------------------------------------------------------
Attorney Country Appl. No. Filing Date Priority Date Patent No. Issue Date Exp. Date
Reference No.
- ---------------------------------------------------------------------------------------------------------------------------------
[________] [________] [________] [________] [________]
- ---------------------------------------------------------------------------------------------------------------------------------
[___________________________________________]
- ---------------------------------------------------------------------------------------------------------------------------------
Attorney Country Appl. No. Filing Date Priority Date Patent No. Issue Date Exp. Date
Reference No.
- ---------------------------------------------------------------------------------------------------------------------------------
[________] [________] [________] [________] [________]
- ---------------------------------------------------------------------------------------------------------------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
29
60
FORM OF NONEXCLUSIVE LICENSE AGREEMENT
This Nonexclusive License Agreement ("Agreement") is made effective as
of as of _____________, 20__ (the "Effective Date") by and between IMMUNOGEN,
INC., a Massachusetts corporation with a principal place of business at 128
Sidney Street, Cambridge, Massachusetts 02139 ("IMMUNOGEN"), and ABGENIX, INC.,
a Delaware corporation with a place of business at 7601 Dumbarton Circle,
Fremont, California 94555 ("ABX"). IMMUNOGEN and ABX are each hereafter referred
to individually as a "Party" and together as the "Parties".
WHEREAS, ABX is the owner of or otherwise controls certain patents and
technology relating to antibodies; and
WHEREAS, IMMUNOGEN is the owner of or otherwise controls certain
proprietary patents and technology relating to or otherwise useful in the
conjugation of certain cytotoxic compounds such as DM1 (as hereinafter defined)
to antibodies; and
WHEREAS, ABX desires to obtain certain rights from IMMUNOGEN to develop
and commercialize one or more conjugates of certain cytotoxic compounds and
antibodies and IMMUNOGEN is willing to grant to ABX such rights on the terms
provided herein; and
WHEREAS, the Parties have heretofore executed an Option and License
Agreement (as hereinafter defined) pursuant to which IMMUNOGEN has granted ABX
certain options related to IMMUNOGEN's proprietary technology and know-how; and
WHEREAS, ABX has exercised an Option (as hereinafter defined) to obtain
such rights and, in connection therewith, desires to enter into this Agreement
in accordance with the terms of the Option and License Agreement.
NOW, THEREFORE, in consideration of the mutual covenants contained
herein, and for other good and valuable consideration, the receipt and adequacy
of which are hereby acknowledged, the Parties hereby agree as follows:
1. DEFINITIONS
Whenever used in the Agreement with an initial capital letter, the
terms defined in this Section 1 shall have the meanings specified.
1.1 "ABX ANTIBODY" shall mean any antibody or fragment thereof
directed to the Target.
1.2 "ADVERSE EVENT" shall mean any serious adverse event or medical
occurrence in a patient or subject who is administered a Licensed Product,
whether or not
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
1
61
considered related to the Licensed Product, (including, without
limitation, any undesirable sign (including abnormal laboratory findings of
clinical concern), symptom or disease temporally associated with the use of such
Licensed Product.
1.3 "AFFILIATE" shall mean any corporation, firm, limited liability
company, partnership or other entity which directly controls or is controlled by
or is under common control with a Party to this Agreement. "Control" for
purposes of this Section 1.3 means ownership, directly or indirectly through one
or more Affiliates, of fifty percent (50%) or more of the shares of stock
entitled to vote for the election of directors, in the case of a corporation, or
fifty percent (50%) or more of the equity interests in the case of any other
type of legal entity, status as a general partner in any partnership, or any
other arrangement whereby a Party controls or has the right to control the Board
of Directors or equivalent governing body of a corporation or other entity.
1.4 "BLA" shall mean a biologics license application (as defined in
Title 21 of the United States Code of Federal Regulations, as amended from time
to time) filed with the FDA seeking Regulatory Approval to market and sell any
Licensed Product in the United States for a particular indication within the
Field.
1.5 "CLINICAL MATERIALS" shall mean (a) supplies of ansamitocin P-3,
DM1, and/or any other May Compound as manufactured in accordance with all
applicable GMPs and other legal requirements and all applicable Specifications
for such May Compound for use in human clinical testing, and (b) supplies of any
Licensed Product as manufactured in accordance with all applicable GMPs and
other legal requirements and all applicable Specifications for such Licensed
Product for use in human clinical testing of any Licensed Product
1.6 "COMBINATION PRODUCT" shall mean any Licensed Product that
contains, in addition to any conjugate of any ABX Antibody with any May
Compound, one or more other ingredients that has biologic activity.
1.7 "CONTROL" OR "CONTROLLED" shall mean (a) with respect to patents,
know-how or other intangible rights, the possession by Party of the ability to
grant a license or sublicense of such patent rights, know-how or other
intangible rights as provided for herein without violating the terms of any
arrangement or agreements between such Party and any Third Party and (b) with
respect to any material, the possession by a Party of the ability to use such
material as provided herein without violating the terms of any agreement between
such Party and any Third Party.
1.8 "DEVELOPMENT" AND "DEVELOP" shall mean, with respect to any
Licensed Product, all activities with respect to such Licensed Product relating
to research, development and seeking, obtaining and/or maintaining any
Regulatory Approval for such Licensed Product in the Field in the Territory,
including without limitation, all pre-clinical research and development
activities, all human clinical studies, all activities relating to developing
the ability to manufacture any Licensed Product or any component thereof
(including, without limitation,
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
2
62
process development work), and all other activities relating to seeking,
obtaining and/or maintaining any Regulatory Approvals from the FDA and/or any
Foreign Regulatory Authority.
1.9 "DM1" shall mean that certain maytansine derivative having the
specific chemical name N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine.
1.10 "DRUG APPROVAL APPLICATION" shall mean any application for
Regulatory Approval (including pricing and reimbursement approvals) required
prior to any commercial sale or use of a Licensed Product in any country or
jurisdiction in the Territory, including, without limitation, (a) any BLA, NDA
or other regulatory application filed with the FDA required prior to any
commercial sale or use of a Licensed Product in the United States, and (b) any
equivalent application (including an MAA) filed with any Foreign Regulatory
Authority for Regulatory Approval (including pricing and reimbursement
approvals) required prior to any commercial sale or use of a Licensed Product in
any country or jurisdiction in the Territory.
1.11 "FDA" shall mean the United States Food and Drug Administration
and any successor agency or authority thereto.
1.12 "FIELD" shall mean any human medical use.
1.13 "FIRST COMMERCIAL SALE" shall mean the date of the first
commercial sale (other than for purposes of obtaining Regulatory Approval) of a
Licensed Product by or on behalf of ABX or an Affiliate or Sublicensee of ABX.
1.14 "FOREIGN REGULATORY AUTHORITIES" shall mean any applicable
supranational, national, federal, state or local regulatory agency, department,
bureau or other governmental entity of any country or jurisdiction in the
Territory (other than the FDA in the United States), having responsibility in
such country or jurisdiction for any Regulatory Approvals of any kind in such
country or jurisdiction, and any successor agency or authority thereto.
1.15 "FULLY BURDENED MANUFACTURING COST" shall mean, with respect to
any Preclinical Materials or Clinical Materials produced by IMMUNOGEN for ABX
under this Agreement, the sum of the following components as determined by
IMMUNOGEN in accordance with generally accepted accounting principles in the
United States, consistently applied, and consistent with the application given
to other goods produced by IMMUNOGEN: (a) the costs of goods produced,
including, without limitation, direct labor, material and product testing costs
of such Preclinical Materials or Clinical Materials; (b) any Third Party royalty
costs that are actually paid by IMMUNOGEN and are based solely and directly on
the manufacture and sale to ABX of such Preclinical Materials or Clinical
Materials; (c) all overhead costs incurred by IMMUNOGEN directly and solely
attributable to the cost of goods under clause (a) above, including, without
limitation, supervisory services, occupancy costs, payroll, information systems,
human relations, purchasing, accounts receivable or accounts payable functions,
and other general and administrative functions; and (d) any other costs borne by
IMMUNOGEN
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
3
63
directly and solely for the transport, customs clearance, duty and/or
insurance for such Preclinical Materials or Clinical Materials to ABX hereunder.
1.16 "GMPs" shall mean all good manufacturing practices under Title 21
of the United States Code of Federal Regulations, as amended from time to time.
1.17 "IMMUNOGEN BACKGROUND TECHNOLOGY" shall mean all inventions,
discoveries, patent rights, trade secrets and know-how, including without
limitation, laboratory scientific information and procedural techniques,
Controlled by IMMUNOGEN during the term of the Option and License Agreement or
the Term of this Agreement that are necessary or useful for ABX to research,
develop, make, have made, use, have used, sell, offer for sale, have sold,
import or have imported Licensed Products (or any component thereof, including
any linker) for use in the Field; provided, however, that IMMUNOGEN Background
Technology shall expressly exclude any Target Specific Rights.
1.18 "IND" shall mean an investigational new drug application (as
defined in Title 21 of the United States Code of Federal Regulation, as amended
from time to time) filed or to be filed with the FDA with regard to any Licensed
Product.
1.19 "IND ACCEPTANCE" shall mean the expiration of thirty (30) days
following receipt by ABX of a notice from the FDA to ABX that the FDA has
received an IND for a Licensed Product filed by ABX for the purpose of obtaining
approval or authority to commence human clinical trials in the United States
with such Licensed Product; provided, however, that if the FDA puts a clinical
hold on the IND during such thirty (30) day period, the term "IND Acceptance"
shall mean that date during the term of this Agreement when ABX receives written
confirmation from the FDA that the clinical hold has been removed and that ABX
has the approval or authority to commence human clinical trials of such Licensed
Product under such IND in the United States. Notwithstanding anything set forth
herein, "IND Acceptance" shall not have occurred in any circumstances where ABX
withdraws any IND filed with the FDA for a Licensed Product at any time prior to
the commencement of human clinical trials with such Licensed Product in the
United States.
1.20 "INDEMNITEES" AND "INDEMNIFYING PARTY" shall have the meanings
set forth in Section 9.
1.21 "JPDC" shall have the meaning set forth in Section 3.4.1.
1.22 "LICENSED PATENT RIGHTS" shall mean all Patent Rights covering
IMMUNOGEN Background Technology. All Licensed Patent Rights as of the Effective
Date are listed on Schedule I attached hereto.
1.23 "LICENSED PRODUCT" shall mean any product containing any
conjugate of any ABX Antibody with any May Compound, and shall include, without
limitation, any formulation thereof (including, without limitation, any
lyophilized, liquid, sustained release or
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
4
64
aerosolized formulation). "Licensed Product" shall also include any and all
Combination Products (if any).
1.24 "MAA" shall mean an application filed with the relevant Foreign
Regulatory Authorities in Europe seeking Regulatory Approval to market and sell
any Licensed Product in Europe or any country or territory therein for a
particular indication within the Field.
1.25 "MAY COMPOUND" shall mean any and all maytansinoid compounds
(including, without limitation, maytansine, ansamitocin P-3 and DM1), whether
produced by a botanical source, natural fermentation or chemical synthesis, and
shall include, without limitation, all variants, fragments or derivatives of any
of the foregoing, in each case owned or otherwise Controlled by IMMUNOGEN. May
Compounds shall include, without limitation, DM1.
1.26 "NDA" shall mean a new drug application (as defined in Title 21
of the United States Code of Federal Regulations, as amended from time to time)
filed with the FDA seeking Regulatory Approval to market and sell any Licensed
Product in the United States for a particular indication within the Field.
1.27 "NET SALES" shall mean, as to each calendar quarter during the
Term, the gross invoiced sales prices charged for all Licensed Products sold by
ABX, its Affiliates or its Sublicensees to Third Parties throughout the
Territory during such calendar quarter, less the following amounts incurred or
paid by ABX or its Affiliates or Sublicensees during such calendar quarter with
respect to sales of Licensed Products regardless of the calendar quarter in
which such sales were made:
1.27.1 trade, cash and quantity discounts or rebates actually allowed
or taken, including discounts or rebates to governmental or managed care
organizations;
1.27.2 credits or allowances actually given or made for rejection of
or return of, and for uncollectible amounts on, previously sold Licensed
Products or for retroactive price reductions (including Medicare and similar
types of rebates);
1.27.3 any charges for insurance, freight, and other transportation
costs directly related to the delivery of Licensed Product to the extent
included in the gross invoiced sales price;
1.27.4 any tax, tariff, duty or governmental charge levied on the
sales, transfer, transportation or delivery of a Licensed Product (including any
tax such as a value added or similar tax or government charge) borne by the
seller thereof, other than franchise or income tax of any kind whatsoever; and
1.27.5 any import or export duties or their equivalent borne by the
seller. "Net Sales" shall not include sales or transfers between ABX and its
Affiliates or Sublicensees, unless the Licensed Product is consumed by the
Affiliate or Sublicensee.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
5
65
1.28 "OPTION" shall have the meaning set forth in the Option and
License Agreement.
1.29 "OPTION AND LICENSE AGREEMENT" shall mean that certain
Option and License Agreement dated as of September 5, 2000, by and between
IMMUNOGEN and ABX.
1.30 "PATENT RIGHTS" shall mean the rights and interests in and
to any and all issued patents and pending patent applications (including
inventor's certificates and utility models) in any country or jurisdiction in
the Territory, including any and all provisionals, non-provisionals,
substitutions, continuations, continuations-in-part, divisionals and other
continuing applications, supplementary protection certificates, renewals, all
letters patent on any of the foregoing, and any and all reissues,
reexaminations, extensions, confirmations, registrations and patents of addition
on any of the foregoing.
1.31 "PHASE II CLINICAL STUDY" shall mean, as to a particular
Licensed Product for a particular indication, a controlled and lawful study in
humans of the safety, dose ranging and efficacy of such Licensed Product for
such indication, which is prospectively designed to generate sufficient data (if
successful) to commence a Phase III Clinical Trial of such Licensed Product for
such indication.
1.32 "PHASE III CLINICAL TRIAL" shall mean, as to a particular
Licensed Product for a particular indication, a controlled and lawful study in
humans of the safety and efficacy of such Licensed Product for such indication,
which is prospectively designed to demonstrate statistically whether such
Licensed Product is safe and effective for use in such indication in a manner
sufficient to file a BLA or NDA to obtain Regulatory Approval to market and sell
that Licensed Product in the United States for the indication under
investigation in such study.
1.33 "PRECLINICAL MATERIALS" shall mean (a) supplies of ansamitocin
P-3, DM1 and/or any other May Compound as manufactured in accordance with all
applicable legal requirements and all applicable Specifications for such May
Compound for use in preclinical testing, and (b) supplies of any Licensed
Product as manufactured in accordance with all applicable legal requirements and
all applicable Specifications for such Licensed Product for use in preclinical
testing of any Licensed Product.
1.34 "REGULATORY APPROVAL" shall mean any and all approvals (including
pricing and reimbursement approvals), product and establishment licenses,
registrations or authorizations of any kind of the FDA or its foreign equivalent
necessary for the development, pre-clinical and/or human clinical testing,
manufacture, quality testing, supply, use, storage, importation, export,
transport, marketing and sale of a Licensed Product (or any component thereof)
for use in the Field in any country or other jurisdiction in the Territory.
1.35 "SPECIFICATIONS" shall mean any specifications specified by ABX
and reasonably acceptable to IMMUNOGEN relating to the manufacturing and supply
of any May Compound and/or Licensed Product hereunder.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
6
66
1.36 "SUBLICENSEE" shall have the meaning set forth in Section
2.1.1(b).
1.37 "TARGET" shall mean _________________________.
1.38 "TARGET SPECIFIC RIGHTS" shall mean all inventions, discoveries,
patent rights, trade secrets and know-how, including without limitation,
laboratory scientific information and procedural techniques, Controlled by
IMMUNOGEN during the term of the Option and License Agreement or the Term of
this Agreement constituting (a) the composition of matter or use of the Target,
(b) the composition of matter or use of an antibody binding to the Target, or
(c) the composition of matter or use of a conjugate of an antibody binding to
the Target with a May Compound.
1.39 "TECHNOLOGY" shall mean and include any and all unpatented
proprietary ideas, inventions, discoveries, Confidential Information, materials,
data, results, formulae, designs, specifications, methods, processes,
formulations, techniques, ideas, know-how, technical information (including,
without limitation, structural and functional information), process information,
pre-clinical information, clinical information, and any and all proprietary
biological, chemical, pharmacological, toxicological, pre-clinical, clinical,
assay, control and manufacturing data and materials.
1.40 "TERM" shall mean the period commencing on the Effective Date and
continuing until the expiration or termination of this Agreement in accordance
with the terms hereof (including Section 7).
1.41 "TERRITORY" shall mean all countries and jurisdictions of the
world.
1.42 "THIRD PARTY" shall mean any person or entity other than ABX,
IMMUNOGEN and their respective Affiliates.
1.43 "THIRD PARTY PAYMENTS" shall have the meaning set forth in
Section 4.3.2.
1.44 "VALID CLAIM" shall mean a claim in an issued, unexpired patent
within the Licensed Patent Rights that (i) has not been finally cancelled,
withdrawn, abandoned or rejected by any administrative agency or other body of
competent jurisdiction, and (ii) has not been revoked, held invalid, or declared
unpatentable or unenforceable in a decision of a court or other body of
competent jurisdiction that is unappealable or unappealed within the time
allowed for appeal, and (iii) has not been rendered unenforceable through
disclaimer or otherwise, and (iv) is not lost through an interference
proceeding.
2. GRANT OF RIGHTS
2.1 LICENSE GRANT.
2.1.1 LICENSE TO ABX.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
7
67
(a) IMMUNOGEN hereby grants to ABX a nonexclusive license
within the Territory, including the right to grant sublicenses as described in
Section 2.2 below, under the Licensed Patent Rights and IMMUNOGEN Background
Technology to research, develop, make, have made, use, have used, sell, offer
for sale, have sold, import and have imported Licensed Products, for any and all
uses within the Field, subject to the other terms and conditions of this
Agreement. Promptly, but not less than quarterly, IMMUNOGEN shall deliver to ABX
all IMMUNOGEN Background Technology not previously delivered to ABX.
(b) ABX shall have the right freely to grant sublicenses to
all or any portion of its rights under the license granted pursuant to Section
2.1.1 hereof to any Affiliate or Third Party (in any case, a "Sublicensee");
provided, however, that ABX shall remain obligated for payment of royalty and
milestone obligations as set forth in Section 4.
2.1.2 License to IMMUNOGEN.
--------------------
(a) To the extent legally possible, [______] hereby
[______ ____________] a [______________________________________ ______________],
if any, in any [_____________________________] to the [______________________]
to or [________] of the [_____________] that are [_______ ____________] of
this Agreement, [_______] to the [____________] to [_________________
___________________] and [____________] to [_____________________________ _____]
to [_________] and/or [___________] and/or [__________(______________________]
to a [_________________] or a [________________], each as defined in the
Option and License Agreement). [_________________________] of the [______] of
[__________________] of which it [_____________].
(b) Such [_____] to [________] includes the [__________ __________] to
[____________] from [__________________________________________ __________] to
the [____] they [_______________] or [_________] of the [____________] with the
[_______________________________], and [_____________________] to
[_________________________]. Notwithstanding the foregoing, the
[_________________ _____________] pursuant to this Section 2.1.2 [____________]
the [_____________________ _________________________] (as defined in the Option
and License Agreement).
2.2 IMMUNOGEN RETAINED RIGHTS; ABX TECHNOLOGY OR PATENT RIGHTS. Except
as otherwise expressly set forth in Section 2.1.2, nothing in this Agreement
shall be construed as a grant to IMMUNOGEN of any license or other rights with
respect to any Technology (including, without limitation, any Confidential
Information) or Patent Rights owned or Controlled (in whole or in part) by ABX.
2.3 In Licenses. IMMUNOGEN represents and warrants to ABX that it has
provided ABX true and correct copies of all agreements pursuant to which
Licensed Patent Rights or IMMUNOGEN Background Technology existing as of the
Effective Date, is licensed to or otherwise acquired by IMMUNOGEN from a Third
Party. IMMUNOGEN promptly shall provide ABX with true and correct copies of all
agreements pursuant to which Licensed Patent
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
8
68
Rights or IMMUNOGEN Background Technology licensed or acquired after the
Effective Date, is licensed to or otherwise acquired by IMMUNOGEN from a Third
Party; provided, however, that IMMUNOGEN shall have the right to redact
confidential financial information and any provisions that shall not bind ABX.
To the extent the Licensed Patent Rights or IMMUNOGEN Background Technology are
licensed to or acquired by IMMUNOGEN from a Third Party and are reasonably
necessary to permit ABX to exercise its rights granted hereunder, IMMUNOGEN
shall use reasonable commercial efforts to maintain in full force and effect
such license. In the event of the termination of any such license with a Third
Party, IMMUNOGEN shall cause such Third Party to grant a direct license to ABX
to the extent necessary to permit ABX to exercise its rights granted hereunder,
and all sums owing by ABX to such Third Party shall be fully deducted from any
amounts owing to IMMUNOGEN hereunder.
3. DEVELOPMENT AND COMMERCIALIZATION OF LICENSED PRODUCTS.
3.1 DEVELOPMENT AND COMMERCIALIZATION.
3.1.1 RESPONSIBILITY. On and after the Effective Date, ABX shall
have full control and authority over all Development and commercialization of
Licensed Products in the Field in the Territory, including, without limitation,
(i) all pre-clinical Development activities (including any pharmaceutical
development work on formulations or process development relating to any Licensed
Product), (ii) all activities related to human clinical trials (including any
phase I studies, any Phase II Clinical Studies or any Phase III Clinical
Trials), (iii) all activities relating to manufacture and supply of all ABX
Antibodies, all May Compounds (including ansamitocin P-3 and DM1) and all
Licensed Products, solely to the extent such activities relate to the
Development and commercialization of Licensed Products (including all required
process development and scale up work with respect thereto), (iv) all marketing,
promotion, sales, distribution, import and export activities relating to any
Licensed Product (including any post-marketing trials or databases and
post-marketing safety surveillance), and (v) all activities relating to any
regulatory filings, registrations, applications and Regulatory Approvals
relating to any of the foregoing (including any INDs or foreign equivalents, any
manufacturing facility validation and/or licensure, any Drug Approval
Applications and any other Regulatory Approvals). Except as described in the
next sentence, ABX shall own all data, results and all other information arising
from any such activities under this Agreement, including, without limitation,
all regulatory filings, registrations, applications and Regulatory Approvals
relating to Licensed Products (including any INDs or foreign equivalents, any
Drug Approval Applications and any other Regulatory Approvals), and all of the
foregoing information, documentation and materials shall be considered
Confidential Information and Technology solely owned by ABX. IMMUNOGEN shall own
all data, results and all other information arising from IMMUNOGEN's activities
directly regarding the manufacture and supply of May Compounds to ABX (other
than activities undertaken at the request of ABX), and all of the foregoing
information, documentation and materials shall be considered Confidential
Information and Technology solely owned by IMMUNOGEN. All activities relating to
Development and commercialization by or on behalf of ABX under this Agreement
shall be undertaken at ABX's sole cost and expense, except as otherwise
expressly provided in this Agreement.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
9
69
3.1.2 DILIGENCE. ABX will exercise its good faith efforts in
Developing and commercializing Licensed Products in accordance with its
business, legal, medical and scientific judgment, and in undertaking
investigations and actions required to obtain appropriate Regulatory Approvals
necessary to market Licensed Products in the Field in the Territory. In the
event that ABX materially breaches its obligation to use good faith efforts as
required hereunder, then on a Licensed Product-by-Licensed Product basis as to
the Licensed Product for which ABX has materially breached its obligation to use
good faith efforts as required hereunder, IMMUNOGEN's exclusive remedy shall be,
in its sole discretion, to terminate the licenses granted under Section 2.1 of
this Agreement for breach under Section 7.2.1 below (including the notice and
cure provisions therein), only as such licenses apply to such Licensed Product,
which termination shall be effective upon expiration of the cure period
specified in Section 7.2.1 below provided that such failure remains uncured upon
such expiration.
3.2 UPDATES AND REPORTS; EXCHANGES OF ADVERSE EVENT INFORMATION.
3.2.1 UPDATES AND REPORTS. ABX (or its Sublicensee) shall provide
IMMUNOGEN with brief written reports no less frequently than on the anniversary
of the Effective Date during the Term (commencing with the first anniversary of
the Effective Date) summarizing ABX's material efforts to Develop and
commercialize all Licensed Products hereunder, identify the Drug Approval
Applications with respect to any Licensed Product that ABX and its Sublicensees
have filed, sought or obtained in the prior twelve (12)-month period, and any
they reasonably expect to make, seek or attempt to obtain in the following
twelve (12)-month period. In addition, ABX (or its Sublicensee) shall provide
IMMUNOGEN with prompt written notice of the occurrence of any event giving rise
to an obligation to make a milestone payment to IMMUNOGEN under Section 4.2, and
shall provide IMMUNOGEN with prompt written notice of the occurrence of the
First Commercial Sale of any particular Licensed Product.
3.2.2 ADVERSE EVENTS. In addition to such reports, ABX agrees to
provide IMMUNOGEN with Adverse Event information relating to Licensed Products
(but not relating to any other products of ABX) as compiled by ABX in the normal
course of business in connection with the Development, commercialization or sale
of any Licensed Product, within time frames consistent with IMMUNOGEN's
reporting obligations under applicable laws and regulations. IMMUNOGEN agrees to
provide ABX with Adverse Event information relating to any product containing
any May Compound (but not any other products of IMMUNOGEN or such Third Party)
that is compiled by IMMUNOGEN or any Third Party in the normal course of
business in connection with the development, commercialization or sale of any
such product, within time frames consistent with ABX's reporting obligations
under applicable laws and regulations.
3.2.3 CONFIDENTIAL INFORMATION. All reports, updates, Adverse
Event and other information provided by one Party to the other Party under this
Agreement (including under this Section 3), shall be considered Confidential
Information of the disclosing Party, subject to the terms of Section 5.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
10
70
3.3 TECHNICAL ASSISTANCE BY IMMUNOGEN. In connection with the
nonexclusive grant of rights to ABX under Section 2.1 above, and subject to the
other terms of this Agreement, IMMUNOGEN shall provide ABX such information and
materials comprising the IMMUNOGEN Background Technology and/or Licensed Patent
Rights as ABX may reasonably request. Without limiting the generality of the
foregoing, IMMUNOGEN shall provide all of such technical assistance within
IMMUNOGEN's area of expertise concerning the Development and commercialization
of Licensed Products as may be reasonably requested by ABX from time to time
during the Term, provided that such technical assistance and expertise is within
the scope of the IMMUNOGEN Background Technology and/or Licensed Patent Rights
covered under this Agreement. Such technical assistance and expertise shall
include, but not be limited to, visits by IMMUNOGEN personnel to ABX and visits
by ABX personnel to IMMUNOGEN, at ABX's expense, at such times and for such
periods of time as may be reasonably acceptable to the Parties. Additionally, at
the reasonable request of ABX, IMMUNOGEN shall transfer all applicable IMMUNOGEN
Background Technology, and provide such technical assistance, to such Third
Party collaborator, sublicensee or contract manufacturer as ABX designates.
3.4 JOINT PROCESS DEVELOPMENT COMMITTEE.
3.4.1 MANDATE AND ESTABLISHMENT OF COMMITTEE. The Joint Process
Development Committee ("JPDC") formed pursuant to the Option and License
Agreement, shall serve as a forum for coordination and communication between the
Parties with respect to Development (to the extent ABX requests the assistance
or services of IMMUNOGEN) of manufacturing processes applicable to any May
Compound or Licensed Product covered by this Agreement (including, without
limitation, all process science and process development work, formulation work,
and quality control/assurance work hereunder), to assist ABX in its exercise of
its rights to make or have made Licensed Products under this Agreement. The
input of the IMMUNOGEN representatives on the JPDC shall be reasonably
considered by the JPDC; provided, however, that, all decisions of the JPDC shall
be subject to the final approval of ABX.
3.4.2 CHAIR OF COMMITTEE; MEETINGS. The chair of the JPDC shall
be one of the ABX representatives on the JPDC, as designated by ABX. All
decisions of the JPDC shall be subject to the approval of ABX. The JPDC shall
meet on a semi-annual basis or other schedule agreed upon by the Parties, unless
at least thirty (30) days in advance of any meeting there is a determination by
the Chair of the JPDC that no new business or other activity has transpired
since the previous meeting, and that there is no need for a meeting. In such
instance, the next JPDC meeting shall also be scheduled as agreed upon by the
Parties. The location of such meetings shall alternate between IMMUNOGEN's
offices in the Cambridge, Massachusetts metropolitan area and ABX's offices in
the Fremont, California metropolitan area unless otherwise agreed upon between
the Parties. As agreed upon by the Parties, JPDC meetings may be face-to-face
meetings or may be conducted through teleconferences and/or videoconferences. In
addition to its JPDC representatives, each Party shall be entitled to have such
additional number (as the Parties mutually agree) of other employees attend such
meetings to present and participate, though not in a decision-making capacity.
Each Party shall bear all costs and expenses, including travel and lodging
expense, that may be incurred by its JPDC representatives
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
11
71
or other of its attendees at JPDC meetings. Minutes of each JPDC meeting will be
transcribed and issued to the members of the JPDC by the Chair within thirty
(30) days after each meeting and shall be reviewed and modified as mutually
required to obtain approval promptly thereafter.
3.5 SUPPLY OF PRECLINICAL MATERIALS. In the event that, during the
Term of this Agreement, ABX desires IMMUNOGEN to supply ABX with quantities of
Preclinical Materials in order to conduct all pre-clinical Development
activities relating to Licensed Products, ABX shall provide IMMUNOGEN with
written notice of same and the Parties shall negotiate in good faith and execute
a supply agreement providing for such supply. IMMUNOGEN shall deliver all
ordered amounts in accordance with advance ordering timeframes and delivery
timeframes to be agreed upon by the Parties through such mutually acceptable
written supply agreement for such purpose. In connection with any ordering of
Preclinical Materials by ABX, IMMUNOGEN shall provide ABX promptly with
IMMUNOGEN's good faith estimate of the Fully Burdened Manufacturing Cost for
manufacture and supply of such Preclinical Materials. IMMUNOGEN's price to
supply Preclinical Materials to ABX shall equal [______] of IMMUNOGEN's Fully
Burdened Manufacturing Cost for such Preclinical Materials as approved by ABX.
Nothing herein shall preclude ABX from making its own arrangements for
manufacture and supply of Preclinical Materials on its own or with Third
Parties. ABX hereby agrees that (a) it shall not use the Preclinical Materials
in any human subject, and (b) it shall use the Preclinical Materials in
compliance with all applicable federal, state and local laws and regulations.
3.6 SUPPLY OF CLINICAL MATERIALS. In the event that, during the Term
of this Agreement, IMMUNOGEN desires to supply ABX with quantities of Clinical
Materials in order to conduct all human clinical trials of Licensed Products
through the conclusion of Phase II Clinical Studies, ABX shall provide IMMUNOGEN
with written notice of same and the Parties shall negotiate in good faith and
execute a supply agreement providing for such supply. IMMUNOGEN shall deliver
all ordered amounts in accordance with forecasting parameters, advance ordering
timeframes and delivery timeframes to be agreed upon by the Parties such
mutually acceptable written supply agreement for such purpose. In connection
with any ordering of Clinical Materials by ABX, IMMUNOGEN shall provide ABX
promptly with IMMUNOGEN's good faith estimate of the Fully Burdened
Manufacturing Cost for manufacture and supply of such Clinical Materials.
IMMUNOGEN's price to supply Clinical Materials to ABX shall equal [_______] of
IMMUNOGEN's Fully Burdened Manufacturing Cost for such Clinical Materials as
approved by ABX. Nothing herein shall preclude ABX from making its own
arrangements for manufacture and supply of Clinical Materials on its own or with
Third Parties. ABX hereby agrees that it shall use the Clinical Materials in
compliance with all applicable federal, state and local laws. IMMUNOGEN shall
provide ABX with all information, filings and assistance regarding manufacturing
as reasonably requested by ABX in connection with applications for Regulatory
Approvals.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
12
72
4. PAYMENTS AND ROYALTIES
4.1 LICENSE FEE. Within thirty (30) days after the Effective Date,
ABX shall pay to IMMUNOGEN the nonrefundable, noncreditable license fee of
[_________________ ____________________].
4.2 MILESTONE PAYMENTS FOR LICENSED PRODUCTS.
4.2.1 MILESTONES. ABX will make the following nonrefundable,
noncreditable payments to IMMUNOGEN within thirty (30) days after the first
achievement of each of the milestones set forth below:
Milestone Milestone Payment
(a) [__________________________] [________________]
(b) [__________________________] [________________]
(c) [__________________________] [________________]
(d) [__________________________] [________________]
(e) [__________________________] [________________]
(f) [__________________________] [________________]
(g) [__________________________] [________________]
4.2.2 If the milestone described in [________] is [___________
___________] of the milestone described [_____________], then [__________] to
IMMUNOGEN hereunder of the milestone payment described [____________], [_______
_________________________________________] of the milestone payment described in
[_______________].
4.2.3 It is hereby acknowledged and agreed that any milestone
payment shall be made only once, with respect to the first achievement of the
relevant milestone for the first Licensed Product, regardless of how many times
such milestones are achieved by Licensed Products and regardless of how many
times a particular Licensed Product achieves such milestones. ABX shall notify
IMMUNOGEN of the achievement of milestones hereunder as provided in Section
3.2.1 above.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
13
73
4.3 PAYMENT OF ROYALTIES; ROYALTY RATES; ACCOUNTING FOR ROYALTIES AND
RECORDS.
4.3.1 ROYALTY PAYMENTS.
(a) In consideration of the grant of the license by
IMMUNOGEN hereunder, and subject to the other terms of this Agreement (including
the remainder of this Section 4), commencing on the first date of First
Commercial Sale of each Licensed Product in such country or jurisdiction in the
Territory, ABX shall pay to IMMUNOGEN the following royalties based on total Net
Sales of each Licensed Product sold by ABX and/or its Affiliates, on an
incremental basis in each calendar year during the Term, at the following rates:
For Net Sales of Licensed Product Royalty Rate
in any Calendar Year During the Term: (% of Net Sales)
------------------------------------ ----------------
[_________________] [_____]
[_________________] [_____]
(b) In consideration of the grant of the license by
IMMUNOGEN hereunder, and subject to the other terms of this Agreement (including
the remainder of this Section 4), commencing on the first date of First
Commercial Sale of each Licensed Product in such country or jurisdiction in the
Territory, ABX shall pay to IMMUNOGEN the following royalties based on total Net
Sales of each Licensed Product sold by each Sublicensee, on an incremental basis
in each calendar year during the Term, at a rate equal to
[__________________________________________________________________ ________] in
consideration for the grant of the sublicense under the Licensed Patents and
IMMUNOGEN Background Technology; provided, however, that the royalty rate under
this Section 4.3.1(b) for any royalty period shall not be (i) less than
[______________________ ___________________________________], or (ii) more than
[_________________________ _____________________________________].
4.3.2 [______________________]. Notwithstanding anything set
forth in Section 4.3.1 above, [_______] set forth therein shall apply,
[_________________________ ______________________________], to [_______] of
[______________________________ ____________] or
[__________________________________] would, [___________________
___________________________________________________________] (excluding any [___
______________________________________________]). Subject to the other terms of
this Agreement, [__________________________________________________________]
where and as of when [____________] under Section 4.3.1 [_____________________]
this Section 4.3.2, [_________________] a
[_______________________________________] set forth in Section 4.3.1 for
[______] of [___________________________].
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
14
74
4.3.3 [________________]. In the event that in any royalty
period, [______], in order to [__________________________________] of this
Agreement [_______ _______] , is [________________________] to
[_____________________ ("_____________ ________] ") (a) to
[________________________________] in the [_____________] the [____
_____________] of a [_________________________________________________________
_________] and/or (b) to [_______________________________________] to the [_____
______________________________________] to [__________], in the [___________]
the [______________________] to [__________________] to an [___________] as part
of a [____________________________________](as evidenced, to the
[_____________________ ___________], by [___________________]), then
[____________] the [_____] to [_________
________________________________________________________________] for [________
_____________] by [_____________] of [__________________]. Notwithstanding the
foregoing, such [____________________________________] for [______________] in
[_____ __________] to [____________________________________________] of
[__________ __________] in [____________].
4.3.4 [________________]. In determining [_______]of any
[________________] under this Agreement, [________]shall first [_________] in
accordance with the definition of "Net Sales" above, then [________] by
[___________] of the [________ _______________] in the [________________],
[____________________________________
____________________________________________________________________________] of
the [__________]. The [___________________] of the [______________] shall be for
a [_______________] to that [_____________________________] and of the
[______________ _________]. When [__________________] is [_______] for the
[________________, _____ ____________________] a [___________________] for the
[_________________, _________ ____________] of [_________________] as are then
[_________] to all [_________________ __________________________] and having an
[___________________]; provided, however, that if
[____________________________________________], the Parties shall [___________
_________________________________________] and [______________________________
_______________________].
4.3.5 [______________________________________]. If IMMUNOGEN
[______________] or [_________________] a [_____] to a
____________________________________________ [_____] for a
[__________________________________________], then the [__________] set forth in
this Section 4.3 that are [________] as a
[______________________________________________ ________________________].
4.4 ONE ROYALTY. Only one royalty, calculated at the highest
applicable royalty rate under this Section 4, shall be payable to IMMUNOGEN
hereunder for each sale of a Licensed Product.
4.5 ROYALTY TERM. ABX shall pay royalties with respect to each
Licensed Product on a country-by-country and Licensed Product-by-Licensed
Product basis until [______ ___] (a) the [_________________] of [_____________]
of [_____________________________ ___________________________], or (b)
[_______________________] of the [____________
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
15
75
_____] of [______________] in [_________]. Following such royalty term, ABX
shall have a fully paid-up, irrevocable, freely transferable and sublicensable
license in such country under the relevant Licensed Patent Rights and IMMUNOGEN
Background Technology, to research, develop, make, have made, use, have used,
sell, offer for sale, have sold, import and have imported Licensed Products for
any and all uses within the Field in such country.
4.6 PAYMENT TERMS.
4.6.1 PAYMENT OF MILESTONES; PAYMENT OF ROYALTIES; ROYALTY
REPORTS. ABX shall make any milestone payments owed to IMMUNOGEN hereunder in
United States Dollars, using the wire transfer provisions of this Section 4.6.
ABX shall make any royalty payments owed to IMMUNOGEN in United States Dollars,
[__________________________ __________________________________________] for
which such royalties accrue (as provided in the next sentence), using the wire
transfer provisions of this Section 4.6. For purposes of determining when a sale
of any Licensed Product occurs under this Agreement, royalties shall accrue on
the date of the invoice to the purchaser of the Licensed Product. Each royalty
payment shall be accompanied by a report for each country in the Territory in
which sales of Licensed Products occurred in the calendar quarter covered by
such statement, specifying: the gross sales (if available) and Net Sales in each
country's currency; the applicable royalty rate under this Agreement; the
royalties payable in each country's currency, including an accounting of
deductions taken in the calculation of Net Sales; the applicable exchange rate
to convert from each country's currency to United States Dollars under this
Section 4.6; and the royalties payable in United States Dollars.
4.6.2 FOREIGN CURRENCY EXCHANGE. All royalties shall be payable
in full in the United States in United States Dollars, regardless of the
countries in which sales are made. For the purpose of computing Net Sales for
Licensed Products sold in any currency other than United States Dollars, the
quarterly royalty payment will be calculated as follows:
(A/B) x C = United States Dollars royalty payment on foreign current
sales, where A = foreign "Net Sales" (as defined above) per quarter; B
= foreign exchange conversion rate, expressed in local currency per
United States Dollar (using as the applicable foreign exchange rate
the rate published in the western edition of The Wall Street Journal,
under the heading "Money Rates," or any other mutually agreed upon
source, for the last business day of the calendar quarter); and C =
the royalty rate applicable to such Net Sales under this Agreement.
4.6.3 TAX WITHHOLDING; RESTRICTIONS ON PAYMENT. All payments
hereunder shall be made free and clear of any taxes, duties, levies, fees or
charges, except for withholding taxes (to the extent applicable). ABX shall make
any applicable withholding payments due on behalf of IMMUNOGEN and shall
promptly provide IMMUNOGEN with such written documentation of any such payment
as available to ABX relating to an application by IMMUNOGEN for a foreign tax
credit for such payment with the United States Internal Revenue Service. If by
law, regulations or fiscal policy of a particular country in the Territory,
remittance of royalties in United States Dollars is restricted or forbidden,
written notice thereof shall
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
16
76
promptly be given to IMMUNOGEN, and payment of the royalty shall be made by the
deposit thereof in local currency to the credit of IMMUNOGEN in a recognized
banking institution reasonably designated by IMMUNOGEN by written notice to ABX.
When in any country in the Territory the law or regulations prohibit both the
transmittal and the deposit of royalties on sales in such country, royalty
payments shall be suspended for as long as such prohibition is in effect and as
soon as such prohibition ceases to be in effect, all royalties that ABX would
have been under an obligation to transmit or deposit but for the prohibition
shall forthwith be deposited or transmitted, to the extent allowable.
4.6.4 WIRE TRANSFERS. All payments hereunder shall be made to
IMMUNOGEN by bank wire transfer in immediately available funds to the account
designated by IMMUNOGEN by written notice to ABX from time to time.
4.7 RECORDS RETENTION; REVIEW.
4.7.1 ROYALTIES. Commencing as of the date of First Commercial
Sale of the first Licensed Product, ABX and its Sublicensees shall keep for at
least [___________] from the end of the calendar year to which they pertain
complete and accurate records of sales by ABX or its Sublicensees, as the case
may be, of each Licensed Product, in sufficient detail to allow the accuracy of
the royalties to be confirmed.
4.7.2 FULLY BURDENED MANUFACTURING COSTS. Commencing as of the
Effective Date, IMMUNOGEN shall keep for at least [_________] following the end
of the calendar year to which they pertain complete and accurate records of all
of IMMUNOGEN's Fully Burdened Manufacturing Costs for Preclinical Materials and
Clinical Materials supplied to ABX (or its Sublicensee) hereunder, in sufficient
detail to allow the accuracy of the Fully Burdened Manufacturing Costs to be
confirmed.
4.7.3 REVIEW. Subject to the other terms of this Section 4.7.3,
at the request of either Party, upon at least thirty (30) days' prior written
notice from the requesting Party, and at the expense of the requesting Party
(except as otherwise provided herein), the other Party shall permit an
independent certified public accountant of nationally recognized standing
reasonably selected by the requesting Party and reasonably acceptable to the
other Party to inspect (during regular business hours) the relevant records
required to be maintained by the other Party under this Section 4.7. At
IMMUNOGEN's request (which shall not be made more frequently than once per year
during the Term), the accountant shall be entitled to review the then-preceding
[_______] of ABX's records under this Section 4.7 for purposes of verifying
ABX's royalty calculations. At ABX's request (which shall not be made more
frequently than once per year during the Term), the accountant shall be entitled
to review the then-preceding [__________] of IMMUNOGEN's records under this
Section 4.7 for purposes of verifying IMMUNOGEN's Fully Burdened Manufacturing
Cost calculations. In every case the accountant must have previously entered
into a confidentiality agreement with both Parties substantially similar to the
provisions of Section 5 and limiting the disclosure and use of such information
by such accountant to authorized representatives of the Parties and the purposes
germane to this Section 4.7. Such accountant shall report to the Parties only
whether or not such calculations are
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
17
77
correct and the amount of any discrepancy. No other information shall be shared.
Results of any such review shall be binding on both Parties absent manifest
error. Each Party agrees to treat the results of any such accountant's review of
the other Party's records under this Section 4.7 as Confidential Information of
the other Party subject to the terms of Section 5. If any review reveals a
deficiency in the calculation of royalties resulting from any underpayment by
ABX, ABX shall promptly pay IMMUNOGEN the amount remaining to be paid, and if
such underpayment is by [______________] or more, ABX shall pay the reasonable
out-of-pocket costs and expenses of the review. If any review reveals a
deficiency in the calculation of Fully Burdened Manufacturing Costs resulting
from any overpayment by ABX, IMMUNOGEN shall promptly refund ABX the amount of
any such overpayment, and if such overpayment is by [___ ____________] or more,
IMMUNOGEN shall pay the reasonable out-of-pocket costs and expenses of the
review.
5. TREATMENT OF CONFIDENTIAL INFORMATION
5.1 CONFIDENTIAL INFORMATION. During the Term of this Agreement, each
Party may disclose to the other Party confidential information, including but
not limited to IMMUNOGEN Background Technology, Research Inventions, Research
Data and Research Materials. Such information of the disclosing Party hereunder,
if so identified in writing by the disclosing Party to the receiving Party
either pursuant to this Section 5.1 or otherwise upon disclosure to the
receiving Party, shall be "Confidential Information" of the disclosing Party.
During the Term of this Agreement and during the term of any License Agreement,
and for a period of five (5) years thereafter, except as expressly permitted
hereunder, the receiving Party shall keep confidential all such Confidential
Information of the other Party and will not disclose such Confidential
Information of the other Party to Third Parties by publication or otherwise.
Each Party further agrees not to use Confidential Information of the other Party
for any purpose other than conducting research hereunder or exercising any
rights granted to it or reserved by it hereunder. Upon any termination or
expiration of this Agreement, upon request, a Party shall return to a requesting
Party all copies of any of such requesting Party's Confidential Information
which is not the subject of a License Agreement or the grant of a license
hereunder, provided that it may retain one copy for its legal files.
Notwithstanding the foregoing, it is understood and agreed that the receiving
Party's obligations of confidentiality and nonuse herein shall not apply to any
information which:
(a) is, at the time of disclosure by the disclosing Party
hereunder, or thereafter becomes, a part of the public domain or publicly known
or available through no fault or negligence of the receiving Party or any of its
Affiliates; or
(b) was otherwise in the receiving Party's lawful possession
prior to disclosure by the disclosing Party, other than under an obligation of
confidentiality; or
(c) was independently discovered or developed by the receiving
Party or any of its Affiliates, without use of the other Party's Confidential
Information, as can be demonstrated by competent proof; or
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
18
78
(d) is lawfully disclosed to the receiving Party or any of its
Affiliates on a non-confidential basis by a third party who is not in violation
of an obligation of confidentiality to the disclosing Party relative to such
information.
Each Party may disclose information to the extent such disclosure is
reasonably necessary in (i) filing and prosecuting patent applications and
maintaining patents, or (ii) filing, prosecuting or defending litigation or
(iii) complying with applicable laws, regulations or court orders; provided,
however, that if a Party is required to make any such disclosure of the other
Party's Confidential Information or the terms of this Agreement, it will give
reasonable advance notice to the other Party of such disclosure requirement and
will use reasonable efforts to assist such other Party in efforts to secure
confidential treatment of such information required to be disclosed.
5.2 PUBLICITY. A Party may not use the name of the other Party in any
publicity or advertising and, except as provided in Section 5.1, may not issue a
press release or otherwise publicize or disclose any information related to the
other Party's activities under this Agreement or the terms or conditions hereof,
without the prior written consent of the other Party. Prior to execution of this
Agreement, the parties have agreed upon the substance of information that can be
used to describe the terms and conditions of this Agreement, and each party may
disclose such information, as modified by mutual written agreement the parties,
without the consent of the other party. Once any written statement is approved
for disclosure by both Parties, either Party may make subsequent public
disclosures of the contents of such statement without the further approval of
the other Party. Nothing in the foregoing, however, shall prohibit a Party from
making such disclosures to the extent deemed necessary under applicable federal
or state securities laws or any rule or regulation of any nationally recognized
securities exchange; provided, however, that such party shall provide written
notice thereof to the other party, consult with the other party with respect to
such disclosure and provide the other party sufficient opportunity to comment on
or object to any such disclosure or to request confidential treatment thereof.
6. PROVISIONS CONCERNING THE FILING, PROSECUTION AND
MAINTENANCE OF PATENT RIGHTS
6.1 PATENT FILING, PROSECUTION AND MAINTENANCE. Subject to the other
terms of this Section 6.1, IMMUNOGEN shall have the right to prepare, file,
prosecute, obtain and maintain, at its sole cost and expense, all Licensed
Patent Rights. Any such preparation, filing, prosecution and maintenance shall
be conducted with commercially reasonable diligence by IMMUNOGEN, using patent
counsel selected by IMMUNOGEN and reasonably acceptable to ABX. IMMUNOGEN (i)
will provide ABX with a copy of any proposed patent application within Licensed
Patent Rights for review and comment reasonably in advance of filing (which
shall under no circumstances be in excess of thirty (30) days), and (ii) will
keep ABX reasonably informed of the status of such filing, prosecution and
maintenance, including, without limitation, (A) by providing ABX with copies of
all communications received from or filed in patent office(s) with respect to
such filing, and (B) by providing ABX, a reasonable time prior to taking or
failing to take any action that would affect the scope or validity of any such
of any such filing
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
19
79
(including the substantially narrowing, cancellation or abandonment of any
claim(s) without retaining the right to pursue such subject matter in a separate
application, or the failure to file or perfect the filing of any claim(s) in any
country), with prior written notice of such proposed action or inaction so that
ABX has a reasonable opportunity to review and comment. [______ __________] for
[______] of [_________________________________________________ ______] with
respect to [________________] shall be [______________________________
________]. If IMMUNOGEN fails to undertake the filing(s) of any patent
application or submission with respect to any invention under such Licensed
Patent Rights, then not less than ninety (90) days prior to the last date for
making the applicable filing or submission to preserve rights under such patent
application, ABX may undertake such filing(s) at its own expense, in which case
IMMUNOGEN will assign to ABX all of its rights to such patent application and
invention and any subsequently issued patent thereon, each of which thereafter
will be owned solely by ABX.
6.2 NOTICE OF INFRINGEMENT. If, during the Term of this Agreement,
either Party learns of any actual, alleged or threatened infringement by a Third
Party of any Licensed Patent Rights under this Agreement, such Party shall
promptly notify the other Party and shall provide such other Party with
available evidence of such infringement.
6.3 INFRINGEMENT OF PATENT RIGHTS. IMMUNOGEN shall have the first
right (but not the obligation), at its own expense and with legal counsel of its
own choice, to bring suit (or take other appropriate legal action) against any
actual, alleged or threatened infringement of the Licensed Patent Rights caused
by the research, development, manufacture, use, offer for sale, sale or import
of Licensed Products. ABX shall have the right, at its own expense, to be
represented in any such action by IMMUNOGEN by counsel of ABX's own choice;
provided, however, that under no circumstances shall the foregoing affect the
right of IMMUNOGEN to control the suit as described in the first sentence of
this Section 6.3. If IMMUNOGEN does not file any action or proceeding against
such infringement within one hundred twenty (120) days after the later of (i)
IMMUNOGEN's notice to ABX under Section 6.2 above, (ii) ABX's notice to
IMMUNOGEN under Section 6.2 above, or (iii) a written request from ABX to take
action with respect to such infringement, then ABX shall have the right (but not
the obligation), at its own expense, to bring suit (or take other appropriate
legal action) against such actual, alleged or threatened infringement, with
legal counsel of its own choice. Any damages, monetary awards or other amounts
recovered, whether by judgment or settlement, pursuant to any suit, proceeding
or other legal action taken under this Section 6.3, shall applied as follows:
6.3.1 First, to reimburse the Parties for their respective costs
and expenses (including reasonable attorneys' fees and costs) incurred in
prosecuting such enforcement action;
6.3.2 Second, [_________________________________] associated with
[_________________] and to [_________________________________________] based on
[_______________]
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
20
80
6.3.3 Third, any amounts remaining shall be allocated as follows:
(a) if IMMUNOGEN is the Party bringing such suit or proceeding or taking such
other legal action, [_________________________], (b) if ABX is the Party
bringing such suit or proceeding or taking such other legal action,
[______________________], and (c) if the suit is brought jointly,
[________________________].
If a Party brings any such action or proceeding hereunder, the other Party
agrees to be joined as party plaintiff if necessary to prosecute such action or
proceeding, and to give the Party bringing such action or proceeding reasonable
assistance and authority to file and prosecute the suit; provided, however, that
neither Party shall be required to transfer any right, title or interest in or
to any property to the other Party or any Third Party to confer standing on a
Party hereunder.
6.4 THIRD PARTY PATENTS. If any Third Party claims that a patent it
owns or controls claims any aspect of a Licensed Product or its manufacture, use
or sale, the Party with notice of such claim shall notify the other Party
promptly, and the Parties shall as soon as practicable thereafter discuss in
good faith regarding a response.
6.5 TRADEMARKS. All Licensed Products shall be sold under one (1) or
more trademarks and tradenames selected by ABX (or its Sublicensee) in the
Territory. IMMUNOGEN shall notify ABX promptly upon learning of any actual,
alleged or threatened infringement of a trademark or tradename applicable to a
Licensed Product in the Territory, or of any unfair trade practices, trade dress
imitation, passing off of counterfeit goods, or like offenses in the Territory.
All of the costs, expenses and legal fees in bringing, maintaining and
prosecuting any action to maintain, protect or defend any trademarks or
tradenames owned by ABX (or its Sublicensee) hereunder, and any damages or other
recovery, shall be ABX's (or its Sublicensee's) sole responsibility, and taken
in its sole discretion.
7. TERM AND TERMINATION
7.1 TERM; EXPIRATION. The term of this Agreement shall expire upon the
expiration of the final royalty payment obligation under Section 4.5 above. Upon
such expiration of the Term of this Agreement, ABX shall have a fully paid-up,
irrevocable, freely transferable and sublicensable license in such country under
the relevant Licensed Patent Rights and IMMUNOGEN Background Technology, to
research, develop, make, have made, use, have used, sell, offer for sale, have
sold, import and have imported Licensed Products, for any and all uses within
the Field in the Territory.
7.2 TERMINATION. Subject to the other terms of this Agreement:
7.2.1 BREACH. This Agreement and the rights and options granted
herein may be terminated by either Party upon any material breach by the other
Party of any material obligation or condition, effective [____________] after
giving written notice to the breaching Party of such termination in the case of
a payment breach and [_____________] after giving written notice to the
breaching Party of such termination in the case of any other breach, which
notice shall describe such breach in reasonable detail. The foregoing
notwithstanding, if such
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
21
81
default or breach is cured or shown to be non-existent within the aforesaid
[______] or [_____ ______] period, the notice shall be automatically withdrawn
and of no effect. However, prior to giving any notice for breach, the Parties
shall first attempt to resolve any disputes as to the existence of any breach as
set forth in Section 8.14.
7.2.2 UNILATERAL TERMINATION BY ABX. ABX, in its sole discretion,
at any time may terminate this Agreement, and the rights and obligations
hereunder, or may remove any Licensed Product and the licenses related thereto
from operation of this Agreement, in any case effective [_____________] after
written notice thereof to IMMUNOGEN. In the event of any termination under this
Section 7.2.2 only as to a Licensed Product, the consequences set forth in
Section 7.3 below relating to termination of the Agreement under this Section
7.2.2 shall apply only with respect to such terminated Licensed Product, and
this Agreement and the rights and obligations hereunder shall continue in full
force and effect as to any and all other Licensed Products.
7.3 EFFECTS OF TERMINATION.
7.3.1 Upon any termination of this Agreement by IMMUNOGEN under
Section 7.2.1 or by ABX under Section 7.2.2, as of the effective date of
such termination, all relevant licenses and sublicenses granted by
IMMUNOGEN to ABX hereunder shall terminate automatically. Notwithstanding
the foregoing, (a) no such termination of this Agreement shall be construed
as a termination of any valid sublicense of any Sublicensee hereunder, and
thereafter each such Sublicensee shall be considered a direct licensee of
IMMUNOGEN, provided that (i) such Sublicensee is then in full compliance
with all terms and conditions of its sublicense, (ii) all accrued payments
obligations to IMMUNOGEN have been paid, and (iii) such Sublicensee agrees
in writing to assume all applicable obligations of ABX under this
Agreement, and (b) ABX and its Sublicensees shall have the right, for
[__________] or such longer time period (if any) on which the Parties
mutually agree in writing, to sell or otherwise dispose of all Licensed
Products then on hand, with royalties to be paid to IMMUNOGEN on all Net
Sales of such Licensed Products as provided for in this Agreement. Nothing
set forth in this Section 7 or any other provision of this Agreement shall
entitle IMMUNOGEN to any ownership interest in, or to any license under or
other rights with respect to (including any rights to use or request any
transfer to IMMUNOGEN or any Third Party), any Confidential Information of
ABX or any Technology or Patent Rights owned by ABX under this Agreement.
7.3.2 Upon any termination of this Agreement by ABX under Section
7.2.1, as of the effective date of such termination, ABX thereafter
automatically shall have a fully sublicensable, fully paid up (subject to
the remainder of this Section 7.3.2), nonexclusive license in the Territory
under the Licensed Patent Rights and IMMUNOGEN Background Technology, to
research, develop, make, have made, use, have used, sell, offer for sale,
have sold, import and have imported Licensed Products, for any and all uses
within the Field in the Territory, provided that ABX shall pay, for the
remainder of the royalty term under Section 4.5 above, in lieu of any
payments including milestones or royalties it would otherwise owe to
IMMUNOGEN under this Agreement, a royalty equal to [______________________
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
22
82
________________________] with respect to the Licensed Product under Section 4
of this Agreement.
7.4 REMEDIES. Except as otherwise expressly set forth in this
Agreement, the termination provisions of this Section 7 are in addition to any
other relief and remedies available to either Party at law.
7.5 SURVIVING PROVISIONS. Notwithstanding any provision herein to the
contrary, the rights and obligations of the Parties set forth in Sections 4.7,
5, 6, 7.3, 7.4, 8.3, 8.4, 8.7, 8.14, 8.16, 8.17, 8.18 and 8.19 hereof, as well
as any rights or obligations otherwise accrued hereunder (including any accrued
payment obligations), shall survive the expiration or termination of the Term of
this Agreement. Without limiting the generality of the foregoing, ABX shall have
no obligation to make any milestone or royalty payment to IMMUNOGEN that has not
accrued prior to the effective date of any termination of this Agreement, but
shall remain liable for all such payment obligations accruing prior to the
effective date of such termination.
8. MISCELLANEOUS
8.1 IMMUNOGEN REPRESENTATIONS. IMMUNOGEN represents and warrants to
ABX that: (a) the execution and delivery of this Agreement and the performance
of the transactions contemplated hereby have been duly authorized by all
appropriate IMMUNOGEN corporate action; (b) this Agreement is a legal and valid
obligation binding upon IMMUNOGEN and enforceable in accordance with its terms,
and the execution, delivery and performance of this Agreement by the Parties
does not conflict with any agreement, instrument or understanding to which
IMMUNOGEN is a party or by which it is bound; (c) IMMUNOGEN has the full right
and legal capacity to grant the rights to ABX pursuant to Section 2 above
without violating the rights of any Third Party; (d) IMMUNOGEN is the sole owner
or exclusive licensee of the IMMUNOGEN Background Technology; (e) IMMUNOGEN is
not aware of any Third Party patent, patent application or other intellectual
property rights that would be infringed (i) by practicing any process or method
or by making, using or selling any composition which is claimed or disclosed in,
or which constitutes, IMMUNOGEN Background Technology, or (ii) by making, using,
offering for sale, selling or importing Licensed Products; and (f) IMMUNOGEN is
not aware of any infringement or misappropriation by a Third Party of the
IMMUNOGEN Background Technology.
8.2 ABX REPRESENTATIONS. ABX represents and warrants to IMMUNOGEN
that: (a) the execution and delivery of this Agreement and the performance of
the transactions contemplated hereby have been duly authorized by all
appropriate ABX corporate action; (b) this Agreement is a legal and valid
obligation binding upon ABX and enforceable in accordance with its terms, and
the execution, delivery and performance of this Agreement by the Parties does
not conflict with any agreement, instrument or understanding to which ABX is a
party of or by which it is bound; and (c) ABX has the full right and legal
capacity to grant the rights to IMMUNOGEN pursuant to Section 2 above without
violating the rights of any Third Party.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
23
83
8.3 NO WARRANTIES.
8.3.1 Nothing in this Agreement is or shall be construed as:
(a) a warranty or representation by either Party as to the
validity or scope of any patent application or patent licensed hereunder;
(b) a warranty or representation that anything made, used,
sold or otherwise disposed of under any license granted pursuant to this
Agreement is or will be free from infringement of patents, copyrights, and other
rights of third parties.
8.3.2 Except as expressly set forth in this Agreement, NEITHER
PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER
EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR OF NON-INFRINGEMENT OF
ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF THIRD PARTIES, OR ANY OTHER
EXPRESS OR IMPLIED WARRANTIES.
8.4 [______]. NOTWITHSTANDING ANYTHING ELSE IN THIS AGREEMENT OR
OTHERWISE, [________________] WILL BE __________ [_________________] TO
[__________________] OF THIS AGREEMENT [___________________________
_________________________________________________] OR [_________________] FOR
(I) [___________________________________________________________________] OR
[____________________] OR (II) [____________________________________________
__________________________.
8.5 NOTICES. Any notices, requests, deliveries, approvals or consents
required or permitted to be given under this Agreement to ABX or IMMUNOGEN shall
be in writing and shall be effective on receipt when delivered to the applicable
address specified below (or to such other address as may be specified in writing
to the other Party hereto):
If to IMMUNOGEN: IMMUNOGEN, Inc.
128 Sidney Street
Cambridge, MA 02139
Attn: Chief Executive Officer
With a copy to: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, MA 02111
Attn: Jeffrey M. Wiesen, Esq
Telecopy: 617-542-2241
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
24
84
If to ABX: Abgenix, Inc.
7601 Dumbarton Circle
Fremont, California 94555
Attn: President
With a copy to: Gray Cary Ware & Freidenrich LLP
4365 Executive Drive, Suite 1600
San Diego, California 92121-2189
Attn: Mark R. Wicker
8.6 GOVERNING LAW. This Agreement will be construed, interpreted and
applied in accordance with the laws of the Commonwealth of Massachusetts
(excluding its body of law controlling conflicts of law).
8.7 LIMITATIONS. Except as set forth elsewhere in this Agreement,
neither Party grants to the other Party any right or license to any of its
intellectual property.
8.8 ENTIRE AGREEMENT. This is the entire Agreement between the Parties
with respect to the subject matter hereof and supersedes all prior
representations, understandings and agreements between the Parties with respect
to the subject matter hereof. No modification shall be effective unless in
writing with specific reference to this Agreement and signed by the Parties.
8.9 WAIVER. The terms or conditions of this Agreement may be waived
only by a written instrument executed by the Party waiving compliance. The
failure of either Party at any time or times to require performance of any
provision hereof shall in no manner affect its rights at a later time to enforce
the same. No waiver by either Party of any condition or term shall be deemed as
a continuing waiver of such condition or term or of another condition or term.
8.10 HEADINGS. Section and subsection headings are inserted for
convenience of reference only and do not form part of this Agreement.
8.11 ASSIGNMENT. Neither this Agreement nor any right or obligation
hereunder may be assigned, delegated or otherwise transferred , in whole or
part, by either party without the prior express written consent of the other;
provided, however, that either party may, without the written consent of the
other, assign this Agreement and its rights and delegate its obligations
hereunder to its Affiliates, or in connection with the transfer or sale of all
or substantially all of such party's assets or business related to this
Agreement, or in the event of its merger, consolidation, change in control or
similar transaction. Any permitted assignee shall assume all obligations of its
assignor under this Agreement. Any purported assignment in violation of this
Section 8.11 shall be void. The terms and conditions of this Agreement shall be
binding upon and inure to the benefit of the permitted successors and assigns of
the parties.
8.12 FORCE MAJEURE. Neither Party shall be liable for failure of or
delay in performing obligations set forth in this Agreement, and neither shall
be deemed in breach of its obligations, if such failure or delay is due to
natural disasters or any causes beyond the
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
25
85
reasonable control of such Party. In event of such force majeure, the Party
affected thereby shall use reasonable efforts to cure or overcome the same and
resume performance of its obligations hereunder.
8.13 CONSTRUCTION. The Parties hereto acknowledge and agree that: (i)
each Party and its counsel reviewed and negotiated the terms and provisions of
this Agreement and have contributed to its revision; (ii) the rule of
construction to the effect that any ambiguities are resolved against the
drafting Party shall not be employed in the interpretation of this Agreement;
and (iii) the terms and provisions of this Agreement shall be construed fairly
as to all Parties hereto and not in favor of or against any Party, regardless of
which Party was generally responsible for the preparation of this Agreement.
8.14 DISPUTES.
8.14.1 The Parties recognize that a bona fide dispute as to
certain matters may from time to time arise during the term of this Agreement
which relates to either Party's rights and/or obligations hereunder. In the
event of the occurrence of such a dispute, either Party may, by written notice
to the other Party, have such dispute referred to their respective senior
officials designated below or their successors, for attempted resolution by good
faith negotiations within thirty (30) days after such notice is received. Said
designated senior officials are as follows:
For ABX: Chief Executive Officer
For IMMUNOGEN: Chief Executive Officer
In the event the designated senior officials are not able to resolve
such dispute within the thirty (30) day period, either Party may invoke the
provisions of Section 8.14.2.
8.14.2 Any dispute, controversy or claim initiated by either
Party arising out of, resulting from or relating to this Agreement, or the
performance by either Party of its obligations under this Agreement (other than
bona fide third party actions or proceedings filed or instituted in an action or
proceeding by a Third Party against a Party), whether before or after
termination of this Agreement, shall be finally resolved by binding arbitration.
Whenever a Party shall decide to institute arbitration proceedings, it shall
give written notice to that effect to the other Party. Any such arbitration
shall be conducted under the Commercial Arbitration Rules of the American
Arbitration Association by a panel of three arbitrators appointed in accordance
with such rules. Any such arbitration shall be held in Boston, Massachusetts if
initiated by ABX, and in San Francisco, California if initiated by IMMUNOGEN.
The method and manner of discovery in any such arbitration proceeding shall be
governed by California Code of Civil Procedure ss. 1282 ET SEQ. (including
without limitation California Code of Civil Procedure ss. 1283.05). The
arbitrators shall have the authority to grant specific performance and to
allocate between the parties the costs of arbitration in such equitable manner
as they determine. Judgment upon the award so rendered may be entered in any
court having jurisdiction or application may be made to such court for judicial
acceptance of any award and an order of
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
26
86
enforcement, as the case may be. In no event shall a demand for arbitration be
made after the date when institution of a legal or equitable proceeding based
upon such claim, dispute or other matter in question would be barred by the
applicable statute of limitations. Notwithstanding the foregoing, either Party
shall have the right, without waiving any right or remedy available to such
Party under this Agreement or otherwise, to seek and obtain from any court of
competent jurisdiction any interim or provisional relief that is necessary or
desirable to protect the rights or property of such Party, pending the selection
of the arbitrators hereunder or pending the arbitrators' determination of any
dispute, controversy or claim hereunder.
8.15 SEVERABILITY. If any provision(s) of this Agreement are or become
invalid, are ruled illegal by any court of competent jurisdiction or are deemed
unenforceable under then current applicable law from time to time in effect
during the Term hereof, it is the intention of the Parties that the remainder of
this Agreement shall not be affected thereby provided that a Party's rights
under this Agreement are not materially affected. The Parties hereto covenant
and agree to renegotiate any such term, covenant or application thereof in good
faith in order to provide a reasonably acceptable alternative to the term,
covenant or condition of this Agreement or the application thereof that is
invalid, illegal or unenforceable, it being the intent of the Parties that the
basic purposes of this Agreement are to be effectuated.
8.16 STATUS. Nothing in this Agreement is intended or shall be deemed
to constitute a partner, agency, employer-employee, or joint venture
relationship between the Parties.
8.17 INDEMNIFICATION.
8.17.1 ABX Indemnity. ABX shall [______________] and [________
___________________________________________ __________________] and [_____] and
[___________________________________] (the "Indemnitees") [____________________
______________________] (including [___________________] and [______________])
[_________] or [_______________________], or [________], in connection with
[__________ ______________________________________], including, without
limitation, [____________ _______________________] (but
[__________________________________________ ________], which are
[_______________]), to the extent arising out of (i) [_____________
_______________] in the [_____________________________________________________
___________________________] of [_______________(____________________)
_______________________________________] under this Agreement, (ii)
[_____________] of this Agreement [______], or (iii)
[___________________________] of the [________], in any [______] under this
Section 8.17.1 except to [_______________________________] therefor under
Section 8.17.2 below.
8.17.2 IMMUNOGEN INDEMNITY. Subject to Section 8.17.1 above,
IMMUNOGEN shall indemnify, defend and hold harmless ABX, its Affiliates and
their respective directors, officers, employees, and agents, and their
respective successors, heirs and assigns (also the "Indemnitees"), from and
against any liability, damage, loss or expense (including reasonable attorneys'
fees and expenses of litigation) incurred by or imposed upon
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
27
87
such Indemnitees, or any of them, in connection with any Third Party claims,
suits, actions, demands or judgments, including, without limitation, personal
injury and product liability matters (but excluding any patent, trademark or
tradename infringement matters, which are governed by Section 6 above), to the
extent arising out of (i) any actions or omissions of IMMUNOGEN or subcontractor
of IMMUNOGEN in the development, testing, production, manufacture or supply of
any Licensed Product (or any component thereof) manufactured and supplied by
IMMUNOGEN or any subcontractor of IMMUNOGEN under this Agreement, (ii) any
material breach of this Agreement by IMMUNOGEN, or (iii) gross negligence or
willful misconduct on the part of IMMUNOGEN.
8.18 INDEMNIFICATION PROCEDURES. In the event that any Indemnitee is
seeking indemnification under Section 8.17 above from a Party (the "Indemnifying
Party"), the other Party shall notify the Indemnifying Party of such claim with
respect to such Indemnitee as soon as reasonably practicable after the
Indemnitee receives notice of the claim, and the Party (on behalf of itself and
such Indemnitee) shall permit the Indemnifying Party to assume direction and
control of the defense of the claim (including the right to settle the claim
solely for monetary consideration) and shall cooperate as requested (at the
expense of the Indemnifying Party) in the defense of the claim. The
indemnification obligations under Section 8.17 shall not apply to amounts paid
in settlement of any claim, demand, action or other proceeding if such
settlement is effected without the consent of the Indemnifying Party, which
consent shall not be withheld or delayed unreasonably. The Indemnitee, its
employees and agents, shall reasonably cooperate with the Indemnifying Party and
its legal representatives in the investigation of any claim, demand, action or
other proceeding covered by Section 8.17.
8.19 SECTION 365(n). All licenses granted under this Agreement are
deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code,
licenses of right to "intellectual property" as defined in Section 101 of such
Code. The Parties agree that the licensee may fully exercise all of its rights
and elections under the U.S. Bankruptcy Code, regardless of whether either Party
files for bankruptcy in the United States or other jurisdiction. The Parties
further agree that, in the event a licensee elects to retain its rights as a
licensee under such Code, the licensee shall be entitled to complete access to
any technology licensed to it hereunder and all embodiments of such technology.
Such embodiments of the technology shall be delivered to the licensee not later
than:
8.19.1 the commencement of bankruptcy proceedings against the
licensor, upon written request, unless the licensor elects to perform its
obligations under the Agreement, or
8.19.2 if not delivered under Section 8.19.1 above, upon the
rejection of this Agreement by or on behalf of the licensor, upon written
request.
8.20 FURTHER ASSURANCES. Each Party agrees to execute, acknowledge and
deliver such further instructions, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
28
88
8.21 COUNTERPARTS. This Agreement may be executed simultaneously in
one or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument.
8.22 [__________________].
8.22.1 If [_____________________________] or [___________] to a
[_____________] a [__________] under the [_________________] or
[_________________ ____________________] to
[____________________________________________________
_______________________________________________________].
8.22.2 If the [______________________] of [___________________]
are [___________ (________)] to [___________] than the [_____________________]
hereunder are to [___________________________] in the [______________________
_____________________________________________] of [________________________
_______] after [_______] of any [__________], if [_____________________________]
of [________], the [______________________] of this Agreement shall be
[_________________] to [_____] to [____________________________]. If
[____________________] as set forth in this Section 8.22.2 [_________________],
then [_____________] in accordance with this Section 8.22 with respect to a
[______________________] shall [___________].
8.22.3 If [___________________] that the [______________________]
of [____________________] are [______________(_____________)] than the
[___________ _________________] are to [____], then
[___________________________________________ _____] an
[______________________(____________] and [_______________] to [__________] and
[_____________________________________________] as may be reasonably requested
[______________]) to have [________] and [__________________ ______] at
[____________________________________] and to [________] whether such
[_________________________________________] are [___________(_____________])
than the [_____________________________] are to [____] (without disclosing to
[___] the [__________] or [__________________________] of
[____________________]). In the event of [____________________________] as to
[______________________________________ ______ (_____________)], then
[_____________] shall be [_________________________ ______________].
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed
by their duly authorized representative in two (2) originals.
ABGENIX, INC. IMMUNOGEN, INC.
By: ______________________________ By: ______________________________
Title: ___________________________ Title: ___________________________
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
29
89
SCHEDULE I
LICENSED PATENT RIGHTS
[_________________________________]
- ---------------------------------------------------------------------------------------------------------------------------------
Attorney Country Appl. No. Filing Date Priority Date Patent No. Issue Date Exp. Date
Reference No.
- ---------------------------------------------------------------------------------------------------------------------------------
[________] [________] [________] [________] [________]
- ---------------------------------------------------------------------------------------------------------------------------------
[________] [________] [________] [________] [________] [________] [________] [________]
- ---------------------------------------------------------------------------------------------------------------------------------
[________] [________] [________] [________] [________] [________] [________] [________]
- ---------------------------------------------------------------------------------------------------------------------------------
[________] [________]* [________] [________] [________] [________] [_______] [______]
- ---------------------------------------------------------------------------------------------------------------------------------
*[________]
- ---------------------------------------------------------------------------------------------------------------------------------
[________] [________] [________] [________] [________] [________]
- ---------------------------------------------------------------------------------------------------------------------------------
[________] [________] [________] [________] [________] [________]
- ---------------------------------------------------------------------------------------------------------------------------------
[________________________________________________________________________]
- ---------------------------------------------------------------------------------------------------------------------------------
Attorney Country Appl. No. Filing Date Priority Date Patent No. Issue Date Exp. Date
Reference No.
- ---------------------------------------------------------------------------------------------------------------------------------
[________] [________]
[________] [________] [________]
- ---------------------------------------------------------------------------------------------------------------------------------
[-------------------------]
- ---------------------------------------------------------------------------------------------------------------------------------
Attorney Country Appl. No. Filing Date Priority Date Patent No. Issue Date Exp. Date
Reference No.
- ---------------------------------------------------------------------------------------------------------------------------------
[________]
[________] [________] [________] [________]
- ---------------------------------------------------------------------------------------------------------------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
30
1
LETTER AGREEMENT
FOR STOCK PURCHASE
September 6, 2000
ImmunoGen, Inc.
128 Sidney Street
Cambridge MA 02139
Ladies and Gentlemen:
Abgenix, Inc. ("Abgenix") agrees to buy, and ImmunoGen, Inc. ("ImmunoGen")
agrees to sell to Abgenix Seven Hundred Eighty Nine Thousand Four Hundred
Seventy Three (789,473) shares of ImmunoGen common stock, $.01 par value per
share (the "Shares") at a price per share equal to Nine Teen Dollars ($19.00)
per Share, constituting an aggregate purchase price of $15,000,000. On September
7, 2000, Abgenix shall wire an aggregate of $15,000,000 in immediately available
funds to an account designated by ImmunoGen and ImmunoGen shall deliver into
escrow with Chase Mellon Shareholder Services a stock certificate evidencing the
Shares (and on or before such date, a copy of such certificate shall be faxed to
Abgenix). On or before September 8, 2000, contingent only upon ImmunoGen's
receipt of the purchase price on September 7, 2000, ImmunoGen shall cause the
Shares to be delivered to Abgenix.
A. REPRESENTATIONS AND WARRANTIES OF ABGENIX
1. Abgenix represents and warrants to ImmunoGen that it is acquiring the
Shares for its own account for the purpose of investment. Abgenix is not
acquiring the Shares with a view to, or for resale in connection with, a
distribution, nor with any present intention of distributing or selling the
Shares and understands that the Shares have not been registered under the
Securities Act of 1933, as amended (the "Securities Act"), or the
securities laws of any state. Abgenix understands that until the Shares
have been registered under the Securities Act and applicable state
securities laws each certificate representing such Shares shall bear a
legend substantially similar to the following:
THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OR ANY APPLICABLE STATE SECURITIES LAWS AND
MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR HYPOTHECATED UNLESS
THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT
COVERING SUCH SECURITIES, THE SALE IS MADE IN ACCORDANCE WITH
RULE 144 UNDER THE ACT, OR THE COMPANY RECEIVES AN OPINION OF
COUNSEL FOR THE HOLDER OF THESE SECURITIES REASONABLY
SATISFACTORY TO THE COMPANY, STATING THAT SUCH SALES,
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
-1-
2
TRANSFER, ASSIGNMENT OR HYPOTHECATION IS EXEMPT FROM THE
REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SUCH ACT.
2. Abgenix represents and warrants to ImmunoGen that it is an "accredited
investor" as such term is defined in Regulation D under the Securities Act.
3. Abgenix represents and warrants that (i) it has the right and power
under its charter and bylaws or other organizational documents to execute,
deliver and perform its obligations hereunder; (ii) it is a corporation
duly organized, validly existing and in good standing under the laws of the
state of its jurisdiction or organization; (iii) this Letter Agreement has
been duly authorized by all necessary corporate action; and (iv) the
officer executing and delivering this Letter Agreement has the requisite
right, power, capacity and authority to do so on behalf of Abgenix, and
this Letter Agreement when so duly executed and delivered, will constitute
the legal, valid and binding obligation of Abgenix enforceable against
Abgenix in accordance with its respective terms.
B. REPRESENTATIONS AND WARRANTIES OF IMMUNOGEN
1. ImmunoGen represents and warrants that (i) it has the right and power
under its charter and bylaws to execute, deliver and perform its
obligations hereunder; (ii) it is a corporation duly organized, validly
existing and in good standing under the laws of the state of its
jurisdiction or organization; (iii) this Letter Agreement has been duly
authorized by all necessary corporate action; and (iv) the officer
executing and delivering this Letter Agreement has the requisite right,
power, capacity and authority to do so on behalf of ImmunoGen, and this
Letter Agreement when so duly executed and delivered, will constitute the
legal, valid and binding obligation of ImmunoGen enforceable against
ImmunoGen in accordance with its respective terms, except as enforceability
may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditors' and contracting parties'
rights generally.
2. ImmunoGen represents and warrants that since January 1, 1998,
ImmunoGen has filed all reports ("Designated SEC Reports") required to be
filed by it with the Securities Exchange Commission ("SEC") pursuant to the
reporting requirements of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"). To the best of ImmunoGen's knowledge, as of their
respective dates, the Designated SEC Reports complied in all material
respects with the requirements of the Exchange Act and the rules and
regulations of the SEC promulgated thereunder applicable to the Designated
SEC Reports, and none of the Designated SEC Reports, at the time they were
filed with the SEC, contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances
under which they were made, not misleading except to the extent superseded
by a Designated SEC Report filed subsequently and prior to the date hereof.
To
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
-2-
3
the best of ImmunoGen's knowledge, as of their respective dates, the
financial statements of ImmunoGen included in the Designated SEC Reports
complied as to form in all material respects with applicable accounting
requirements and the published rules and regulations of the SEC with
respect thereto. Such financial statements have been prepared in accordance
with generally accepted accounting principles, consistently applied during
the periods involved (except (i) as may be otherwise indicated in such
financial statement or the notes thereto, or (ii) in the case of unaudited
interim statements, to the extent they may exclude footnotes or may be
condensed or summary statements) and fairly present in all material
respects the financial position of ImmunoGen as of the dates thereof and
the results of its operations and cash flows for the periods then ended
(subject, in the case of unaudited statements, to normal year-end audit
adjustments).
3. ImmunoGen represents and warrants that, (i) the Shares have been duly
authorized and when issued and paid for in accordance with this Agreement
will be validly issued, fully paid and non-assessable, and (ii) assuming
the accuracy of the representations and warranties of Abgenix set forth in
Section A above, the offer, sale and issuance of the Shares will be exempt
from the registration requirements of the Securities Act, and will have
been registered or qualified (or are exempt from registration and
qualification) under the registration, permit or qualification requirements
of all applicable state securities laws.
4. Immunogen represents and warrants to Abgenix that on or before
[_______________], the Shares will be approved for listing on the Nasdaq
Stock Market.
C. LOCK-UP RESTRICTION
Abgenix and its "affiliates" or "associates," as such terms are used
in Rule 12b-2 of the Exchange Act, (these terms to have such meaning
throughout Sections C and D) hereby agree that, without the prior
written consent of ImmunoGen, they will not, during the period
commencing on the date hereof and ending on [___________], (1) offer,
pledge, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option,
right or warrant to purchase, lend, or otherwise transfer or dispose
of, directly or indirectly, any of the Shares or any securities
convertible into or exercisable or exchangeable for the Shares or (2)
enter into any swap or other arrangement that transfers to another, in
whole or in part, any of the economic consequences of ownership of the
Shares, whether any such transaction described in clause (1) or (2)
above is to be settled by delivery of shares of ImmunoGen common stock
or such other securities, in cash or otherwise. The foregoing sentence
shall not apply to (i) the transfer of the Shares by Abgenix to its
affiliates or associates, PROVIDED, THAT, the transferee(s) agrees in
writing as a condition precedent to such transfer to be bound by the
terms of this Letter Agreement, (ii) the transfer of Shares by Abgenix
to the acquiring entity in the event that ImmunoGen is consolidated
with or acquired by another entity in a merger, tender offer or
otherwise, or (iii) the transfer of Shares by Abgenix to the acquiring
entity in the event that Abgenix is consolidated with or acquired by
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
-3-
4
another entity in a merger, tender offer or otherwise PROVIDED, THAT,
the transferee(s) agrees in writing as a condition precedent to such
transfer to be bound by the terms of this Letter Agreement.
Abgenix understands that the Shares shall bear a legend
substantially similar to the following:
THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AN
AGREEMENT BY THE REGISTERED HOLDER HEREOF NOT TO OFFER, PLEDGE,
SELL, CONTRACT TO SELL, SELL ANY OPTION OR CONTRACT TO PURCHASE,
PURCHASE ANY OPTION OR CONTRACT TO SELL, GRANT ANY OPTION, RIGHT
OR WARRANT TO PURCHASE, LEND OR OTHERWISE TRANSFER OR DISPOSE OF
SUCH SECURITIES UNTIL [_______________].
D. STANDSTILL
1. Abgenix agrees that for a period of [_________] from the date hereof,
Abgenix will not, nor will it permit any of its affiliates or associates
to, from and after the date that such person becomes an affiliate or
associate, unless in any such case specifically invited to do so by the
Board of Directors of ImmunoGen (1) acquire, announce an intention to
acquire, offer or propose to acquire, solicit an offer to sell or agree to
acquire by purchase, by gift, by joining a partnership, limited
partnership, syndicate or other "group," as such term is used in Section
13(d)(3) of the Exchange Act (such term to have such meaning throughout
this Section D) or otherwise, any (i) material assets, businesses or
properties of ImmunoGen other than in the ordinary course of business, or
(ii) shares of ImmunoGen common stock, or any other ImmunoGen securities
convertible into, exchangeable for or exercisable for ImmunoGen common
stock (all such securities, collectively, "Voting Securities"), except that
the foregoing shall not apply to the purchase of the Shares pursuant to
this Letter Agreement, (2) solicit, or participate in any "solicitation" of
"proxies" or become a "participant" in any "election contest" (as such
terms are defined or used in Regulation 14A under the Exchange Act, these
terms to have such meaning throughout this Agreement) with respect to
ImmunoGen, (3) initiate, publicly propose or otherwise solicit stockholders
for the approval of, one or more stockholder proposals with respect to
ImmunoGen, or induce any other person to initiate any stockholder proposal,
(4) seek to place any representative on the Board of Directors of
ImmunoGen, or seek to have called any meeting of the stockholders of
ImmunoGen; (5) deposit any Voting Securities in a voting trust or subject
them to a voting agreement or other agreement or arrangement with respect
to the voting of such Voting Securities, other than this Agreement, (6)
otherwise act, alone or in concert with others, to seek to control the
management, Board of Directors, policies or affairs of ImmunoGen or
solicit, publicly propose, seek to effect or negotiate with any other
person with respect to any form of business combination or other
extraordinary transaction with ImmunoGen or any restructuring,
recapitalization or similar transaction with respect to ImmunoGen, or
solicit, make or publicly
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
-4-
5
propose or negotiate with any other person with respect to, or announce an
intent to make, any tender offer or exchange offer for any securities of
ImmunoGen, or publicly disclose an intent, purpose, plan or proposal with
respect to ImmunoGen, or any securities or assets of ImmunoGen, that would
violate the provisions of this Section D, or assist, participate in,
facilitate or solicit any effort or attempt by any person to do so or seek
to do any of the foregoing.
2. Notwithstanding the limitations and restrictions set forth above in
Section D(1), Abgenix shall have the right to acquire Voting Securities
which, when added to the Voting Securities already owned by Abgenix
(including the Shares), would constitute not more than 5% of the number of
shares of ImmunoGen common stock reported by ImmunoGen to be outstanding in
the Company's most recently available filing with the SEC or other public
announcement.
E. MISCELLANEOUS
1. Abgenix acknowledges and agrees that irreparable damage may occur if
any of the provisions of Sections C and D were not performed in accordance
with their specific terms or were otherwise materially breached. Immunogen
acknowledges and agrees that irreparable damage may occur if any of the
provisions of Section B were not performed in accordance with their
specific terms or were otherwise materially breached. Accordingly,
ImmunoGen will be entitled to seek an injunction or injunctions to prevent
breaches of Sections C and D and to seek specific enforcement of its
provisions, and Abgenix will be entitled to seek an injunction or
injunctions to prevent breaches of Section B and to seek specific
enforcement of its provisions, in any court of the United States or any
state having jurisdiction, this being in addition to any other remedy to
which ImmunoGen or Abgenix may be entitled at law or in equity.
2. No failure or delay on the part of Abgenix or ImmunoGen in the
exercise of any power, right or privilege hereunder shall operate as a
waiver thereof, nor shall any single or partial exercise of any such power,
right or privilege preclude other or further exercise thereof or of any
other right, power or privilege.
3. This Letter Agreement may be executed in one or more counterparts,
each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.
IN WITNESS WHEREOF, the undersigned have executed this Letter Agreement on
September 6, 2000.
ABGENIX, INC.
By:
------------------------------------------
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.
-5-
6
Name: Kurt Leutzinger
Title: CFO
IMMUNOGEN, INC.
By:
------------------------------------------
Name:
Title:
Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company's application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act.
-6-
